
<html lang="en"     class="pb-page"  data-request-id="bd3a4cd1-7b14-40ad-a916-0fbbc2f9ded5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b00426;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor" /></meta><meta name="dc.Creator" content="Ronald  Knegtel" /></meta><meta name="dc.Creator" content="Jean-Damien  Charrier" /></meta><meta name="dc.Creator" content="Steven  Durrant" /></meta><meta name="dc.Creator" content="Chris  Davis" /></meta><meta name="dc.Creator" content="Michael  O’Donnell" /></meta><meta name="dc.Creator" content="Pierre  Storck" /></meta><meta name="dc.Creator" content="Somhairle  MacCormick" /></meta><meta name="dc.Creator" content="David  Kay" /></meta><meta name="dc.Creator" content="Joanne  Pinder" /></meta><meta name="dc.Creator" content="Anisa  Virani" /></meta><meta name="dc.Creator" content="Heather  Twin" /></meta><meta name="dc.Creator" content="Matthew  Griffiths" /></meta><meta name="dc.Creator" content="Philip  Reaper" /></meta><meta name="dc.Creator" content="Peter  Littlewood" /></meta><meta name="dc.Creator" content="Steve  Young" /></meta><meta name="dc.Creator" content="Julian  Golec" /></meta><meta name="dc.Creator" content="John  Pollard" /></meta><meta name="dc.Description" content="The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in..." /></meta><meta name="Description" content="The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 10, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00426" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00426" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00426" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00426" /></link>
        
    
    

<title>Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00426" /></meta><meta property="og:title" content="Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0017.jpeg" /></meta><meta property="og:description" content="The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer. Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage. However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR. In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclinical studies, while healthy tissue with functional ATM can tolerate ATR inhibition. ATR therefore represents a very attractive anticancer target. Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clinical studies, which is based on a 2-aminopyrazine core first reported by Charrier  ( J. Med. Chem. 2011, 54, 2320–2330, DOI: 10.1021/jm101488z)." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer. Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage. However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR. In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclinical studies, while healthy tissue with functional ATM can tolerate ATR inhibition. ATR therefore represents a very attractive anticancer target. Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clinical studies, which is based on a 2-aminopyrazine core first reported by Charrier  ( J. Med. Chem. 2011, 54, 2320–2330, DOI: 10.1021/jm101488z)." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0017.jpeg" /></meta><meta name="twitter:title" content="Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00426"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00426">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00426&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00426&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00426&amp;href=/doi/10.1021/acs.jmedchem.9b00426" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5547-5561</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00472" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00504" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ronald Knegtel</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ronald Knegtel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#ff8d90919e939ba094919a988b9a93bf898d8b87d19c9092"><span class="__cf_email__" data-cfemail="1d6f72737c7179427673787a6978715d6b6f6965337e7270">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ronald++Knegtel">Ronald Knegtel</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7192-3174" title="Orcid link">http://orcid.org/0000-0002-7192-3174</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean-Damien Charrier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean-Damien Charrier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Damien++Charrier">Jean-Damien Charrier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven Durrant</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven Durrant</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Durrant">Steven Durrant</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chris Davis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chris Davis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chris++Davis">Chris Davis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael O’Donnell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael O’Donnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++O%E2%80%99Donnell">Michael O’Donnell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pierre Storck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre Storck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++Storck">Pierre Storck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Somhairle MacCormick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Somhairle MacCormick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Somhairle++MacCormick">Somhairle MacCormick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Kay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Kay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Kay">David Kay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joanne Pinder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joanne Pinder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joanne++Pinder">Joanne Pinder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anisa Virani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anisa Virani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anisa++Virani">Anisa Virani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Heather Twin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heather Twin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heather++Twin">Heather Twin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew Griffiths</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew Griffiths</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Griffiths">Matthew Griffiths</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip Reaper</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Reaper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Reaper">Philip Reaper</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Littlewood</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Littlewood</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Littlewood">Peter Littlewood</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steve Young</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve Young</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Young">Steve Young</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julian Golec</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julian Golec</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julian++Golec">Julian Golec</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">John Pollard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Pollard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Pollard">John Pollard</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00426&amp;href=/doi/10.1021%2Facs.jmedchem.9b00426" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5547–5561</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 10, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 March 2019</li><li><span class="item_label"><b>Published</b> online</span>10 May 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 June 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00426" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00426</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5547%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRonald%2BKnegtel%252C%2BJean-Damien%2BCharrier%252C%2BSteven%2BDurrant%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D11%26contentID%3Dacs.jmedchem.9b00426%26title%3DRational%2BDesign%2Bof%2B5-%25284-%2528Isopropylsulfonyl%2529phenyl%2529-3-%25283-%25284-%2528%2528methylamino%2529methyl%2529phenyl%2529isoxazol-5-yl%2529pyrazin-2-amine%2B%2528VX-970%252C%2BM6620%2529%253A%2BOptimization%2Bof%2BIntra-%2Band%2BIntermolecular%2BPolar%2BInteractions%2Bof%2Ba%2BNew%2BAtaxia%2BTelangiectasia%2BMutated%2Band%2BRad3-Related%2B%2528ATR%2529%2BKinase%2BInhibitor%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5561%26publicationDate%3DJune%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00426"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2657</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00426" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ronald&quot;,&quot;last_name&quot;:&quot;Knegtel&quot;},{&quot;first_name&quot;:&quot;Jean-Damien&quot;,&quot;last_name&quot;:&quot;Charrier&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Durrant&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;Davis&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;O’Donnell&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;Storck&quot;},{&quot;first_name&quot;:&quot;Somhairle&quot;,&quot;last_name&quot;:&quot;MacCormick&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Kay&quot;},{&quot;first_name&quot;:&quot;Joanne&quot;,&quot;last_name&quot;:&quot;Pinder&quot;},{&quot;first_name&quot;:&quot;Anisa&quot;,&quot;last_name&quot;:&quot;Virani&quot;},{&quot;first_name&quot;:&quot;Heather&quot;,&quot;last_name&quot;:&quot;Twin&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Griffiths&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Reaper&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Littlewood&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Young&quot;},{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;Golec&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Pollard&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;5547-5561&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00426&quot;},&quot;abstract&quot;:&quot;The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer. Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage. However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR. In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclinical studies, while healthy tissue with functional ATM can tolerate ATR inhibition. ATR therefore represents a very attractive anticancer target. Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clinical studies, which is based on a 2-aminopyrazine core first r&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00426&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00426" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00426&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00426" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00426&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00426" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00426&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00426&amp;href=/doi/10.1021/acs.jmedchem.9b00426" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00426" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00426" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00426%26sid%3Dliteratum%253Aachs%26pmid%3D31074988%26genre%3Darticle%26aulast%3DKnegtel%26date%3D2019%26atitle%3DRational%2BDesign%2Bof%2B5-%25284-%2528Isopropylsulfonyl%2529phenyl%2529-3-%25283-%25284-%2528%2528methylamino%2529methyl%2529phenyl%2529isoxazol-5-yl%2529pyrazin-2-amine%2B%2528VX-970%252C%2BM6620%2529%253A%2BOptimization%2Bof%2BIntra-%2Band%2BIntermolecular%2BPolar%2BInteractions%2Bof%2Ba%2BNew%2BAtaxia%2BTelangiectasia%2BMutated%2Band%2BRad3-Related%2B%2528ATR%2529%2BKinase%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D11%26spage%3D5547%26epage%3D5561%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/11" title="Go to Volume 62, Issue 11"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/jmcmar.2019.62.issue-11/20190613/jmcmar.2019.62.issue-11.largecover.jpg" alt="Go to Volume 62, Issue 11"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer. Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage. However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR. In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclinical studies, while healthy tissue with functional ATM can tolerate ATR inhibition. ATR therefore represents a very attractive anticancer target. Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clinical studies, which is based on a 2-aminopyrazine core first reported by <contrib-group><span class="NLM_string-name">Charrier</span></contrib-group>  (  <cite><i>J. Med. Chem.</i></cite> <span class="NLM_year">2011</span>, <em>54</em>, 2320–2330, DOI: <pub-id pub-id-type="doi" type="simple">10.1021/jm101488z</pub-id>).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">DNA-damaging agents such as cisplatin, etoposide, gemcitabine, and ionizing radiation (IR) are important and commonly used agents in cancer therapy. Their mechanism of action is to induce potentially lethal DNA damage including double strand breaks and replication stress (RS). RS commonly arises when the replication machinery encounters a lesion in the DNA, resulting in a stalled and unstable replication fork that in turn can collapse to form a double strand break. The effectiveness of DNA damaging chemotherapy can be limited by the cell’s ability to detect and repair the DNA damage.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The related kinases ataxia telangiectasia mutated (ATM) and Rad3-related (ATR) kinase are apical regulators of the DNA damage response (DDR), a surveillance and repair process that enables cells to survive double strand breaks and replication stress. Although each kinase recognizes different DNA damage structures (double strand breaks in the case of ATM and single stranded DNA within double stranded DNA in the case of ATR), they share many downstream substrates and have overlapping roles in maintaining cell survival. ATR and ATM share a high degree of sequence homology and are members of the phosphoinositol 3-kinase-like kinase (PIKK) family of serine/threonine protein kinases,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> which includes other important DNA repair kinases such as DNA-dependent protein kinase (DNA-PK). Despite the importance of the DDR for cell survival following DNA damage, ATM function is often found to be impaired in tumor cells (from defects in activation, expression, or downstream signaling proteins such as p53). Loss of ATM or its effectors is thought to enable a genomically unstable environment, which is advantageous to the developing tumor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, impaired ATM function places additional burden on remaining repair proteins, such as ATR, to maintain survival. This Achilles’ heel reliance on ATR may be exploited with drugs. Consistent with this hypothesis, a series of preclinical studies have demonstrated that cancer cells treated with DNA damaging drugs are especially sensitive to ATR inhibition when they harbor defects in ATM signaling.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> In contrast, normal tissue can tolerate ATR inhibition by activating an ATM-mediated compensatory DDR.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Furthermore, several studies have shown that some tumors are sensitive to ATR inhibition as a single agent and to combinations of ATR inhibitors with inhibitors of other repair proteins such as poly (ADP-ribose) polymerase (PARP) and Chk1. As such, ATR inhibition represents an attractive anticancer target.<a onclick="showRef(event, 'ref5 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref5 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20">(5,8−20)</a></div><div class="NLM_p">The first reported series of potent and selective ATR inhibitors, typified by compound <b>1</b> (VE-821, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), is based on a 2-aminopyrazine amide hinge binding motif.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Compound <b>1</b> has proven to be a useful tool to assess the biology of ATR in cells and the potentially beneficial profile for ATR inhibition. However, certain properties of <b>1</b> were not fully optimized in the initial chemistry campaign. These include enzyme and cell potency, physical properties such as solubility and the metabolic profile, specifically the potential to form aniline metabolites.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Here we present the optimization of the 2-aminopyrazine series to a more potent and stable heteroaromatic scaffold from which compound <b>2</b> (VX-970, M6620, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), the first ATR inhibitor to enter clinical studies,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> is derived.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of compound <b>1</b> (VE-821) and compound <b>2</b> (VX-970/M6620).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our initial optimization efforts of <b>1</b>, replacement of the anilide group with a range of fused bicyclics such as benzimidazole, benzoxazole, benzothiazole, and indole<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> was well tolerated by ATR but resulted in reduced selectivity for ATR against ATM. The loss of selectivity over ATM was attributed to a rotation of the bound inhibitor (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a) caused by a steric clash between the bulkier fused bicyclic aromatic systems with the tyrosine gatekeeper residue of the PIKK family. This movement in turn resolves a second steric clash between Pro2775 of ATM (which is a smaller glycine residue in ATR) and the isopropylsulfone of the inhibitor, leading to tighter binding to ATM.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Comparison of anilide <b>1</b> (in green) versus a benzimidazole isostere (in cyan) in a model of the active site of ATM based on PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a>. The benzimidazole is thought to experience steric hindrance from Tyr2755 in ATM. In response it rotates away from Tyr2755, which allows it to escape a steric clash with Pro2775 (Gly in ATR). (b) Replacing the benzimidazole with a phenyl substituted monocyclic heteroaryl (in cyan) yields a better mimic of the original anilide and avoids movement of the inhibitor due to steric hindrance with Tyr2755.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of homology models (derived from a crystal structure of the homologous kinase PI3Kγ, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a>),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> we hypothesized that phenyl substituted five-membered heteroaromatic groups can bind without causing steric clashes with the gatekeeper residue as it mimics the shape of the original anilide more closely. Thus, we expected selectivity for ATR over ATM to be retained (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). Furthermore, we speculated that functionalization of the phenyl ring would enable exploitation of a highly negatively charged area of the ATP binding site. This would have potential to increase potency and selectivity and also provide an opportunity to modulate physical properties to improve solubility. In keeping with this, substitution with a 4-benzylamine on the five-membered heteroaryl core yielded compounds with picomolar ATR inhibition, good retention of selectivity, and potent cellular activity, culminating in the discovery of the clinical candidate <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The commercially available methyl 3-amino-6-bromopyrazine-2-carboxylate <b>21</b> was readily converted into the 4-isopropylsulfonylphenyl using Suzuki cross-coupling conditions to provide <b>22</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref1 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref1 ref22 ref23">(1,22,23)</a> The carboxylic acid in <b>22</b> was then transformed into the anilide <b>3</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> or used in a sequence leading to 5-phenylisoxazole <b>7</b>, via formation of a Weinreb amide, methyl ketone, or benzylidene ketone intermediate.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Acid <b>22</b> was also engaged in a cyclodehydration with <i>N</i>-hydroxybenzamidine to furnish 3-phenyl-1,2,4-oxadiazole <b>10</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (4-isopropylsulfonylphenyl)boronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd[P(<i>t</i>-Bu)<sub>3</sub>]<sub>2</sub>, MeCN/H<sub>2</sub>O (4:1), 60 °C, 2 h, 97%; (b) LiOH, THF, rt, 2 h, 96%; (c) diethoxyphosphorylformonitrile, aniline, Et<sub>3</sub>N, DME, 120 °C, 18 h, 96%; (d) <i>N</i>-methoxymethanamine hydrochloride, HOBt, DIPEA, 3-(ethyliminomethyleneamino)-<i>N</i>,<i>N</i>-dimethylpropan-1-amine, THF, rt, 18 h, 77%; (e) MeMgBr 3 M in THF, THF, −20 °C, 1 h, 80%; (f) benzaldehyde, NaOH, MeOH/DCM (1:1), rt, 18 h, 70%; (g) hydroxylamine hydrochloride, NaOAc, EtOH/AcOH (10/3), 130 °C, 1 h, 17%; (h) CDI, <i>N</i>-hydroxybenzamidine, rt to 120 °C, 5 h, 67%.</p></p></figure><div class="NLM_p">Compound <b>25</b> was used as a versatile intermediate in the preparation of 1-phenyl-1,2,3-triazole <b>6</b> and 3-phenylisoxazole <b>4</b> (as well as analogues <b>2</b>, <b>14</b>–<b>20</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Commercially available 5-bromopyrazin-2-amine <b>23</b> was subjected to Suzuki palladium cross-coupling with 4-isopropylsulfonylphenylboronic acid and then brominated at position 3 using NBS to provide intermediate <b>24</b> in high yield.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Copper assisted Sonogashira coupling with TMS-acetylene<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> followed by di-BOC protection of the amino group and TMS deprotection afforded advanced intermediate <b>25</b>. The acetylene functional group in <b>25</b> was then used as a coupling partner for click chemistry with azidobenzene to lead to the 1,2,3-triazole <b>6</b> after BOC removal.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> [3 + 2] Cycloaddition between <b>25</b> and phenylnitrile oxides, generated in situ from the corresponding <i>N</i>-hydroxyimidoyl chlorides, delivered the 3-arylisoxazoles <b>4</b> (as well as <b>2</b> and <b>14</b>–<b>20</b> after additional steps; see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (4-isopropylsulfonylphenyl)boronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd[P(<i>t</i>-Bu)<sub>3</sub>]<sub>2</sub>, MeCN/H<sub>2</sub>O (4/1), 60 °C, 1 h, 87%; (b) NBS, DMF, rt, 3 h, 84%; (c) (trimethylsilyl)acetylene, CuI, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 0 °C to rt, 1 h, 81%; (d) Boc<sub>2</sub>O, DMAP, Et<sub>3</sub>N, DCM, rt, 18 h, 100%; (e) Na<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 1 h, 97%; (f) azidobenzene (0.5 M in MTBE), (+)-sodium <span class="smallcaps smallerCapital">l</span>-ascorbate, CuSO<sub>4</sub>·5H<sub>2</sub>O, <i>t</i>-BuOH/H<sub>2</sub>O (1:1), rt to 40 °C, 12 h, 41%; (g) TFA/DCM (1/3), rt, 1 h, 80%; (h) <i>N</i>-hydroxybenzimidoyl chloride, Et<sub>3</sub>N, DMF, 60 °C, 45 min, then TFA/DCM, rt, 1 h, 52%.</p></p></figure><div class="NLM_p">Compound <b>24</b> was also used as a coupling partner to 2- and 5-phenyloxazoles under CH insertion conditions to produce inhibitors <b>11</b> and <b>12</b>, respectively (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31−33)</a> The 2-vinyl intermediate, <b>26</b>, prepared from the bromo precursor, <b>24</b>, and vinyl potassium trifluoroborate under palladium catalysis,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> underwent [3 + 2] cycloaddition with phenylnitrile oxide, generated in situ from the corresponding <i>N</i>-hydroxyimidoyl chloride, to provide the 3-phenyl-4,5-dihydroisoxazole <b>5</b>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-phenyloxazole, Ag<sub>2</sub>CO<sub>3</sub>, PPh<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, water, 70 °C, 24 h, 29%; (b) 5-phenyloxazole, <i>t</i>-BuOLi, Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, 140 °C in μwave, 3 h, 46%; (c) vinylpotassium trifluoroborate, Pd(dppf)Cl<sub>2</sub>, Et<sub>3</sub>N, <i>n</i>-PrOH, 100 °C in μwave, 40 min, 57%; (d) <i>N</i>-hydroxybenzimidoyl chloride, Et<sub>3</sub>N, DMF, 65 °C, 1 h, 58%.</p></p></figure><div class="NLM_p">The carboxylic acid group in the commercial starting point, <b>27</b>, was used to build the 1,3,4-oxadiazole and the 1,3,4-thiadiazole rings in intermediates <b>28</b> and <b>29</b>, via cyclodehydration with benzohydrazide and benzothiohydrazide, respectively (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> These intermediates were then functionalized using Suzuki cross-couplings to afford 2-phenyl-1,3,4-oxadiazole <b>8</b> and 2-phenyl-1,3,4-thiadiazole <b>13</b>. By use of a similar strategy, building block <b>30</b> was converted into the 5-phenyl-1,2,4-oxadiazole, <b>9</b>. The nitrile at position 2 in <b>30</b> was transformed into a hydroxyimidamide with hydroxylamine and subsequently O-benzoylated prior to a cyclodehydration under acidic conditions.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzohydrazide, PPh<sub>3</sub>Br<sub>2</sub>, MeCN, rt, 1 h, then DIPEA, 0 °C, 1 h, 80%; (b) benzothiohydrazide, PPh<sub>3</sub>Br<sub>2</sub>, MeCN, rt, 3 h, 39%; (c) hydroxylamine hydrochloride, Et<sub>3</sub>N, MeOH, 0 °C to rt, 3 h, 76%; (d) benzoyl chloride, Et<sub>3</sub>N, DCM, rt, 16 h, 93%; (e) PPA, 70 °C, 7 h, 88%; (f) (4-isopropylsulfonylphenyl)boronic acid, Na<sub>3</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, dioxane, 100 °C in μwave, 25 min, 34–69%.</p></p></figure><div class="NLM_p last">The preparation of intermediates <b>22</b>, <b>24</b>–<b>26</b>, <b>28</b>–<b>29</b>, <b>31</b> is described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62804" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62804" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The main aim of the optimization of the 2-aminopyrazine series was to identify a more potent and water-soluble analogue of <b>1</b> without the potential to form an aniline metabolite. The primary approach was to mimic the anilide of <b>1</b> with an optimally functionalized saturated or unsaturated ring.</div><div class="NLM_p">In our earlier work, a 3-fold gain in ATR inhibitory potency was achieved by replacing the methylsulfone of <b>1</b> with an isopropylsulfone.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Therefore, compound <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was used as a more potent starting point for exploring biaryl replacements of the anilide. Docking analogues of <b>3</b> with five- and six-membered heteroaromatic replacements for the anilide into an ATR homology model<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> suggested that phenyl substituted five-membered heteroaromatics would fit well in the ATP binding site and mimic the shape and planar nature of the original anilide (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). Previously reported initial studies had established that the amide of <b>1</b> linking the phenyl- and aminopyrazine was not making any specific H-bonding interactions with the ATP binding site.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, it had not been determined whether replacement linkers needed to retain a flat profile or whether a degree of three-dimensionality could be accommodated. To test this, we prepared a matched pair with either an unsaturated and planar isoxazole (<b>4</b>) or the partially saturated 4,5-dihydroisoxazole analogue (<b>5</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>4</b> was approximately 90-fold more potent than <b>5</b>, indicating that a flat linker is required for an optimal steric fit in the ATP binding pocket. The energy required to flatten the 4,5-dihydroisoxazole ring system of <b>5</b> (<i>R</i>-isomer) from its minimized, more three-dimensional conformation in vacuum to its docked conformation is estimated to be approximately 2 kcal/mol in the gas phase. This would equate to about a 30-fold reduction of its inhibition constant, which is consistent with the observed data.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme Inhibition Constants (<i>K</i><sub>i</sub>) and Cell Assay IC<sub>50</sub> Values for Aminopyrazine ATR Inhibitors<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0011.gif" alt="" id="GRAPHIC-d7e897-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0012.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Compound <b>5</b> is a racemic mixture.</p></div></div><div></div></div><div class="NLM_p">A selection of diverse five-membered aromatic heterocycles were considered as possible amide replacements and were prioritized by assessing their conformational energies (as outlined below), followed by docking into our ATR kinase homology model.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As a consequence of conjugation, the five-membered heteroayl ring can assume only two orientations with respect to the 2-aminopyrazine hinge binder, as illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. We will refer to the orientation that best mimics the anilide of <b>1</b> as the bioactive conformation.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Intramolecular polar interactions within heteroaryl ATR inhibitors. Polar interactions between the central five-membered heteroaryl ring atoms X and Y and the 2-aminopyrazine hinge binder determine whether the bioactive conformation (left) is energetically preferred.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Complementary intramolecular interactions between the heteroaryl rings of the inhibitor would ensure that the proposed bioactive conformation is energetically favored. Atoms X and Y in the central ring are either opposite the 2-amino group or the 4-sp<sup>2</sup> nitrogen atom of the pyrazine ring, and the nature of their mutual interactions determines the preferred orientation of the five-membered heteroaryl ring. While hydrogen bond acceptors (atom X) are preferred opposite the pyrazine NH<sub>2</sub> and an aromatic CH (atom Y) opposite the pyrazine ring sp<sup>2</sup> nitrogen for reasons of electrostatic complementarity, it is less clear which conformation is preferred when both X and Y are hydrogen bond acceptors. Aromatic nitrogen, oxygen, and sulfur atoms vary in their effectiveness as hydrogen bond acceptors<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and will be tolerated to different degrees opposite the sp<sup>2</sup> nitrogen at position 4 of the pyrazine ring. Therefore, the nature and shape of the five-membered aryl ring determine how readily a compound can assume the proposed bioactive conformation. In order to predict which five-membered heteroaryl rings favor the proposed bioactive conformation, the gas phase energies of the two accessible conformations shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> from a library of putative heteroaryl rings were calculated using density functional theory (DFT) using the B3LYP functional and a 6-31G** basis set.<a onclick="showRef(event, 'ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41">(38−41)</a> Although calculated rotational barriers can give insight into how readily a certain conformation can be assumed, they provide no information on which conformation is more stable and tracked poorly with the binding data when calculated for compounds <b>8</b>, <b>9</b>, and <b>10</b> (results not shown). Calculating the enthalpy difference between two rigid conformers is both computationally less demanding and a better estimator of the free energy of the binding state function. Nine phenyl-substituted five-membered heteroaryl replacements of anilide <b>3</b> were prioritized and synthesized. <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> shows the calculated energy differences between the two accessible conformations for each of these compounds in kcal/mol (a negative energy signifying a preference for the proposed bioactive conformation), along with inhibition constants (<i>K</i><sub>i</sub>) against recombinant full-length ATR, ATM, and DNA-PK and where available IC<sub>50</sub> values from an ATR-mediated cell based biomarker assay (measuring phosphorylation of the ATR substrate variant histone H2A (H2AX) at serine 139 in human colorectal carcinoma HCT116 cells).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzyme Inhibition Constants (<i>K</i><sub>i</sub>), pH2AX Cell Assay IC<sub>50</sub> Values, and Conformational Energy Differences for Aminopyrazine ATR Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0013.gif" alt="" id="GRAPHIC-d7e994-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0014.gif" alt="" id="gr12" /></img><div></div></div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> shows that aromatic five-membered rings are generally well tolerated as an amide replacement with many compounds showing similar ATR inhibition potency to the original amide <b>3</b>. The isoxazole <b>4</b>, oxadiazole <b>8</b>, and thiadiazole <b>13</b> show improvements in potency (<i>K</i><sub>i</sub> of ∼1 nM vs ∼4 nM for the starting compound, <b>3</b>). Encouragingly, these analogues retained the >1000-fold selectivity for ATR over the homologous kinases ATM and DNA-PK, and the cell activity of <b>3</b>.</div><div class="NLM_p">The improvement in affinity for ATR observed for some compounds cannot be attributed to new hydrogen bonding interactions formed between the five-membered heteroaryl rings and the ATR active site. For example, the O-1 and the N-2 atoms of compound <b>10</b> that are accessible to the enzyme are the same as those of compound <b>4</b>; yet these compounds have substantially different inhibition constants (26 nM and 1 nM, respectively). Instead, the observed differences in affinity can be predicted by the conformational energy differences between the bioactive and alternative conformations listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compound <b>4</b> favors the bioactive conformation as this aligns the isoxazole oxygen and CH with the 2-aminopyrazine NH<sub>2</sub> and ring nitrogen, respectively. For compounds <b>10</b> and <b>11</b>, the alternative conformation is favored by 3.8 and 1.7 kcal/mol, respectively, over the bioactive conformation and these energetic penalties are reflected in their elevated <i>K</i><sub>i</sub> values. For compound <b>11</b> to assume the bioactive conformation the aromatic proton of the oxazole ring would need to sit opposite a proton of the hinge binder amine. For compound <b>10</b>, the electrostatic misalignment is less obvious since in both conformations a hydrogen bond acceptor, either the O-1 or N-4 of the 1,2,4-oxadiazole, sits opposite the 2-aminopyrazine 4-nitrogen or amine. The calculated preference for the alternative conformation is in agreement with the observation that aromatic oxygen atoms are weaker hydrogen bond acceptors than aromatic nitrogens.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The alternative conformation, which places the oxadiazole O-1 opposite the pyrazine ring nitrogen, is thus preferred as a consequence of the relatively lower electrostatic repulsion between these two acceptors compared to the repulsion between two nitrogen atoms in the bioactive conformation.</div><div class="NLM_p">Compounds <b>4</b>, <b>8</b>, and <b>12</b> maintain low nanomolar potency against ATR as predicted by the negative relative conformational energies of −4.6, −7.8, and −6.7 kcal/mol, respectively, favoring the bioactive conformation. In compound <b>9</b>, an aromatic nitrogen atom of the 1,2,4-oxadiazole is always positioned opposite the pyrazine ring acceptor. The energy difference between the two conformations is small, but the bioactive conformation is still preferred as confirmed by its low nanomolar <i>K</i><sub>i</sub>. Aromatic sulfur atoms carry a small positive charge and are known to interact favorably with hydrogen bond acceptors.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> This favorable interaction is reflected in the largest negative energy difference calculated for the thiadiazole <b>13</b>, indicating a strong preference for the bioactive conformation.</div><div class="NLM_p">Although ligand preorganization is only one of several factors contributing to the free energy of binding, the calculated conformational energy differences for fully aromatic five-membered rings still show a reasonable trend when plotted against the measured inhibition constants (<i>R</i><sup>2</sup> = 0.72). Overall, the calculated energy differences provided useful guidance for the design of heteroaryl amide replacements.</div><div class="NLM_p">The isoxazole <b>4</b> was selected as a starting point for further optimization because of its superior selectivity profile against unrelated kinases, for example, GSK3β (<b>4</b><i>K</i><sub>i</sub> = 650 nM, <b>7</b><i>K</i><sub>i</sub> = 530 nM, <b>8</b><i>K</i><sub>i</sub> = 22 nM). The phenyl ring of the isoxazole <b>4</b> is predicted to extend deep under the P-loop of ATR near a negatively charged area in our ATR kinase homology model (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). We speculated that this negatively charged environment could be exploited by amines projected from the para position to improve both binding affinity and aqueous solubility. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows enzyme inhibition constants and cell based IC<sub>50</sub> values for a selection of compounds containing para amine substituted benzyl rings.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Compound <b>4</b> docked in a homology model of the ATR active site based on PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a> with ATR represented by its electrostatic potential map. An area of high negative charge (in red) is located to the right of the phenyl ring of compound <b>4</b>. (b) Compound <b>2</b> docked into the active site of ATR. Hydrogen bonds to the hinge, the unique residues Gly2385, Asn2480 and Asp2494 that are part of the conserved magnesium binding site and salt bridge are indicated. Polar residues around the phenyl ring are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enzyme Inhibition Constants, pH2AX Cell Assay IC<sub>50</sub> Values, and Aqueous Solubility for 3-Isoxazole-2-aminopyrazine ATR Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0015.gif" alt="" id="GRAPHIC-d7e1170-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0016.gif" alt="" id="gr13" /></img><div></div></div><div class="NLM_p">Introduction of a benzylamine motif, <b>14</b>, resulted in improved ATR affinity (<i>K</i><sub>i</sub> of 270 pM, cf. 1.3 nM for <b>3</b>); however cell activity was compromised. This may be attributed to poor cell penetration associated with a highly solvated primary amine with a low calculated log <i>D</i> of 0.76. Small amine substituents, to form a secondary amine such as in <b>2</b>, improved cell activity substantially (e.g., 0.019 μM for <b>2</b> vs 1.1 μM for <b>4</b>). The introduction of secondary amines also led to a significant reduction in calculated log <i>D</i> (from 3.6 for compound <b>4</b> to 1.1 for <b>2</b>) with a concomitant increase in aqueous solubility (cf. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Larger amine substituents such as the ethyl in <b>15</b> and pyranyl in <b>16</b> provided only limited improvement in terms of affinity and cell potency over the methylamine <b>2</b>.</div><div class="NLM_p">As an alternative approach to modulate the properties of the primary amine, we considered alkylation of the benzylic position and prepared the two stereoisomers of a methyl substituent on the benzylamine methylene. This was most effective for the <i>R</i>-stereoisomer, which retained good ATR affinity and a substantial improvement in cell potency compared with <b>4</b>. Although introduction of the α-methyl group markedly improved the potency in the pH2AX cell assay compared to <b>14</b>, N-alkylation, as in <b>2</b>, yielded lower cell assay IC<sub>50</sub> values (19 nM for <b>2</b> vs 130 nM for <b>18</b>). Further hydrophobic substitutions on the ortho and meta positions of the phenyl ring in <b>19</b> and <b>20</b> lost potency in both the ATR enzyme and pH2AX cell assays. We speculate that this may be due to the polar local environment and limited available space around the phenyl ring in the ATP binding site.</div><div class="NLM_p">In general little correlation was observed between measured and calculated log <i>D</i> and p<i>K</i><sub>a</sub> values and activity in cellular assays. For example, although compound <b>16</b> had a markedly lower measured p<i>K</i><sub>a</sub> value of 8.2 versus 9.7 for compound <b>2</b>, both compounds are essentially equipotent in the pH2AX cell assay. Despite its relatively high p<i>K</i><sub>a</sub>, compound <b>2</b> showed good permeability in a Caco2 assay (A–B 7.2 × 10<sup>–6</sup> cm/s with an efflux ratio of 2.9). From the set of heteroalkyl secondary amines explored on the isoxazole scaffold, only compounds <b>15</b> and <b>16</b> showed activity comparable to that of compound <b>2</b> in the pH2AX cell assay, and out of these only <b>2</b> and <b>15</b> combined this with good aqueous solubility.</div><div class="NLM_p">Introduction of primary or secondary amines had no impact on affinity for DNA-PK but did increase affinity for ATM kinase (<i>K</i><sub>i</sub> of 44 nM for <b>2</b>, cf. 1400 nM for <b>4</b>) as the amino acids near the benzylamine are conserved between ATR and ATM. For DNAPK, any favorable effects of introducing the benzylamine on binding affinity may be canceled out by the proximity of the positive charge of the unique Arg3733 residue in the P-loop of DNAPK. Despite this increase in ATM enzyme affinity, selectivity for ATR over ATM is maintained at >200-fold.</div><div class="NLM_p">The overall selectivity profile of <b>2</b> was established by testing the compound against a large panel of unrelated kinases at a concentration of 400 nM. 278 out of 291 kinases tested showed <50% inhibition at 400 nM (assuming a competitive mechanism of action and under the conditions of the experiment, this corresponds to an estimated <i>K</i><sub>i</sub> of >200 nM and >1000-fold selectivity for ATR). Inhibition constants for the 13 remaining kinases were determined and are listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Of these only Flt4 kinase showed less than 100-fold selectivity, with an estimated <i>K</i><sub>i</sub> of 8 nM, which corresponds to a selectivity of ∼50-fold.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Human Kinases with Enzyme Inhibition Constants <i>K</i><sub>i</sub> < 200 nM for Compound <b>2</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATR</td><td class="colsep0 rowsep0" align="left">0.165</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl(T315I)</td><td class="colsep0 rowsep0" align="left">59<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit(D816H)</td><td class="colsep0 rowsep0" align="left">39<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYRK2</td><td class="colsep0 rowsep0" align="left">26<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3(D835Y)</td><td class="colsep0 rowsep0" align="left">18<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3</td><td class="colsep0 rowsep0" align="left">130</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt4</td><td class="colsep0 rowsep0" align="left">8<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3a</td><td class="colsep0 rowsep0" align="left">33<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3b</td><td class="colsep0 rowsep0" align="left">140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mer</td><td class="colsep0 rowsep0" align="left">30<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLK1</td><td class="colsep0 rowsep0" align="left">15<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3Kinase (p110α/p85α)</td><td class="colsep0 rowsep0" align="left">140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SYK</td><td class="colsep0 rowsep0" align="left">190</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> estimated based on the ATP concentration in the assay being equal to the Michaelis constant (<i>K</i><sub>m</sub>) for ATP and inhibition is through an ATP-competitive mechanism of action. All data were obtained from a minimum of two replicates.</p></div></div></div><div class="NLM_p">Compound <b>2</b> was selected as the clinical candidate based on its overall profile in terms of potency, selectivity, and solubility. A ligand interaction diagram detailing nearby residues and key hydrogen bonds involving compound <b>2</b> as docked into our ATR homology model is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. This compound showed >200-fold selectivity over cytochrome P450s (IC<sub>50</sub> values against Cyp3A4, 2C9, and 2D6 all >30 μM) and the hErg potassium ion channel (IC<sub>50</sub> = 3 μM). Compound <b>2</b> had a favorable whole blood iv pharmacokinetic profile in male Sprague-Dawley rats (Cl = 26 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> = 21 L/kg; <i>T</i><sub>1/2</sub> = 11.6 h) and oral bioavailability to support in vivo efficacy studies.<a onclick="showRef(event, 'ref8 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref12">(8,12)</a></div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Ligand interaction diagram showing nearby residues, aromatic stacking (green lines), and key hydrogen bonds (purple lines) involving compound <b>2</b> as docked into our ATR homology model derived from PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In cell experiments, compound <b>2</b> markedly sensitized the HCT116 colorectal cell line to the DNA cross-linking agent cisplatin, at concentrations of <b>2</b> of <50 nM, which compares with far higher concentrations of <b>1</b> required to achieve the same levels of cisplatin sensitization (∼500 nM). <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> compares the synergy profiles observed for combinations of cisplatin with compound <b>1</b> or compound <b>2</b> across a range of concentrations. The potential for <b>2</b> to sensitize cancer cells to other DNA damaging agents or radiation has been extensively reported in a range of in vitro and in vivo tumor models.<a onclick="showRef(event, 'ref8 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref11 ref12">(8,11,12)</a> The iv administration of compound <b>2</b> is currently being evaluated in phase I/II clinical studies as monotherapy and in combination with several DNA damaging chemotherapies and radiation therapy for the treatment of solid tumors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Macsynergy plots for compounds <b>1</b> and <b>2</b> dosed in combination with cisplatin in an HCT116 MTS cell assay. Synergistic or antagonistic interactions between ATR inhibitors and cisplatin are represented as deviations above or below the plane (at <i>z</i> = 0) that corresponds to additivity. Compound <b>2</b> achieves similar synergy with cisplatin as <b>1</b> at a ∼10-fold lower concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multiple preclinical studies have shown that ATR inhibition renders many cancer cells, but not noncancer cells, highly sensitive to certain DNA damaging drugs that are widely used in cancer therapy. This differential has been attributed to the ability of noncancer cells to utilize compensatory DNA repair processes, which are commonly impaired in cancer. Furthermore, ATR inhibition has been shown to sensitize cancer cells to other inhibitors of DNA repair such as PARP and Chk1 inhibitors and can have single agent activity in specific cancer cells. Compound <b>1</b> was the first potent and selective ATR inhibitor to be reported and is widely used as an in vitro tool; however, it is limited by poor physical properties and pharmacokinetics. In this manuscript we have described the optimization of <b>1</b> to afford <b>2</b> (VX-970, also known as M6620), the first ATR kinase inhibitor to enter clinical trials. Substantial improvements in ATR affinity, physical properties, and PK were achieved primarily by optimizing the anilide moiety of <b>1</b>. An isoxazole ring substituted with a secondary benzylamine was found to be the optimal replacement for the anilide moiety of <b>1</b> leading to improved ATR affinity, selectivity, aqueous solubility, and activity in cell assays. Compound <b>2</b> maintained >100-fold selectivity over related kinases and unrelated proteins such as hErg and P450 enzymes and had PK properties suitable for iv administration.</div><div class="NLM_p">Three factors helped to optimize the potency and physical properties of compound <b>1</b>. The first was to maximize steric fit to the active site of ATR. While flat, five-membered heteroaryl linkers maintained good ATR affinity, a significant loss of potency was observed for the partially saturated 4,5-dihydroisoxazole <b>5</b> compared to its fully aromatic isoxazole counterpart <b>4</b>. The more three-dimensional shape of <b>5</b>, due to its sp<sup>3</sup> carbon linking the 4,5-dihydroisoxazole to the 2-aminopyrazine, results in the compound incurring an energy penalty when binding to the ATR binding site in a flattened conformation.</div><div class="NLM_p">A second factor was the degree of electrostatic complementarity between the five-membered heteroaryl ring and the 2-aminopyrazine hinge binder. In all cases, except for the 1,2,4-oxadiazole <b>10</b> and the oxazole <b>11</b>, the interactions between the two rings favor the bound conformation as predicted by quantum chemical calculations. Furthermore, the magnitude of the gas phase energy differences between the two possible conformations for each of the inhibitors correlated with ATR enzyme affinity, and as such, this calculation provided a convenient tool for predicting optimal heterocyclic scaffold modifications.</div><div class="NLM_p">Third, we optimized polar interactions between the inhibitor and the ATP binding site of ATR by substituting the phenylisoxazole of <b>4</b> at the para position with amines. Compound <b>2</b>, with a simple <i>N</i>-methylbenzylamine motif, achieved an 8-fold improvement in affinity compared to its unsubstituted counterpart <b>4</b> along with greatly improved cell potency, aqueous solubility, and pharmacokinetics.</div><div class="NLM_p last">The 5-heteroaryl containing inhibitors reported in this study present a new chemical motif for potent ATR kinase inhibition. The resulting compound, <b>2</b> (VX-970/M6620), is currently being evaluated in phase I/II clinical studies in combination with several DNA damaging chemotherapies and PARP inhibitors and as monotherapy for the treatment of solid tumors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General Synthetic Methods</h3><div class="NLM_p last">All commercially available solvents and reagents were used as received. Microwave reactions were carried out using a CEM Discovery microwave. Analytical thin layer chromatography was carried out using glass-backed plates coated with Merck Kieselgel 60 GF<sub>240</sub>. Plates were visualized using UV light (254 or 366 nm) and/or by staining with potassium permanganate followed by heating. Flash chromatography was carried out on an ISCO Combiflash Companion system eluting with a 0–100% EtOAc/petroleum ether gradient. Samples were applied preabsorbed on silica. Semipreparative reverse phase HPLC was carried out on a Waters autopurification HPLC–MS system equipped with a Waters C-18 Sunfire reverse phase column (19 mm × 150 mm, 5 mm). The mobile phases were acetonitrile (0.1% trifluoroacetic acid) and water (0.1% trifluoroacetic acid). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded at 400 or 500 MHz and 125 or 100 MHz, using a Bruker DPX 400 instrument or a Bruker DPX 500 instrument. MS samples were analyzed on a MicroMass Quattro Micro mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using chromatography. All final products had a purity of ≥95%, unless specified otherwise in the experimental details. The purity of the final compounds was determined using HPLC method: analytical reverse phase HPLC–MS was carried out on an agilent 100 HPLC with a Waters Quattro MS system equipped with an ACE 5 mm C-18 reverse phase column (4.6 mm × 150 mm, 5 mm). The mobile phases were acetonitrile/methanol (1:1) and water (10 mM ammonium acetate).</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (<b>2</b>)</h3><div class="NLM_p">To a solution of <i>N</i>,<i>N</i>-di(<i>tert</i>-butoxycarbonyl)-5-(4-(isopropylsulfonyl)phenyl)-3-ethynylpyrazin-2-amine <b>25</b> (6.8 g, 13.56 mmol) and <i>N</i>-hydroxy-4-methylbenzimidoyl chloride (2.71 g, 13.56 mmol) in THF (140 mL) at room temperature was added triethylamine (1.65 g, 2.27 mL, 16.27 mmol) dropwise over l0 min. The mixture was stirred at room temperature overnight then at 60 °C for 2 h. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and brine (50 mL). The organic layer was washed with an aqueous saturated solution of NaHCO<sub>3</sub> (50 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The residue was purified by chromatography on silica gel, eluting with 20% EtOAc/petroleum ether to give <i>N</i>,<i>N</i>-di(<i>tert</i>-butoxycarbonyl)-5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-methyl)phenylisoxazol-5-yl)pyrazin-2-amine as an off-white solid (7.1 g, 82% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, IH), 8.66 (m, 2H), 8.07 (m, 2H), 8.01 (s, 1H), 7.92 (m, 2H), 7.39 (m, 2H), 3.55 (m, 1H), 3.34 (s, 3H), 1.33 (s, 18H), 1.21 (m, 6H); MS (ES+) <i>m</i>/<i>z</i> 635.3 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <i>N</i>,<i>N</i>-di(<i>tert</i>-butoxycarbonyl)-5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-methyl)phenylisoxazol-5-yl)pyrazin-2-amine (3.5 g, 5.51 mmol) in ethyl acetate (35 mL) was added <i>N</i>-bromosuccinimide (1.28 g, 7.17 mmol), followed by AIBN (180 mg, 1.1 mmol). The resulting mixture was placed under a bright lamp and heated to 85 °C for l h. The reaction mixture was allowed to cool to ambient temperature, washed sequentially with brine (50 mL) and an aqueous saturated solution of NaHCO<sub>3</sub> (50 mL), then filtered, dried over MgSO<sub>4</sub>, and concentrated in vacuo to afford <i>N</i>,<i>N</i>-di(<i>tert</i>-butoxycarbonyl)-5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-bromomethyl)phenylisoxazol-5-yl)pyrazin-2-amine as a pale brown foam (4.56 g), which was used directly in the next stage without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.52 (s, 1H), 8.65 (m, 2H), 8.03–8.09 (m, 4H), 7.66 (m, 2H), 4.80 (s, 2H), 3.57 (m, 1H), 1.31 (s, 18H), 1.21 (m, 6H); MS (ES+) <i>m</i>/<i>z</i> 715.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A solution of crude <i>N</i>,<i>N</i>-di(<i>tert</i>-butoxycarbonyl)-5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-bromomethyl)phenylisoxazol-5-yl)pyrazin-2-amine (60 mg, 0.084 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added to methylamine (791 mg, 8.41 mmol) in ethanol (3 mL). The reaction mixture was stirred at room temperature for 1 h. The solvent was then removed in vacuo to provide an oil, which was dissolved in a mixture of CH<sub>2</sub>C1<sub>2</sub> (5 mL) and TFA (479 mg, 4.2 mmol). The reaction mixture was stirred at room temperature for 1 h, then concentrated in vacuo. The residue was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 μm, 100 Å column, gradient 10–95% B (solvent A, 0.05% TFA in water; solvent B, CH<sub>3</sub>CN)]. The product fractions were eluted through a bicarbonate cartridge and lyophilized to give 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine <b>2</b> as a yellow solid (13.6 mg, 28% yield over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1 H), 8.85 (br s, 2H), 8.43 (m, 2H), 8.12 (m, 2H), 7.85 (m, 2H), 7.82 (s, 1H), 7.65 (m, 2H), 7.26 (br s, 2H), 4.21–4.25 (m, 2H), 3.55 (m, <i>J</i> 7.5 Hz, 1H), 2.61–2.65 (m, 3H), 1.22 (d, <i>J</i> 7.5 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.35, 162.38, 152.08, 143.00, 141.66, 138.04, 136.14, 134.81, 131.27, 129.64, 129.10, 127.43, 126.17, 124.86, 102.76, 54.68, 51.10, 32.25, 15.56; MS (ES+) 464.4; HRMS (ES+) calcd for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 464.1751; found 464.1754.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> 3-Amino-6-(4-(isopropylsulfonyl)phenyl)-<i>N</i>-phenylpyrazine-2-carboxamide (<b>3</b>)</h3><div class="NLM_p last">3-Amino-6-(4-isopropylsulfonylphenyl)pyrazine-2-carboxylic acid <b>22</b> (0.8 g, 2.5 mmol), diethoxyphosphorylformonitrile (677 mg, 620 μL, 3.73 mmol), aniline (348 mg, 340 μL, 3.73 mmol), and triethylamine (504 mg, 694 μL, 5 mmol) were stirred in 1,2-dimethoxyethane (10 mL) at 120 °C for 18 h. Water (20 mL) was added, and the solid was collected by filtration. The residue was washed with diethyl ether (20 mL) and dried in vacuo to afford <b>3</b> as a yellow solid. (950 mg, 96% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H), 9.05 (s, 1H), 8.53 (d, <i>J</i> 8.5 Hz, 2H), 7.93 (d, <i>J</i> 8.5 Hz, 2H), 7.82 (d, <i>J</i> 7.8 Hz, 2H), 7.41 (t, <i>J</i> 7.8 Hz, 2H), 7.18 (m, 1H), 3.48 (m, <i>J</i> 6.8 Hz, 1H), 1.19 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.72, 155.14, 145.80, 141.17, 138.20, 136.74, 136.16, 129.36, 128.99, 126.56, 124.87, 124.68, 121.62, 54.56, 15.59; MS (ES+) <i>m</i>/<i>z</i> 397.3 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 397.1334; found 397.1343.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-phenylisoxazol-5-yl)pyrazin-2-amine (<b>4</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>,<i>N</i>-bis-<i>tert</i>-butoxycarbonyl-3-ethynyl-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>25</b> (300 mg, 0.6 mmol) and <i>N</i>-hydroxybenzimidoyl chloride (93.0 mg, 0.6 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (3 mL) was added triethylamine (60.5 mg, 83.4 μL, 0.6 mmol). The mixture was warmed to 60 °C for 45 min. The mixture was diluted with ethyl acetate (20 mL), washed sequentially with water (20 mL) and brine (20 mL). The organic layer was separated and dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), and TFA (2.05 g, 1.4 mL, 17.94 mmol) was added. The mixture was stirred at ambient temperature for 1 h and then concentrated in vacuo. The residue was purified by reverse phase HPLC [Waters Sunfire C18, 10 μm, 100 Å column, gradient 10– 95% B (solvent A, 0.05% TFA in water; solvent B, CH<sub>3</sub>CN)] to give 5-(4-(isopropylsulfonyl)phenyl)-3-(3-phenylisoxazol-5-yl)pyrazin-2-amine <b>4</b> as a yellow solid (136 mg, 52% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.44 (m, 2H), 8.01–8.06 (m, 2H), 7.95 (m, 2H), 7.67 (s, 1H), 7.55–7.63 (m, 2H), 7.22–7.35 (m, 2H), 3.47 (m, <i>J</i> 6.9 Hz, 1H), 1.14 (d, <i>J</i> 6.9 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.93, 163.52, 153.04, 143.78, 142.32, 138.82, 137.00, 131.76, 131.74, 130.44, 129.54, 128.08, 126.96, 125.72, 103.46, 55.46, 16.47; MS (ES+) <i>m</i>/<i>z</i> 421.3 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 421.1334; found 421.1339.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-phenyl-4,5-dihydroisoxazol-5-yl)pyrazin-2-amine (<b>5</b>)</h3><div class="NLM_p last">To a solution of 5-(4-isopropylsulfonylphenyl)-3-vinyl-pyrazin-2-amine <b>26</b> (20 mg, 0.066 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (2 mL) was added <i>N</i>-hydroxybenzimidoyl chloride (13.3 mg, 0.086 mmol), followed by dropwise addition of triethylamine (20 mg, 28 μL, 0.198 mmol). The mixture was stirred at ambient temperature for 20 min, then heated to 65 °C for 1 h. The mixture was cooled to room temperature and diluted with ethyl acetate (5 mL) and water (5 mL), and the layers were separated. The aqueous layer was extracted further with ethyl acetate (5 mL × 2), and the combined organic extracts were washed with water (10 mL × 3), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The product was purified by reverse phase HPLC [Waters Sunfire C18, 10 μm, 100 Å column, gradient 10–95% B (solvent A, 0.05% TFA in water; solvent B, CH<sub>3</sub>CN)] to give 5-(4-(isopropylsulfonyl)phenyl)-3-(3-phenyl-4,5-dihydroisoxazol-5-yl)pyrazin-2-amine <b>5</b> as a white solid (16 mg, 58% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (s, 1H), 8.22 (m, 2H), 7.78–7.85 (m, 4H), 7.48–7.53 (m, 3H), 6.95 (br s, 2H), 6.02 (m, 1H), 4.28 (m, 1H), 3.75 (m, 1H), 3.44 (m, <i>J</i> 6.8 Hz, 1H), 1.15 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.78, 154.40, 142.19, 141.24, 136.48, 136.02, 135.65, 130.70, 129.67, 129.56, 129.37, 127.26, 125.53, 78.88, 54.65, 37.03, 15.66; MS (ES+) <i>m</i>/<i>z</i> 423.4 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 423.1491; found 423.1487.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)pyrazin-2-amine (<b>6</b>)</h3><div class="NLM_p"><i>N</i>,<i>N</i>-Bis-<i>tert</i>-butoxycarbonyl-3-ethynyl-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>25</b> (380 mg, 0.76 mmol) and azidobenzene (0.5 M in MTBE) (3.03 mL of 0.5 M, 1.52 mmol) were suspended in <i>t-</i>BuOH/water (1/1; 15 mL). (+)-Sodium <span class="smallcaps smallerCapital">l</span>-ascorbate (30 mg, 0.15 mmol) followed by CuSO<sub>4</sub>·5H<sub>2</sub>O (3.8 mg, 0.02 mmol) was added and the reaction allowed to stir at 40 °C for 48 h. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate (50 mL), then washed sequentially with water (50 mL) and brine (50 mL × 2). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica, using an ethyl acetate/petroleum ether gradient as eluent, to provide crude <i>tert</i>-butyl <i>N-tert</i>-butoxycarbonyl-<i>N</i>-[5-(4-isopropylsulfonylphenyl)-3-(1-phenyltriazol-4-yl)pyrazin-2-yl]carbamate as an off-white solid (193 mg, 41% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.73 (s, 1H), 9.36 (s, 1H), 8.68 (d, <i>J</i> 8.4 Hz, 2H), 8.09 (d, <i>J</i> 8.4 Hz, 2H), 8.04–8.08 (m, 2H), 7.66–7.70 (m, 2H), 7.57 (m, 1H), 3.55 (m, <i>J</i> 6.8 Hz, 1H), 1.27 (s, 18H), 1.191 (d, <i>J</i> 6.8 Hz, 6H); MS (ES+) <i>m</i>/<i>z</i> 465.1.</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl <i>N-tert</i>-butoxycarbonyl-<i>N</i>-[5-(4-isopropylsulfonylphenyl)-3-(1-phenyltriazol-4-yl)pyrazin-2-yl]carbamate (193 mg, 0.31 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added TFA (1 mL). The reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated in vacuo, and the residue was sonicated in acetonitrile (5 mL). The solid was collected by filtration and dried by suction providing 5-(4-(isopropylsulfonyl)phenyl)-3-(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)pyrazin-2-amine <b>6</b> as a pale yellow solid (105 mg, 80% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.66 (s, 1H), 8.85 (s, 1H), 8.46 (m, 2H), 8.12 (m, 2H), 7.91 (m, 2H), 7.74 (br s, 2H), 7.67 (m, 2H), 7.58 (m, 1H), 3.47 (m, <i>J</i> 6.8 Hz, 1H), 1.19 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.28, 148.04, 142.08, 140.53, 137.22, 136.85, 135.86, 130.40, 129.74, 129.48, 128.22, 125.99, 123.44, 121.08, 54.72, 15.71; MS (ES+) <i>m</i>/<i>z</i> 421.1 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>21</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (M + H)<sup>+</sup> 421.1447; found 421.1445.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenylisoxazol-3-yl)pyrazin-2-amine (<b>7</b>)</h3><div class="NLM_p">3-Amino-6-(4-isopropylsulfonylphenyl)pyrazine-2-carboxylic acid <b>22</b> (10 g, 31.1 mmol) was dissolved in tetrahydrofuran (80 mL), and the mixture was cooled in an ice-bath. <i>N</i>-Methoxymethanamine hydrochloride (3.6 g, 37.3 mmol), 1-hydroxybenzotriazole hydrate (5.2 g, 34.2 mmol), DIPEA (8 g, 10.8 mL, 62.2 mmol), and 3-(ethyliminomethyleneamino)-<i>N</i>,<i>N</i>-dimethyl-propan-1-amine (5.3 g, 34.2 mmol) were added to the cooled solution. The mixture was allowed to warm to ambient temperature and stirred for 18 h. The mixture was concentrated in vacuo and the residue separated between ethyl acetate (200 mL) and water (200 mL). The organic phase was washed sequentially with saturated bicarbonate (200 mL) and brine (200 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica, eluting with 30% ethyl acetate/petroleum ether to afford 3-amino-6-(4-isopropylsulfonylphenyl)-<i>N</i>-methoxy-<i>N</i>-methylpyrazine-2-carboxamide (8.8 g, 77% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.80 (s, 1H), 8.22 (d, 2H), 7.92 (m, 2H), 6.95 (br s, 2H), 3.65–3.71 (m, 3H), 3.41–3.50 (m, 1H), 2.73 (s, 3H), 1.21 (d, 6H); MS (ES+) <i>m</i>/<i>z</i> 365.4 (M + H)<sup>+</sup>.</div><div class="NLM_p">3-Amino-6-(4-isopropylsulfonylphenyl)-<i>N</i>-methoxy-<i>N</i>-methylpyrazine-2-carboxamide (5 g, 13.72 mmol) was dissolved in tetrahydrofuran (60 mL) and cooled to −20 °C. Methylmagnesium bromide (25.2 mL of 3 M, 75.46 mmol) was added dropwise, and the mixture was stirred at −20 °C for 1 h. The reaction was quenched by dropwise addition of saturated ammonium chloride solution (3 mL), then was allowed to warm to ambient temperature. The mixture was concentrated in vacuo to an oil, diluted with ethyl acetate (50 mL), and washed sequentially with water (50 mL) and brine (50 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purifed by column chromatography on silica, eluting with 50–80% ethyl acetate/petroleum ether to afford 1-[3-amino-6-(4-isopropylsulfonylphenyl)pyrazin-2-yl]ethanone as a yellow solid (3.5 g, 80% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.12 (s, 1H), 8.35 (d, 2H), 8.02–7.85 (m, 2H), 3.50–3.42 (m, 1H), 2.71 (s, 3H), 1.21 (d, 6H); MS (ES+) <i>m</i>/<i>z</i> 320.1 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of benzaldehyde (332 mg, 318 μL, 3.13 mmol) and 1-[3-amino-6-(4-isopropylsulfonylphenyl)pyrazin-2-yl]ethanone (1 g, 3.13 mmol) in a mixture of MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/1; 20 mL) was added sodium hydroxide (12.5 mL of 10% w/v, 3.13 mmol) in methanol. The mixture was stirred at ambient temperature for 18 h and then concentrated in vacuo. The residue was diluted with ethyl acetate (30 mL), washed sequentially with water (30 mL) and brine (30 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purifed by column chromatography on silica, eluting with ethyl acetate to afford 1-[3-amino-6-(4-isopropylsulfonylphenyl)pyrazin-2-yl]-3-phenylprop-2-en-1-one as a yellow solid (900 mg, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.82 (s, 1H), 8.50 (d, <i>J</i> 16 Hz, 1H), 8.22 (d, <i>J</i> 8.8 Hz, 2H), 8.06 (d, <i>J</i> 8.8 Hz, 2H), 7.94 (d, <i>J</i> 16 Hz, 1H), 7.74–7.77 (m, 2H), 7.48–7.50 (m, 3H), 3.28 (m, <i>J</i> 7.2 Hz, 1H), 1.38 (d, <i>J</i> 7.2 Hz, 6H); MS (ES+) <i>m</i>/<i>z</i> 408.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of 1-[3-amino-6-(4-isopropylsulfonylphenyl)pyrazin-2-yl]-3-phenylprop-2-en-1-one (50 mg, 0.12 mmol) in ethanol (1 mL) were added hydroxylamine hydrochloride (8.5 mg, 0.12 mmol) and a solution of sodium acetate (10.1 mg, 0.12 mmol) in warm acetic acid (0.3 mL). The reaction was heated under microwave conditions for 1 h at 130 °C. The mixture was concentrated in vacuo, and the residue was diluted with ethyl acetate (10 mL) and washed sequentially with water (10 mL) and brine (10 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was redissolved in methanol and then purified by reverse phase HPLC [Waters Sunfire C18, 10 μm, 100 Å column, gradient 10–95% B (solvent A, 0.05% TFA in water; solvent B, CH<sub>3</sub>CN)] to give 5-(4-(isopropylsulfonyl)phenyl)-3-(5-phenylisoxazol-3-yl)pyrazin-2-amine <b>7</b> as a yellow solid (8 mg, 17% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.42 (m, 2H), 8.02–8.05 (m, 2H), 7.93 (m, 2H), 7.78 (s, 1H), 7.55–7.61 (m, 3H), 7.27 (br s, 2H), 3.55 (m, <i>J</i> 6.9 Hz, 1H), 1.22 (d, <i>J</i> 6.9 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.65, 161.23, 150.76, 141.50, 140.03, 136.52, 134.71, 129.45, 128.17, 128.15, 127.25, 125.79, 124.67, 123.43, 101.18, 53.18, 14.18; MS (ES+) <i>m</i>/<i>z</i> 421.1 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 421.1334; found 421.1354.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-amine (<b>8</b>)</h3><div class="NLM_p last">To a mixture of (4-isopropylsulfonylphenyl)boronic acid (47.8 mg, 0.21 mmol) and 5-bromo-3-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-amine <b>28</b> (66.5 mg, 0.21 mmol) in dioxane (3 mL) was added Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (171 mg, 0.21 mmol), followed by sodium carbonate (2.1 mL of 2 M, 4.2 mmol). The reaction mixture was subjected to microwave irradiation at 100 °C for 25 min. The mixture was then diluted with water (10 mL) and extracted with EtOAc (10 mL × 2). The combined organic extracts were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica, using a diethyl ether/petroleum ether gradient as eluent, to give 5-(4-(isopropylsulfonyl)phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-amine <b>8</b> as an orange solid (60 mg, 69% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.06 (s, 1H), 8.40 (m, 2H), 8.19–8.17 (m, 2H), 7.98 (m, 4H), 7.72–7.66 (m, 3H), 3.47 (m, <i>J</i> 6.8 Hz, 1H), 1.20 (d, <i>J</i> 6.8 Hz, 6H); MS (ES+) <i>m</i>/<i>z</i> 422.0 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 422.1287; found 422.1283.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenyl-1,2,4-oxadiazol-3-yl)pyrazin-2-amine (<b>9</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>8</b>, using 5-bromo-3-(5-phenyl-1,2,4-oxadiazol-3-yl)pyrazin-2-amine <b>31</b>. 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenyl-1,2,4-oxadiazol-3-yl)pyrazin-2-amine <b>9</b> was obtained as a pale orange solid (44.9 mg, 34% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.18 (m, 2H), 8.12 (m, 2H), 7.79 (m, 2H), 7.61 (m, 1H), 7.53 (m, 2H), 7.42 (br s, 2H), 3.29 (m, <i>J</i> 6.8 Hz, 1H), 1.02 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.45, 167.51, 153.68, 144.06, 141.50, 138.15, 136.14, 134.00, 129.99, 129.64, 128.60, 126.09, 123.50, 123.21, 54.60, 15.59; MS (ES+) <i>m</i>/<i>z</i> 422.2 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 422.1287; found 422.1298.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-phenyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine (<b>10</b>)</h3><div class="NLM_p last">To a solution of 3-amino-6-(4-isopropylsulfonylphenyl)pyrazine-2-carboxylic acid <b>22</b> (250 mg, 0.77 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (7.5 mL) was added carbonyldiimidazole (249.2 mg, 1.54 mmol), and the resulting solution was stirred at ambient temperature for 1 h. <i>N</i>′-Hydroxybenzamidine (86.6 mg, 0.64 mmol) was added and the reaction stirred at ambient temperature for a further 2.5 h, then heated to 120 °C for 1.5 h. The reaction mixture was cooled to ambient temperature and added slowly to water (20 mL). The resulting precipitate was filtered, triturated from CH<sub>2</sub>Cl<sub>2</sub>/methanol (1/1, 10 mL), isolated by filtration, and dried in vacuo at 40 °C to give 5-(4-(isopropylsulfonyl)phenyl)-3-(3-phenyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine <b>10</b> as a yellow solid (177 mg, 67% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.16 (s, 1H), 8.37 (m, 2H), 8.26 (m, 2H), 8.07 (br s, 2H), 7.98 (m, 2H), 7.68–7.61 (m, 3H), 3.48 (m, <i>J</i> 6.8 Hz, 1H), 1.20 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.90, 168.02, 153.71, 146.42, 141.05, 138.42, 136.46, 132.25, 129.70, 129.65, 127.82, 126.22, 126.13, 119.48, 54.58, 15.58; MS (ES+) <i>m</i>/<i>z</i> 422.2 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 422.1287; found 422.1283.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(2-phenyloxazol-5-yl)pyrazin-2-amine (<b>11</b>)</h3><div class="NLM_p last">To a mixture of 3-bromo-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine <b>24</b> (88.3 mg, 0.248 mmol) and 2-phenyloxazole (30 mg, 0.21 mmol) in water (3 mL) was added Ag<sub>2</sub>CO<sub>3</sub> (114 mg, 0.41 mmol), followed by PPh<sub>3</sub> (5.4 mg, 0.021 mmol) and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (8.4 mg, 0.010 mmol). The reaction mixture was heated at 70 °C for 24 h before being cooled down and partitioned between CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and water (20 mL). The aqueous layer was extracted further with CH<sub>2</sub>Cl<sub>2</sub> (20 mL × 2), and the combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 μm, 100 Å column, gradient 10–95% B (solvent A, 0.05% TFA in water; solvent B, CH<sub>3</sub>CN)]. The solvents were evaporated to give 5-(4-(isopropylsulfonyl)phenyl)-3-(2-phenyloxazol-5-yl)pyrazin-2-amine <b>11</b> as an off-white solid (25 mg, 29% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (s, 1H), 8.12–8.07 (m, 2H), 8.06–8.01 (m, 2H), 7.97–7.87 (m, 3H), 7.56–7.25 (m, 3H), 3.17 (m, <i>J</i> 6.9 Hz, 1H), 1.27 (d, <i>J</i> 6.9 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.88, 153.04, 151.78, 143.07, 141.75, 137.82, 136.18, 129.76, 129.73, 129.67, 127.47, 126.16, 124.93, 124.16, 122.96, 54.75, 15.74; MS (ES+) <i>m</i>/<i>z</i> 421.0 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 421.1334; found 421.1335.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenyloxazol-2-yl)pyrazin-2-amine (<b>12</b>)</h3><div class="NLM_p last">To a mixture of 3-bromo-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine <b>24</b> (147 mg, 0.413 mmol) and 5-phenyloxazole (49.9 mg, 0.344 mmol) in dioxane (2 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (39.7 mg, 0.034 mmol), followed by lithium <i>tert</i>-butoxide (55 mg, 0.688 mmol). The reaction mixture was heated at 140 °C under microwave irradiation for 3 h. The reaction was cooled to ambient temperature and the mixture was purified by reverse phase chromatography [Waters Sunfire C18, 10 μm, 100 Å column, gradient 10–95% B (solvent A, 0.05% TFA in water; solvent B, CH<sub>3</sub>CN)] to afford 5-(4-(isopropylsulfonyl)phenyl)-3-(5-phenyloxazol-2-yl)pyrazin-2-amine <b>12</b> as an off-white solid (66 mg, 46% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 8.40 (d, <i>J</i> 8.5 Hz, 2H), 8.07 (s, 1H), 7.97 (d, <i>J</i> 8.5 Hz, 2H), 7.94–7.88 (m, 2H), 7.56 (m, 2H), 7.47 (m, 1H), 3.47 (m, <i>J</i> 6.8 Hz, 1H), 1.21 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.47, 151.60, 148.70, 141.84, 140.80, 137.91, 136.08, 131.46, 129.66, 129.16, 129.07, 127.02, 126.87, 126.66, 126.07, 54.72, 15.72; MS (ES+) <i>m</i>/<i>z</i> 421.0 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 421.1334; found 421.1347.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenyl-1,3,4-thiadiazol-2-yl)pyrazin-2-amine (<b>13</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>8</b>, using 5-bromo-3-(5-phenyl-1,3,4-thiadiazol-2-yl)pyrazin-2-amine <b>29</b>. 5-(4-(Isopropylsulfonyl)phenyl)-3-(5-phenyl-1,3,4-thiadiazol-2-yl)pyrazin-2-amine <b>13</b> was obtained as a yellow solid (44.9 mg, 35% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.03 (s, 1H), 8.32 (m, 2H), 8.12–8.18 (m, 3H), 7.98 (m, 2H), 7.61–7.65 (m, 3H), 2.72 (m, <i>J</i> 6.8 Hz, 1H), 1.75 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.60, 169.50, 152.86, 144.74, 141.73, 138.76, 137.06, 132.88, 130.68, 130.43, 130.37, 128.95, 126.74, 126.2, 54.62, 15.63; MS (ES+) <i>m</i>/<i>z</i> 438.0 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub> (M + H)<sup>+</sup> 438.1058; found 438.1056.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 3-(3-(4-(Aminomethyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine (<b>14</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>2</b>, using a methanolic solution of ammonia instead of methylamine. 3-(3-(4-(Aminomethyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>14</b> was obtained as a yellow solid (42% yield over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (s, 1H), 8.21 (br s, 2H), 8.43 (m, 2H), 8.14 (m, 2H), 7.95 (m, 2H), 7.82 (s, 1H), 7.65 (m, 2H), 7.25 (br s, 2H), 4.21–4.25 (m, 2H), 3.55 (m, <i>J</i> 6.8 Hz, 1H), 1.22 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.42, 162.25, 152.27, 143.09, 141.52, 138.12, 136.71, 136.31, 130.06, 129.63, 128.86, 127.49, 126.17, 124.85, 102.70, 54.71, 42.51, 15.70; MS (ES+) <i>m</i>/<i>z</i> 450.4 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 450.1600; found 450.1603.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-(3-(4-((Ethylamino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine (<b>15</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>2</b>, using ethylamine instead of methylamine. 3-(3-(4-((Ethylamino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>15</b> was obtained as a yellow solid (46% yield over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (s, 1H), 8.82 (br m, 1H), 8.41 (m, 2H), 8.10 (m, 2H), 7.95 (m, 2H), 7.82 (s, 1H), 7.65 (m, 2H), 7.25 (br s, 2H), 4.23 (m, 2H), 3.55 (m, <i>J</i> 6.9 Hz, 1H), 3.05 (m, 2H), 1.25 (t, <i>J</i> 7.5 Hz, 3H), 1.22 (d, <i>J</i> 6.9 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.44, 162.21, 152.27, 143.10, 141.52, 138.14, 136.32, 134.81, 131.04, 129.63, 129.29, 127.58, 126.18, 124.83, 102.71, 54.71, 49.74, 42.50, 15.70, 11.45; MS (ES+) <i>m</i>/<i>z</i> 478.4 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 478.1913; found 478.1915.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-(((tetrahydro-2<i>H</i>-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (<b>16</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>2</b>, using 4-aminotetrahydro-2<i>H</i>-pyran instead of methylamine. 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-(((tetrahydro-2<i>H</i>-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine <b>16</b> was obtained as a yellow solid (87% yield over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.93 (s, 1H), 8.37 (m, 2H), 7.93–7.98 (m, 4H), 7.74 (s, 1H), 7.52 (m, 2H), 7.18 (br s, 2H), 3.79–3.82 (m, 4H), 3.44 (m, <i>J</i> 6.8 Hz, 1H), 3.25 (m, 2H), 2.59 (m, 1H), 2.12 (br s, 1H), 1.78 (m, 2H), 1.29 (m, 2H), 1.19 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.56, 162.13, 151.71, 144.04, 142.38, 141.04, 137.57, 135.74, 129.10, 128.45, 126.52, 126.37, 125.65, 124.50, 102.06, 65.79, 54.22, 52.58, 49.18, 33.16, 15.17; MS (ES+) <i>m</i>/<i>z</i> 534.2 (M + H)<sup>+</sup>; HRMS (ES+) calcd for C<sub>28</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>S (M + H)<sup>+</sup> 534.2175; found 534.2173.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-3-(3-(4-(1-Aminoethyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine (<b>17</b>)</h3><div class="NLM_p">To a solution of <i>tert</i>-butyl <i>N</i>-[(1<i>S</i>)-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate (840 mg, 3.34 mmol) in THF (17 mL) was added manganese dioxide (2.9 g, 33.4 mmol). The reaction mixture was stirred at room temperature overnight, then filtered through a pad of Celite, washing through with EtOAc. The filtrate was concentrated in vacuo to afford the crude <i>tert</i>-butyl (<i>S</i>)-(1-(4-formylphenyl)ethyl)carbamate as a colorless oil. This oil was dissolved in ethanol (8 mL), and hydroxylamine (approximately 441 μL of 50% w/v, 6.68 mmol) was added. The resulting solution was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo and partitioned between ethyl acetate (10 mL) and water (10 mL). The aqueous layer was extracted further with ethyl acetate (2 × 10 mL) and the combined organic extracts were dried over MgSO<sub>4</sub> and concentrated in vacuo to provide <i>tert</i>-butyl (<i>S</i>)-(1-(4-((hydroxyimino)methyl)phenyl)ethyl)carbamate as a colorless oil, which was used in the next step without further purification (844 mg, 96%); MS (ES−) <i>m</i>/<i>z</i> 263.0 (M – H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl (<i>S</i>)-(1-(4-((hydroxyimino)methyl)phenyl)ethyl)carbamate (300 mg, 1.14 mmol) in DMF (1.5 mL) was added <i>N</i>-chlorosuccinimide (152 mg, 1.14 mmol), and the reaction mixture was heated at 55 °C for 15 min. The mixture was allowed to cool to room temperature, diluted with ethyl acetate (5 mL) and water (5 mL), and the layers were separated. The aqueous layer was extracted further with ethyl acetate (2 × 5 mL), and the combined organic extracts were washed with water (3 × 5 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was dissolved in THF (7.5 mL), and <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-ethynyl-5-(4-isopropylsulfonylphenyl)pyrazin-2-yl]carbamate (569.3 mg, 1.14 mmol) was added, followed by Et<sub>3</sub>N (190 μL, 1.36 mmol). The mixture was stirred at room temperature for 45 min followed by heating to 65 °C for 4 h. The mixture was cooled to room temperature and diluted with ethyl acetate (5 mL) and water (5 mL), and the layers were separated. The aqueous layer was extracted further with ethyl acetate (2 × 5 mL), and the combined organic extracts were washed with water (3 × 10 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was preabsorbed onto silica and purified by column chromatography, eluting with ethyl acetate/petroleum ether (0–80% EtOAc in petroleum ether, 24 g SiO<sub>2</sub>) to give <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[3-[4-[(1<i>S</i>)-1-(<i>tert</i>-butoxycarbonylamino)ethyl]phenyl]isoxazol-5-yl]-5-(4-isopropylsulfonylphenyl)pyrazin-2-yl]carbamate as a pale yellow solid (645 mg, 74%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.08 (s, 1H), 8.37 (d, 2H), 8.11 (d, 2H), 7.89 (d, 2H), 7.46 (d, 2H), 7.37 (s, 1H), 4.87 (br s, 1H), 4.14 (q, 1H), 3.55 (m, 1H), 1.43 (s, 9H), 1.42 (s, 18H), 1.38 (d, 6H), 1.29 (d, 3H).</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[3-[4-[(1<i>S</i>)-1-(<i>tert</i>-butoxycarbonylamino)ethyl]phenyl]isoxazol-5-yl]-5-(4-isopropylsulfonylphenyl)pyrazin-2-yl]carbamate (644 mg, 0.843 mmol) in DCM (13 mL) was added TFA (1.3 mL, 16.9 mmol), and the resulting solution was stirred overnight at room temperature. The mixture was partitioned between dichoromethane and saturated aqueous sodium hydrogen carbonate solution, and the layers were separated once effervescence has stopped. The organic extracts were dried over MgSO<sub>4</sub> and concentrated in vacuo to leave a solid. The residue was purified by column chromatography on silica, eluting with 0–20% MeOH/DCM to afford 3-[3-[4-[(1<i>S</i>)-1-aminoethyl]phenyl]isoxazol-5-yl]-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine <b>17</b> as a yellow solid (387 mg, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.39 (d, <i>J</i> 8.5 Hz, 2H), 7.96–7.93 (m, 4H), 7.77 (s, 1H), 7.56 (d, <i>J</i> 8.3 Hz, 2H), 7.20 (s, 2H), 4.07 (q, <i>J</i> 6.6 Hz, 1H), 3.47 (m, <i>J</i> 6.8 Hz, 1H), 1.95 (br s, 2H), 1.29 (d, <i>J</i> 6.6 Hz, 3H), 1.20 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.02, 162.66, 152.23, 151.87, 142.91, 141.55, 138.08, 136.25, 129.63, 127.08, 127.05, 126.68, 126.18, 125.01, 102.60, 54.72, 50.97, 26.55, 15.70; MS (ES+) 464.3; HRMS (ES+) calcd for C<sub>24</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>S (M – NH<sub>2</sub>)<sup>+</sup> 447.1485; found 447.1491.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>R</i>)-3-(3-(4-(1-Aminoethyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine (<b>18</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>17</b>, using <i>tert</i>-butyl <i>N</i>-[(1<i>R</i>)-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate instead of <i>tert</i>-butyl <i>N</i>-[(1<i>S</i>)-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate. (<i>R</i>)-3-(3-(4-(1-Aminoethyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>18</b> (TFA salt) was obtained as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 8.39 (m, 3H), 8.38 (d, <i>J</i> 8.5 Hz, 2H), 8.11 (d, <i>J</i> 8.2 Hz, 2H), 7.94 (d, <i>J</i> 8.5 Hz, 2H), 7.83 (s, 1H), 7.69 (d, <i>J</i> 8.3 Hz, 2H), 7.22 (br s, 2H), 4.54 (m, 1H), 3.47 (q, <i>J</i> 6.8 Hz, 1H), 1.56 (d, <i>J</i> 6.8 Hz, 3H) and 1.20 (d, <i>J</i> 6.8 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.38, 162.22, 152.26, 143.07, 141.83, 141.52, 138.12, 136.30, 129.63, 128.86, 128.03, 127.64, 126.18, 124.85, 102.71, 54.71, 50.18, 21.02, 15.70; MS (ES+) 464.1; HRMS (ES+) calcd for C<sub>24</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>S (M – NH<sub>2</sub>)<sup>+</sup> 447.1485; found 447.1497.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-(3-(3-Chloro-4-((methylamino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine (<b>19</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>17</b>, using <i>tert</i>-butyl (2-chloro-4-formylbenzyl)(methyl)carbamate instead of <i>tert</i>-butyl (<i>S</i>)-(1-(4-formylphenyl)ethyl)carbamate. 3-(3-(3-Chloro-4-((methylamino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>19</b> was obtained as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (br s, 2H), 8.38 (m, 2H), 8.25 (m, 1H), 8.12 (m, 1H), 7.94–7.96 (m, 3H), 7.79 (m, 1H), 7.24 (br s, 2H), 4.37 (s, 2H), 3.48 (m, 1H), 2.71 (s, 3H), 1.19 (d, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.64, 161.19, 158.24, 152.27, 143.20, 141.49, 138.14, 136.32, 134.83, 132.67, 132.47, 131.18, 129.64, 128.16, 126.17, 124.66, 102.86, 54.71, 48.85, 33.30, 15.69; MS (ES+) 498.2; HRMS (ES+) calcd for C<sub>24</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 498.1361; found 498.1360.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-(3-(2-Chloro-4-((methylamino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine (<b>20</b>)</h3><div class="NLM_p last">Prepared using the experimental procedure described for <b>17</b>, using <i>tert</i>-butyl (3-chloro-4-formylbenzyl)(methyl)carbamate instead of <i>tert</i>-butyl (<i>S</i>)-(1-(4-formylphenyl)ethyl)carbamate. 3-(3-(2-Chloro-4-((methylamino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-amine <b>20</b> (TFA salt) was obtained as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (s, 1H), 8.87 (br s, 2H), 8.36 (m, 2H), 7.90–7.96 (m, 3H), 7.85 (m, 1H), 7.63–7.65 (m, 2H), 7.25 (br s, 2H), 4.26 (m, 2H), 3.49 (m, 1H), 2.63 (t, 3H), 1.18 (d, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.99, 160.97, 158.32, 152.30, 143.24, 141.44, 138.19, 136.32, 132.46, 132.18, 132.06, 129.66, 129.56, 128.46, 126.19, 124.62, 105.16, 54.70, 50.71, 32.81, 15.69; MS (ES+) 498.2; HRMS (ES+) calcd for C<sub>24</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 498.1361; found 498.1379.</div></div><div id="sec5_1_19_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Molecular Modeling</h3><div class="NLM_p">Energy minimization was performed with Jaguar version 8.7.013 as implemented in Maestro version 10.1.013, release 2015-1 (Schrödinger Inc., New York, USA) using density functional theory (DFT) with the B3LYP functional<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> and a 6-31G** basis set.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Default settings were used with the exception of the accuracy level, which was set to “accurate”, and the maximum number of iterations, which was increased to 200. All energy minimizations converged within 100 iterations. In order to minimize noise in the calculated gas phase energies, the conformationally flexible isopropylsulfone moieties were replaced by a proton prior to minimization. Starting conformations were obtained from the top ranking docking solutions generated with Glide version 6.6.013 against our ATR homology model (see below). Alternative conformations were generated from the docked conformation by changing the dihedral angle of the bond connecting the aminopyrazine and the five-membered heteroaryl ring by 180°. The energy required for the 4,5-dihydroisoxazole <b>5</b> to assume its flatter, bound conformation was estimated by subtracting the gas phase energy of the freely minimized compound from the energy after minimization with the four dihedral angles of the single bonds in the 4,5-dihydroisoxazole ring constrained to their values in the docked conformation.</div><div class="NLM_p last">Homology models for ATR, ATM and DNA-PK were generated using a phosphatidylinositol 3-kinase γ (PI3K-γ) crystal structure as a template as described previously<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> using the Prime version 3.9.013 homology building tool in Maestro and further optimized by manual manipulation and energy minimization with Macromodel version 10.7.013 using the OPLS2.1 force field.</div></div><div id="sec5_1_19_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Kinase Inhibition Assays</h3><div class="NLM_p">HEPES, Tris-HCl, NaCl, KCl, MnCl<sub>2</sub>, MgCl<sub>2</sub>, EGTA, EDTA, BSA, ATP, phosphoric acid, calf thymus DNA, and DMSO were supplied by Sigma-Aldrich. DTT was from Melford Laboratories. Target peptides were synthesized at Biomol International LP. Stock 3 mCi/mmol [γ-<sup>33</sup>P]ATP and Optiphase Supermix scintillation cocktail were supplied by Perkin-Elmer. Phosphocellulose capture plates (MSPHNXB) were from Millipore. Full-length ATR and ATM kinases were produced in-house using methods based on published protocols,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and DNA-PK was purchased from Promega.</div><div class="NLM_p last">The ability of compounds to inhibit ATR, ATM, or DNA-PK kinase activity was tested using a radiometric phosphate incorporation assay<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> as described previously.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> A stock solution was prepared consisting of the appropriate buffer, kinase, and target peptide. To this was added the compound of interest, at varying concentrations in DMSO to a final DMSO concentration of 7%. Assays were initiated by addition of an appropriate [γ-<sup>33</sup>P]ATP solution and incubated at 25 °C. Assays were stopped, after the desired time course, by addition of phosphoric acid and ATP to a final concentration of 100 mM and 0.66 μM, respectively. Peptides were captured on a phosphocellulose membrane, prepared as per manufacturer’s instructions, and washed six times with 200 μL of 100 mM phosphoric acid, prior to the addition of 100 μL of scintillation cocktail and scintillation counting on a 1450 Microbeta liquid scintillation counter (Perkin-Elmer). Dose–response data were analyzed using GraphPad Prism software (version 3.0cx for Macintosh, GraphPad Software). Additional kinase inhibition data for kinases unrelated in sequence to ATR were obtained from MDS Pharma Services.</div></div><div id="sec5_1_19_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Cellular Assays</h3><div class="NLM_p last">Cell lines were purchased from ATCC and maintained according to the distributor’s instructions. Cell assays were performed using exponentially growing cultures. For H2AX phosphorylation analysis using immunofluorescence (IF) microscopy, cells were fixed in 4% formaldehyde, permeabilized with 0.5% Triton X-100, and stained with mouse H2AX pS139 antibody (Upstate), AlexaFluor 488 goat anti-mouse antibody (Invitrogen), and Hoechst (Invitrogen). The cells were then analyzed using the BD Pathway 855 bioimager and BD Attovision software. The cell density was analyzed using the CellTiter96 AQueous cell proliferation (MTS) assay (Promega). Cells were plated in 96-well plates and allowed to adhere overnight. The following day, compounds were added at the indicated concentrations in a final volume of 200 μL, and the cells were then incubated for 96 h. MTS reagent (40 μL) was then added, and 1 h later absorbance at 490 nm was measured using a SpectraMax Plus 384 plate reader (Molecular Devices). Synergy and antagonism were assessed using Macsynergy software.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec5_1_19_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Solubility Assays</h3><div class="NLM_p last">The solubility of compounds was assessed by dissolving them in 100 mL of DMSO or 100 mL of PBS buffer (Dulbecco’s phosphate buffered saline solution, DPBS 1×, catalog no. 21-031 from Corning, containing 10 mM phosphate and 140 mM NaCl) to a maximum concentration of 200 μM in Costar 250 μL 384-well plates. At this concentration most compounds absorb sufficient amount of UV light and signal response is still linearly proportional to concentration. The DMSO standards were run on UPLC–MS using a reverse phase column, and chromatograms were analyzed by determining the area under the UV curve (AUC). Mass spectrometry was used for mass confirmation only. The PBS 384-well plates were sealed and shaken overnight at room temperature and subsequently centrifuged for 45 min at 4000 rpm and 22 °C before being analyzed by determining the AUCs of the UPLC–MS traces as before. The solubility of compounds in PBS was then determined by using the formula<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_m001.gif" alt="" id="_i35" /></img></span></div></div><div id="sec5_1_19_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Intravenous Rat Pharmacokinetics</h3><div class="NLM_p last">For iv dosing, male Sprague-Dawley rats (Charles River, U.K.) selected at a weight of approximately 200–350 g were used. Animals were group housed in cages of 3 in the animal facility at the Northwick Park Institute for Medical Research and maintained under a 12 h light/dark cycle with free access to food and water. Temperature and humidity were controlled according to Home Office regulations. On the first day of the study, in-dwelling catheters were implanted into each animal’s jugular and femoral veins under aseptic conditions using gaseous anesthetic (isoflurane). For iv dosing, 3 rats were administered a single infusion of 3.33 mg/kg/h of <b>2</b> for 3 h. This was equivalent to a nominal dose of 10 mg/kg. All doses of <b>2</b> were expressed as free base equivalent and were formulated as a solution in 5% Captisol/2.5% mannitol in deionized water. Blood samples were collected via the jugular vein catheter at the following time-points: 0 (predose), 1.5, 3, 4, 6, 9, 12, 15, 27, 39, and 51 h postdose. Blood was immediately centrifuged (3000<i>g</i> for 10 min at 4 °C) and the resultant plasma transferred into clean, labeled Eppendorf tubes. Samples were stored frozen at −20 °C prior to dispatch to the bioanalytical laboratory. At all times, these studies were carried out in accordance with the requirements of the U.K. national legislation and conducted using the appropriate guidelines.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00426" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00426" class="ext-link">10.1021/acs.jmedchem.9b00426</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Atomic coordinates of an ATR kinase domain homology model based on PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a> with bound compound <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and enzyme inhibition data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Analytical data for compounds <b>2</b>–<b>20</b> (page S3), HPLC characterization of purity for compounds <b>2</b>–<b>20</b> (page S13), preparation of key intermediates (page S23), enzyme assays (page S29), and cellular assays (page S30) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_001.pdb">jm9b00426_si_001.pdb (185.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_002.csv">jm9b00426_si_002.csv (1.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_003.pdf">jm9b00426_si_003.pdf (1.08 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00426" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronald Knegtel</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7192-3174" title="Orcid link">http://orcid.org/0000-0002-7192-3174</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7c0e13121d1018231712191b0819103c0a0e0804521f1311"><span class="__cf_email__" data-cfemail="fc8e93929d9098a39792999b889990bc8a8e8884d29f9391">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Damien Charrier</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Durrant</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris Davis</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre Storck</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Somhairle MacCormick</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span>; 
    <span>Present Address:
                        S.M.: Acerta Pharma BV, Kloosterstraat 9, 5349 AB, Oss, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Kay</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanne Pinder</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anisa Virani</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heather Twin</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Griffiths</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Reaper</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Littlewood</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Young</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span>; 
    <span>Present Address:
                        S.Y.: Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham, NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian Golec</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Pollard</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals
(Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors were employees of Vertex Pharmaceuticals at the time of the described work and have contributed to and approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank our colleagues at Vertex and Merck KGaA for their helpful suggestions and critical reading of this manuscript.</p></div><table summary="" class="NLM_def-list" id="dl2"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Abl</td><td class="NLM_def"><p class="first last">Abelson murine leukemia viral oncogene homolog 1</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia telangiectasia mutated</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ATM and Rad3-related</p></td></tr><tr><td class="NLM_term">B3LYP</td><td class="NLM_def"><p class="first last">Becke, three-parameter, Lee–Yang–Parr</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">drug clearance</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">DNA damage response</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DNA-PK</td><td class="NLM_def"><p class="first last">DNA-dependent protein kinase</p></td></tr><tr><td class="NLM_term">DFT</td><td class="NLM_def"><p class="first last">density functional theory</p></td></tr><tr><td class="NLM_term">DPBS</td><td class="NLM_def"><p class="first last">Dulbecco’s phosphate buffered saline solution</p></td></tr><tr><td class="NLM_term">DYRK2</td><td class="NLM_def"><p class="first last">dual specificity tyrosine-phosphorylation-regulated kinase 2</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">egtazic acid</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">Flt4</td><td class="NLM_def"><p class="first last">Fms related tyrosine kinase 4</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">H2AX</td><td class="NLM_def"><p class="first last">variant histone H2A</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">ionizing radiation</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MLK1</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase kinase 1</p></td></tr><tr><td class="NLM_term"><i>n</i>-PrOH</td><td class="NLM_def"><p class="first last">1-propanol</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly (ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PIKK</td><td class="NLM_def"><p class="first last">phosphoinositol 3-kinase-like kinase</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">phenylpropanolamine</p></td></tr><tr><td class="NLM_term">PPh<sub>3</sub></td><td class="NLM_def"><p class="first last">triphenylphosphine</p></td></tr><tr><td class="NLM_term">RS</td><td class="NLM_def"><p class="first last">replication stress</p></td></tr><tr><td class="NLM_term">Syk</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term"><i>t-</i>BuOH</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl alcohol</p></td></tr><tr><td class="NLM_term"><i>t</i>-BuOLi</td><td class="NLM_def"><p class="first last">lithium <i>tert</i>-butoxide</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortimore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2320</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1021/jm101488z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101488z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2320-2330&author=J.+D.+Charrierauthor=S.+J.+Durrantauthor=J.+M.+Golecauthor=D.+P.+Kayauthor=R.+M.+Knegtelauthor=S.+MacCormickauthor=M.+Mortimoreauthor=M.+E.+O%E2%80%99Donnellauthor=J.+L.+Pinderauthor=P.+M.+Reaperauthor=A.+P.+Rutherfordauthor=P.+S.+Wangauthor=S.+C.+Youngauthor=J.+R.+Pollard&title=Discovery+of+potent+and+selective+inhibitors+of+ataxia+telangiectasia+mutated+and+Rad3+related+%28ATR%29+protein+kinase+as+potential+anticancer+agents&doi=10.1021%2Fjm101488z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents</span></div><div class="casAuthors">Charrier, Jean-Damien; Durrant, Steven J.; Golec, Julian M. C.; Kay, David P.; Knegtel, Ronald M. A.; MacCormick, Somhairle; Mortimore, Michael; O'Donnell, Michael E.; Pinder, Joanne L.; Reaper, Philip M.; Rutherford, Alistair P.; Wang, Paul S. H.; Young, Stephen C.; Pollard, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2320-2330</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA-damaging agents are among the most frequently used anticancer drugs.  However, they provide only modest benefit in most cancers.  This may be attributed to a genome maintenance network, the DNA damage response (DDR), that recognizes and repairs damaged DNA.  ATR is a major regulator of the DDR and an attractive anticancer target.  Herein, we describe the discovery of a series of aminopyrazines with potent and selective ATR inhibition.  Compd. (I) inhibits ATR with a Ki of 6 nM, shows >600-fold selectivity over related kinases ATM or DNA-PK, and blocks ATR signaling in cells with an IC50 of 0.42 μM.  Using I, here it is shown that ATR inhibition markedly enhances death induced by DNA-damaging agents in certain cancers but not normal cells.  This differential response between cancer and normal cells highlights the great potential for ATR inhibition as a novel mechanism to dramatically increase the efficacy of many established drugs and ionizing radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp56O6NNQ8JNbVg90H21EOLACvtfcHk0lgiOKUkEmZXFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D&md5=4f17e7c44fc6c7bdc32886e3415722c8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm101488z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101488z%26sid%3Dliteratum%253Aachs%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DDurrant%26aufirst%3DS.%2BJ.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DKay%26aufirst%3DD.%2BP.%26aulast%3DKnegtel%26aufirst%3DR.%2BM.%26aulast%3DMacCormick%26aufirst%3DS.%26aulast%3DMortimore%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BE.%26aulast%3DPinder%26aufirst%3DJ.%2BL.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DRutherford%26aufirst%3DA.%2BP.%26aulast%3DWang%26aufirst%3DP.%2BS.%26aulast%3DYoung%26aufirst%3DS.%2BC.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3%2520related%2520%2528ATR%2529%2520protein%2520kinase%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2320%26epage%3D2330%26doi%3D10.1021%2Fjm101488z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">How do real tumors become resistant to cisplatin?</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.4161/cc.7.10.5930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.4161%2Fcc.7.10.5930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=18418074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptF2jtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1353-1359&author=P.+Borstauthor=S.+Rottenbergauthor=J.+Jonkers&title=How+do+real+tumors+become+resistant+to+cisplatin%3F&doi=10.4161%2Fcc.7.10.5930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">How do real tumors become resistant to cisplatin?</span></div><div class="casAuthors">Borst, Piet; Rottenberg, Sven; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1353-1359</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Lab research on cultured tumor cells selected for resistance to platinum compds. has turned up a diverse array of resistance mechanisms.  In contrast, we recently found that mouse mammary tumors contg. irrepairable null alleles of the Brca1 gene do not become resistant to cisplatin ever, although they invariably become resistant to a variety of other anti-cancer drugs.  Each new treatment with cisplatin shrinks the tumor to a very small remnant, but relapse always occurs.  The BRCA1 missing in these mouse tumors is essential for the homol.-directed DNA repair (HR) that allows error-free repair of the duplex breaks caused by the excision of platin-DNA adducts.  The mouse tumor results therefore raise the question whether the cisplatin resistance mechanisms identified in vitro can actually overcome an irreversible defect in DNA repair in real tumors.  This question is underlined by recent analyses of tumor samples of patients with ovarian cancer that have uncovered a new platin resistance mechanism: these tumors were initially sensitive to platin through a defect in the BRCA2 gene, also required for HR, like BRCA1.  Resistance in these patients,-after an initial response of the tumor,-was due to secondary mutations in the defective BRCA2 gene, restoring BRCA2 function.  These clin. observations show the overriding importance of a functional HR system for tumor cells to survive platin-induced DNA lesions.  Taken together with the mouse mammary tumor data, these observations raise the possibility that proliferating cells have no readily available mechanism to escape from cisplatin DNA damage once their HR is irreversibly inactivated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyQw5rHh6uHbVg90H21EOLACvtfcHk0lgiOKUkEmZXFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptF2jtrk%253D&md5=e3da1eaace11c873ce91825ea6963d22</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4161%2Fcc.7.10.5930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.7.10.5930%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHow%2520do%2520real%2520tumors%2520become%2520resistant%2520to%2520cisplatin%253F%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D1353%26epage%3D1359%26doi%3D10.4161%2Fcc.7.10.5930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span> <span> </span><span class="NLM_article-title">ATR signaling: more than meeting at the fork</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>436</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1042/BJ20102162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1042%2FBJ20102162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=21615334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2gs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2011&pages=527-536&author=E.+A.+Namauthor=D.+Cortez&title=ATR+signaling%3A+more+than+meeting+at+the+fork&doi=10.1042%2FBJ20102162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">ATR signalling: more than meeting at the fork</span></div><div class="casAuthors">Nam, Edward A.; Cortez, David</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Preservation of genome integrity via the DNA-damage response is crit. to prevent disease.  ATR (ataxia telangiectasia mutated- and Rad3-related) is essential for life and functions as a master regulator of the DNA-damage response, esp. during DNA replication.  ATR controls and coordinates DNA replication origin firing, replication fork stability, cell cycle checkpoints and DNA repair.  Since its identification 15 years ago, a model of ATR activation and signaling has emerged that involves localization to sites of DNA damage and activation through protein-protein interactions.  Recent research has added an increasingly detailed understanding of the canonical ATR pathway, and an appreciation that the canonical model does not fully capture the complexity of ATR regulation.  In the present article, we review the ATR signaling process, focusing on mechanistic findings garnered from the identification of new ATR-interacting proteins and substrates.  We discuss how to incorporate these new insights into a model of ATR regulation and point out the significant gaps in our understanding of this essential genome-maintenance pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeDUcTrABTZbVg90H21EOLACvtfcHk0lh1hJ7LkZRNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2gs7w%253D&md5=8550e1270a78aef9a1be36a35b7f9606</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2FBJ20102162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20102162%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DE.%2BA.%26aulast%3DCortez%26aufirst%3DD.%26atitle%3DATR%2520signaling%253A%2520more%2520than%2520meeting%2520at%2520the%2520fork%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D436%26spage%3D527%26epage%3D536%26doi%3D10.1042%2FBJ20102162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halazonetis, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgoulis, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span> <span> </span><span class="NLM_article-title">An oncogene-induced DNA damage model for cancer development</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>319</i></span> (<span class="NLM_issue">5868</span>),  <span class="NLM_fpage">1352</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.1140735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1126%2Fscience.1140735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=18323444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislSkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2008&pages=1352-1355&issue=5868&author=T.+D.+Halazonetisauthor=V.+G.+Gorgoulisauthor=J.+Bartek&title=An+oncogene-induced+DNA+damage+model+for+cancer+development&doi=10.1126%2Fscience.1140735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An oncogene-induced DNA damage model for cancer development</span></div><div class="casAuthors">Halazonetis, Thanos D.; Gorgoulis, Vassilis G.; Bartek, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">5868</span>),
    <span class="NLM_cas:pages">1352-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Of all types of DNA damage, DNA double-strand breaks (DSBs) pose the greatest challenge to cells.  One might have, therefore, anticipated that a sizable no. of DNA DSBs would be incompatible with cell proliferation.  Yet recent exptl. findings suggest that, in both precancerous lesions and cancers, activated oncogenes induce stalling and collapse of DNA replication forks, which in turn leads to formation of DNA DSBs.  This continuous formation of DNA DSBs may contribute to the genomic instability that characterizes the vast majority of human cancers.  In addn., in precancerous lesions, these DNA DSBs activate p53, which, by inducing apoptosis or senescence, raises a barrier to tumor progression.  Breach of this barrier by various mechanisms, most notably by p53 mutations, that impair the DNA damage response pathway allows cancers to develop.  Thus, oncogene-induced DNA damage may explain two key features of cancer: genomic instability and the high frequency of p53 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooknsDjHPy5LVg90H21EOLACvtfcHk0lh1hJ7LkZRNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislSkt7c%253D&md5=5cacb04a384638ccc28d82d0ab84dec0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1140735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1140735%26sid%3Dliteratum%253Aachs%26aulast%3DHalazonetis%26aufirst%3DT.%2BD.%26aulast%3DGorgoulis%26aufirst%3DV.%2BG.%26aulast%3DBartek%26aufirst%3DJ.%26atitle%3DAn%2520oncogene-induced%2520DNA%2520damage%2520model%2520for%2520cancer%2520development%26jtitle%3DScience%26date%3D2008%26volume%3D319%26issue%3D5868%26spage%3D1352%26epage%3D1355%26doi%3D10.1126%2Fscience.1140735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nchembio.573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1038%2Fnchembio.573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=21490603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1agtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=428-430&author=P.+M.+Reaperauthor=M.+R.+Griffithsauthor=J.+M.+Longauthor=J.+D.+Charrierauthor=S.+Maccormickauthor=P.+A.+Charltonauthor=J.+M.+Golecauthor=J.+R.+Pollard&title=Selective+killing+of+ATM-+or+p53-deficient+cancer+cells+through+inhibition+of+ATR&doi=10.1038%2Fnchembio.573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR</span></div><div class="casAuthors">Reaper, Philip M.; Griffiths, Matthew R.; Long, Joanna M.; Charrier, Jean-Damien; MacCormick, Somhairle; Charlton, Peter A.; Golec, Julian M. C.; Pollard, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-430</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we report a comprehensive biol. characterization of a potent and selective small-mol. inhibitor of the DNA damage response (DDR) kinase ATR.  We show a profound synthetic lethal interaction between ATR and the ATM-p53 tumor suppressor pathway in cells treated with DNA-damaging agents and establish ATR inhibition as a way to transform the outcome for patients with cancer treated with ionizing radiation or genotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRYth09UxMbVg90H21EOLACvtfcHk0lh1hJ7LkZRNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1agtrs%253D&md5=58c63122b550b1ca5e9064c4bbf3d68f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.573%26sid%3Dliteratum%253Aachs%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DGriffiths%26aufirst%3DM.%2BR.%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DMaccormick%26aufirst%3DS.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DSelective%2520killing%2520of%2520ATM-%2520or%2520p53-deficient%2520cancer%2520cells%2520through%2520inhibition%2520of%2520ATR%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D428%26epage%3D430%26doi%3D10.1038%2Fnchembio.573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoddusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holash, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taricani, L.</span></span> <span> </span><span class="NLM_article-title">A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1158%2F1541-7786.MCR-14-0240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25232030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1amu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=120-129&author=D.+L.+Menezesauthor=J.+Holtauthor=Y.+Tangauthor=J.+Fengauthor=P.+Barsantiauthor=Y.+Panauthor=M.+Ghoddusiauthor=W.+Zhangauthor=G.+Thomasauthor=J.+Holashauthor=E.+Leesauthor=L.+Taricani&title=A+synthetic+lethal+screen+reveals+enhanced+sensitivity+to+ATR+inhibitor+treatment+in+mantle+cell+lymphoma+with+ATM+loss-of-function&doi=10.1158%2F1541-7786.MCR-14-0240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function</span></div><div class="casAuthors">Menezes, Daniel L.; Holt, Jenny; Tang, Yan; Feng, Jiajia; Barsanti, Paul; Pan, Yue; Ghoddusi, Majid; Zhang, Wei; Thomas, George; Holash, Jocelyn; Lees, Emma; Taricani, Lorena</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mechanisms to maintain genomic integrity are essential for cells to remain viable.  Not surprisingly, disruption of key DNA damage response pathway factors, such as ataxia telangiectasia-mutated (ATM)/ataxia telangiectasia and RAD3-related (ATR) results in loss of genomic integrity.  Here, a synthetic lethal siRNA-screening approach not only confirmed ATM but identified addnl. replication checkpoint proteins, when ablated, enhanced ATR inhibitor (ATRi) response in a high-content γ-H2AX assay.  Cancers with inactivating ATM mutations exhibit impaired DNA double-stranded break (DSB) repair and rely on compensatory repair pathways for survival.  Therefore, impairing ATR activity may selectively sensitize cancer cells to killing.  ATR inhibition in an ATM-deficient context results in phosphorylation of DNA-dependent protein kinase catalytic subunits (DNA-PKcs) and leads to induction of γ-H2AX.  Using both in vitro and in vivo models, ATR inhibition enhanced efficacy in ATM loss-of-function mantle cell lymphoma (MCL) compared with ATM wild-type cancer cells.  In summary, single-agent ATR inhibitors have therapeutic utility in the treatment of cancers, like MCL, in which ATM function has been lost.  Implications: These data suggest that single-agent ATR inhibitors have therapeutic utility and that ATR uses a complex and coordinated set of proteins to maintain genomic stability that could be further exploited.  Mol Cancer Res; 13(1); 120-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodCbVkU8MDzLVg90H21EOLACvtfcHk0lg4TSMcFMfvrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1amu7s%253D&md5=9e2b1d1832e9ead204ad96caa90d41e2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0240%26sid%3Dliteratum%253Aachs%26aulast%3DMenezes%26aufirst%3DD.%2BL.%26aulast%3DHolt%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DBarsanti%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DGhoddusi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DTaricani%26aufirst%3DL.%26atitle%3DA%2520synthetic%2520lethal%2520screen%2520reveals%2520enhanced%2520sensitivity%2520to%2520ATR%2520inhibitor%2520treatment%2520in%2520mantle%2520cell%2520lymphoma%2520with%2520ATM%2520loss-of-function%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26spage%3D120%26epage%3D129%26doi%3D10.1158%2F1541-7786.MCR-14-0240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vendetti, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrads, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakkenist, C. J.</span></span> <span> </span><span class="NLM_article-title">The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">42</span>),  <span class="NLM_fpage">44289</span>– <span class="NLM_lpage">44305</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.18632%2Foncotarget.6247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=26517239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BC28zmvVyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44289-44305&issue=42&author=F.+P.+Vendettiauthor=A.+Lauauthor=S.+Schamusauthor=T.+P.+Conradsauthor=M.+J.+O%E2%80%99Connorauthor=C.+J.+Bakkenist&title=The+orally+active+and+bioavailable+ATR+kinase+inhibitor+AZD6738+potentiates+the+anti-tumor+effects+of+cisplatin+to+resolve+ATM-deficient+non-small+cell+lung+cancer+in+vivo&doi=10.18632%2Foncotarget.6247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo</span></div><div class="casAuthors">Vendetti Frank P; Schamus Sandra; Bakkenist Christopher J; Lau Alan; O'Connor Mark J; Conrads Thomas P; Bakkenist Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">44289-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ATR and ATM are DNA damage signaling kinases that phosphorylate several thousand substrates.  ATR kinase activity is increased at damaged replication forks and resected DNA double-strand breaks (DSBs).  ATM kinase activity is increased at DSBs.  ATM has been widely studied since ataxia telangiectasia individuals who express no ATM protein are the most radiosensitive patients identified.  Since ATM is not an essential protein, it is widely believed that ATM kinase inhibitors will be well-tolerated in the clinic.  ATR has been widely studied, but advances have been complicated by the finding that ATR is an essential protein and it is widely believed that ATR kinase inhibitors will be toxic in the clinic.  We describe AZD6738, an orally active and bioavailable ATR kinase inhibitor.  AZD6738 induces cell death and senescence in non-small cell lung cancer (NSCLC) cell lines.  AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells.  In contrast to expectations, daily administration of AZD6738 and ATR kinase inhibition for 14 consecutive days is tolerated in mice and enhances the therapeutic efficacy of cisplatin in xenograft models.  Remarkably, the combination of cisplatin and AZD6738 resolves ATM-deficient lung cancer xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGZGrn92xggGyYR5VtavbzfW6udTcc2ebfHHXo_TcNnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zmvVyhsA%253D%253D&md5=eeb235ade15503e435eb69f929c64068</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6247%26sid%3Dliteratum%253Aachs%26aulast%3DVendetti%26aufirst%3DF.%2BP.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DSchamus%26aufirst%3DS.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBakkenist%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520orally%2520active%2520and%2520bioavailable%2520ATR%2520kinase%2520inhibitor%2520AZD6738%2520potentiates%2520the%2520anti-tumor%2520effects%2520of%2520cisplatin%2520to%2520resolve%2520ATM-deficient%2520non-small%2520cell%2520lung%2520cancer%2520in%2520vivo%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D42%26spage%3D44289%26epage%3D44305%26doi%3D10.18632%2Foncotarget.6247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcina, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies McKenna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span> <span> </span><span class="NLM_article-title">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/cddis.2012.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1038%2Fcddis.2012.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=23222511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=e441-450&author=E.+Fokasauthor=R.+Prevoauthor=J.+R.+Pollardauthor=P.+M.+Reaperauthor=P.+A.+Charltonauthor=B.+Cornelissenauthor=K.+A.+Vallisauthor=E.+M.+Hammondauthor=M.+M.+Olcinaauthor=W.+Gillies+McKennaauthor=R.+J.+Muschelauthor=T.+B.+Brunner&title=Targeting+ATR+in+vivo+using+the+novel+inhibitor+VE-822+results+in+selective+sensitization+of+pancreatic+tumors+to+radiation&doi=10.1038%2Fcddis.2012.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span></div><div class="casAuthors">Fokas, E.; Prevo, R.; Pollard, J. R.; Reaper, P. M.; Charlton, P. A.; Cornelissen, B.; Vallis, K. A.; Hammond, E. M.; Olcina, M. M.; McKenna, W. Gillies; Muschel, R. J.; Brunner, T. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">e441, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application.  Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells.  We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization.  Chk1 phosphorylation was used to indicate ATR activity, γH2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity.  Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo.  Murine intestinal damage was evaluated after abdominal XRT.  VE-822 inhibited ATR in vitro and in vivo.  VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells.  VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.  VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity.  These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp66nE6ZdMorVg90H21EOLACvtfcHk0lgtNjhc7c0eTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D&md5=7223df6ec5dbca8c50889b5df8e4cce6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2012.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2012.181%26sid%3Dliteratum%253Aachs%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DPrevo%26aufirst%3DR.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DCornelissen%26aufirst%3DB.%26aulast%3DVallis%26aufirst%3DK.%2BA.%26aulast%3DHammond%26aufirst%3DE.%2BM.%26aulast%3DOlcina%26aufirst%3DM.%2BM.%26aulast%3DGillies%2BMcKenna%26aufirst%3DW.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26atitle%3DTargeting%2520ATR%2520in%2520vivo%2520using%2520the%2520novel%2520inhibitor%2520VE-822%2520results%2520in%2520selective%2520sensitization%2520of%2520pancreatic%2520tumors%2520to%2520radiation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2012%26volume%3D3%26spage%3De441%26epage%3D450%26doi%3D10.1038%2Fcddis.2012.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prevo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span> <span> </span><span class="NLM_article-title">The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1072</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.4161/cbt.21093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.4161%2Fcbt.21093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=22825331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1arurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1072-1081&author=R.+Prevoauthor=E.+Fokasauthor=P.+M.+Reaperauthor=P.+A.+Charltonauthor=J.+R.+Pollardauthor=W.+G.+McKennaauthor=R.+J.+Muschelauthor=T.+B.+Brunner&title=The+novel+ATR+inhibitor+VE-821+increases+sensitivity+of+pancreatic+cancer+cells+to+radiation+and+chemotherapy&doi=10.4161%2Fcbt.21093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy</span></div><div class="casAuthors">Prevo, Remko; Fokas, Emmanouil; Reaper, Philip M.; Charlton, Peter A.; Pollard, John R.; McKenna, W. Gillies; Muschel, Ruth J.; Brunner, Thomas B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1072-1081</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">DNA damaging agents such as radiotherapy and gemcitabine are frequently used for the treatment of pancreatic cancer.  However, these treatments typically provide only modest benefit.  Improving the low survival rate for pancreatic cancer patients therefore remains a major challenge in oncol.  Inhibition of the key DNA damage response kinase ATR has been suggested as an attractive approach for sensitization of tumor cells to DNA damaging agents, but specific ATR inhibitors have remained elusive.  Here we investigated the sensitization potential of the first highly selective and potent ATR inhibitor, VE-821, in vitro.  VE-821 inhibited radiation- and gemcitabine-induced phosphorylation of Chk1, confirming inhibition of ATR signaling.  Consistently, VE-821 significantly enhanced the sensitivity of PSN-1, MiaPaCa-2 and primary PancM pancreatic cancer cells to radiation and gemcitabine under both normoxic and hypoxic conditions.  ATR inhibition by VE-821 led to inhibition of radiation-induced G2/M arrest in cancer cells.  Reduced cancer cell radiosurvival following treatment with VE-821 was also accompanied by increased DNA damage and inhibition of homologous recombination repair, as evidenced by persistence of γH2AX and 53BP1 foci and inhibition of Rad51 foci, resp.  These findings support ATR inhibition as a novel approach to improve the efficacy and therapeutic index of std. cancer treatments across a large proportion of pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSSwRbubi0WbVg90H21EOLACvtfcHk0lgtNjhc7c0eTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1arurw%253D&md5=186dd5276627880104362bf7b5c47556</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4161%2Fcbt.21093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.21093%26sid%3Dliteratum%253Aachs%26aulast%3DPrevo%26aufirst%3DR.%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMcKenna%26aufirst%3DW.%2BG.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26atitle%3DThe%2520novel%2520ATR%2520inhibitor%2520VE-821%2520increases%2520sensitivity%2520of%2520pancreatic%2520cancer%2520cells%2520to%2520radiation%2520and%2520chemotherapy%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2012%26volume%3D13%26spage%3D1072%26epage%3D1081%26doi%3D10.4161%2Fcbt.21093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thommes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2125</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6-%5B1-%28methylsulfonyl%29cyclopropyl%5Dpyrimidin-2-yl%7D-1H-indole+%28AZ20%29%3A+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity</span></div><div class="casAuthors">Foote, Kevin M.; Blades, Kevin; Cronin, Anna; Fillery, Shaun; Guichard, Sylvie S.; Hassall, Lorraine; Hickson, Ian; Jacq, Xavier; Jewsbury, Philip J.; McGuire, Thomas M.; Nissink, J. Willem M.; Odedra, Rajesh; Page, Ken; Perkins, Paula; Suleman, Abid; Tam, Kin; Thommes, Pia; Broadhurst, Rebecca; Wood, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2125-2138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways.  We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition.  Optimization from a high quality screening hit within tight SAR space led to compd. I (AZ20) which inhibits ATR immunopptd. from HeLa nuclear exts. with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.  Compd. I potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses.  At well tolerated doses I leads to significant growth inhibition of LoVo xenografts grown in nude mice.  Compd. I is a useful compd. to explore ATR pharmacol. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpY5_RVxXl9LVg90H21EOLACvtfcHk0lhLOQ0j_wpqng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D&md5=60d2f6fe78e2b82695198b9cba930ae7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6-%255B1-%2528methylsulfonyl%2529cyclopropyl%255Dpyrimidin-2-yl%257D-1H-indole%2520%2528AZ20%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520ATR%2520protein%2520kinase%2520with%2520monotherapy%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jossé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormanoglu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">6968</span>– <span class="NLM_lpage">6979</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1158%2F0008-5472.CAN-13-3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25269479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=6968-6979&author=R.+Joss%C3%A9author=S.+E.+Martinauthor=R.+Guhaauthor=P.+Ormanogluauthor=T.+D.+Pfisterauthor=P.+M.+Reaperauthor=C.+S.+Barnesauthor=J.+Jonesauthor=P.+Charltonauthor=J.+R.+Pollardauthor=J.+Morrisauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=ATR+inhibitors+VE-821+and+VX-970+sensitize+cancer+cells+to+topoisomerase+I+inhibitors+by+disabling+DNA+replication+initiation+and+fork+elongation+responses&doi=10.1158%2F0008-5472.CAN-13-3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses</span></div><div class="casAuthors">Josse, Rozenn; Martin, Scott E.; Guha, Rajarshi; Ormanoglu, Pinar; Pfister, Thomas D.; Reaper, Philip M.; Barnes, Christopher S.; Jones, Julie; Charlton, Peter; Pollard, John R.; Morris, Joel; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6968-6979</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">By showing how the DNA damage sensing kinase ATR confers resistance to topoisomerase I inhibitors, a widely used class of cytotoxic drugs in the oncol. clinic, this study provides a mechanistic rationale for combination trials to evaluate the efficacy of ATR inhibitors.  Camptothecin and its derivs., topotecan and irinotecan, are specific topoisomerase I (Top1) inhibitors and potent anticancer drugs killing cancer cells by producing replication-assocd. DNA double-strand breaks, and the indenoisoquinoline LMP-400 (indotecan) is a novel Top1 inhibitor in clin. trial.  To develop novel drug combinations, we conducted a synthetic lethal siRNA screen using a library that targets nearly 7,000 human genes.  Depletion of ATR, the main transducer of replication stress, came as a top candidate gene for camptothecin synthetic lethality.  Validation studies using ATR siRNA and the ATR inhibitor VE-821 confirmed marked antiproliferative synergy with camptothecin and even greater synergy with LMP-400.  Single-cell analyses and DNA fiber combing assays showed that VE-821 abrogates the S-phase replication elongation checkpoint and the replication origin-firing checkpoint induced by camptothecin and LMP-400.  As expected, the combination of Top1 inhibitors with VE-821 inhibited the phosphorylation of ATR and Chk1; however, it strongly induced γH2AX.  In cells treated with the combination, the γH2AX pattern changed over time from the well-defined Top1-induced damage foci to an intense peripheral and diffuse nuclear staining, which could be used as response biomarker.  Finally, the clin. deriv. of VE-821, VX-970, enhanced the in vivo tumor response to irinotecan without addnl. toxicity.  A key implication of our work is the mechanistic rationale and proof of principle it provides to evaluate the combination of Top1 inhibitors with ATR inhibitors in clin. trials.  Cancer Res; 74(23); 6968-79. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz9ocPrt4fmrVg90H21EOLACvtfcHk0lhLOQ0j_wpqng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrvK&md5=438498ef25a2b0e8637c36dbb74427e5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-3369%26sid%3Dliteratum%253Aachs%26aulast%3DJoss%25C3%25A9%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DOrmanoglu%26aufirst%3DP.%26aulast%3DPfister%26aufirst%3DT.%2BD.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DBarnes%26aufirst%3DC.%2BS.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DATR%2520inhibitors%2520VE-821%2520and%2520VX-970%2520sensitize%2520cancer%2520cells%2520to%2520topoisomerase%2520I%2520inhibitors%2520by%2520disabling%2520DNA%2520replication%2520initiation%2520and%2520fork%2520elongation%2520responses%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D6968%26epage%3D6979%26doi%3D10.1158%2F0008-5472.CAN-13-3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eustace, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5674</span>– <span class="NLM_lpage">5685</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.18632%2Foncotarget.2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25010037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5674-5685&author=A.+B.+Hallauthor=D.+Newsomeauthor=Y.+Wangauthor=D.+M.+Boucherauthor=B.+Eustaceauthor=Y.+Guauthor=B.+Hareauthor=M.+A.+Johnsonauthor=H.+Liauthor=S.+Miltonauthor=C.+E.+Murphyauthor=D.+Takemotoauthor=C.+Tolmanauthor=M.+Woodauthor=P.+Charltonauthor=J.+D.+Charrierauthor=B.+Fureyauthor=J.+Golecauthor=P.+M.+Reaperauthor=J.+R.+Pollard&title=Potentiation+of+tumor+responses+to+DNA+damaging+therapy+by+the+selective+ATR+inhibitor+VX-970&doi=10.18632%2Foncotarget.2158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span></div><div class="casAuthors">Hall Amy B; Newsome Dave; Wang Yuxin; Boucher Diane M; Eustace Brenda; Gu Yong; Hare Brian; Johnson Mac A; Milton Sean; Murphy Cheryl E; Takemoto Darin; Tolman Crystal; Wood Mark; Furey Brinley; Charlton Peter; Charrier Jean-Damien; Golec Julian; Reaper Philip M; Pollard John R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5674-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor.  This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR).  ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents.  However, there are limited in vivo proof-of-concept data for ATR inhibition.  To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1.  VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed.  In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts.  The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model.  These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8Vj8UJVglDeLt9HypzAgQfW6udTcc2eabDz-j5buZF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D&md5=8901708b1d60ad622d534a14da665414</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2158%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%2BB.%26aulast%3DNewsome%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBoucher%26aufirst%3DD.%2BM.%26aulast%3DEustace%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMilton%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DC.%2BE.%26aulast%3DTakemoto%26aufirst%3DD.%26aulast%3DTolman%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DFurey%26aufirst%3DB.%26aulast%3DGolec%26aufirst%3DJ.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DPotentiation%2520of%2520tumor%2520responses%2520to%2520DNA%2520damaging%2520therapy%2520by%2520the%2520selective%2520ATR%2520inhibitor%2520VX-970%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5674%26epage%3D5685%26doi%3D10.18632%2Foncotarget.2158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeitany, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryll, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganem, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bersani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvà, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussin, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span> <span> </span><span class="NLM_article-title">Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1126/science.1257216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1126%2Fscience.1257216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25593184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=273-277&author=R.+L.+Flynnauthor=K.+E.+Coxauthor=M.+Jeitanyauthor=H.+Wakimotoauthor=A.+R.+Bryllauthor=N.+J.+Ganemauthor=F.+Bersaniauthor=J.+R.+Pinedaauthor=M.+L.+Suv%C3%A0author=C.+H.+Benesauthor=D.+A.+Haberauthor=F.+D.+Boussinauthor=L.+Zou&title=Alternative+lengthening+of+telomeres+renders+cancer+cells+hypersensitive+to+ATR+inhibitors&doi=10.1126%2Fscience.1257216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors</span></div><div class="casAuthors">Flynn, Rachel Litman; Cox, Kelli E.; Jeitany, Maya; Wakimoto, Hiroaki; Bryll, Alysia R.; Ganem, Neil J.; Bersani, Francesca; Pineda, Jose R.; Suva, Mario L.; Benes, Cyril H.; Haber, Daniel A.; Boussin, Francois D.; Zou, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6219</span>),
    <span class="NLM_cas:pages">273-277</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cancer cells rely on telomerase or the alternative lengthening of telomeres (ALT) pathway to overcome replicative mortality.  ALT is mediated by recombination and is prevalent in a subset of human cancers, yet whether it can be exploited therapeutically remains unknown.  Loss of the chromatin-remodeling protein ATRX assocs. with ALT in cancers.  Here, we show that ATRX loss compromises cell-cycle regulation of the telomeric noncoding RNA TERRA and leads to persistent assocn. of replication protein A (RPA) with telomeres after DNA replication, creating a recombinogenic nucleoprotein structure.  Inhibition of the protein kinase ATR, a crit. regulator of recombination recruited by RPA, disrupts ALT and triggers chromosome fragmentation and apoptosis in ALT cells.  The cell death induced by ATR inhibitors is highly selective for cancer cells that rely on ALT, suggesting that such inhibitors may be useful for treatment of ALT-pos. cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41jOdyYH-ILVg90H21EOLACvtfcHk0ljY6zpMC1372Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFGgsQ%253D%253D&md5=4ae9bc8508056a59454748ad679208bd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1257216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1257216%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DR.%2BL.%26aulast%3DCox%26aufirst%3DK.%2BE.%26aulast%3DJeitany%26aufirst%3DM.%26aulast%3DWakimoto%26aufirst%3DH.%26aulast%3DBryll%26aufirst%3DA.%2BR.%26aulast%3DGanem%26aufirst%3DN.%2BJ.%26aulast%3DBersani%26aufirst%3DF.%26aulast%3DPineda%26aufirst%3DJ.%2BR.%26aulast%3DSuv%25C3%25A0%26aufirst%3DM.%2BL.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DBoussin%26aufirst%3DF.%2BD.%26aulast%3DZou%26aufirst%3DL.%26atitle%3DAlternative%2520lengthening%2520of%2520telomeres%2520renders%2520cancer%2520cells%2520hypersensitive%2520to%2520ATR%2520inhibitors%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D273%26epage%3D277%26doi%3D10.1126%2Fscience.1257216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A. J.</span></span> <span> </span><span class="NLM_article-title">ATM and ATR as therapeutic targets in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.pharmthera.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25512053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2015&pages=124-138&author=A.+M.+Weberauthor=A.+J.+Ryan&title=ATM+and+ATR+as+therapeutic+targets+in+cancer&doi=10.1016%2Fj.pharmthera.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ATM and ATR as therapeutic targets in cancer</span></div><div class="casAuthors">Weber, Anika Maria; Ryan, Anderson Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  In order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA damage or DNA replication stress to be resolved.  Key mediators of this DNA damage response (DDR) are the ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets.  Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to genotoxic therapies has been assocd. with increased DDR signalling, and (ii) many cancers have defects in certain components of the DDR rendering them highly dependent on the remaining DDR pathways for survival.  ATM and ATR act as the apical regulators of the response to DNA double strand breaks and replication stress, resp., with overlapping but non-redundant activities.  Highly selective small mol. inhibitors of ATM and ATR are currently in preclin. and clin. development, resp.  Preclin. data have provided a strong rationale for clin. testing of these compds. both in combination with radio- or chemotherapy, and in synthetic lethal approaches to treat tumors with deficiencies in certain DDR components.  Whole genome sequencing studies have reported that mutations in DDR genes occur with a high frequency in many common tumor types, suggesting that a synthetic lethal approach with ATM or ATR inhibitors could have widespread utility, providing that appropriate biomarkers are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNTHNVGQUGbVg90H21EOLACvtfcHk0liNVK-Z8geIYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D&md5=204198bfeef4fc9cdf3d0e8968334363</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BM.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26atitle%3DATM%2520and%2520ATR%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D149%26spage%3D124%26epage%3D138%26doi%3D10.1016%2Fj.pharmthera.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Sanad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasheminasab, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panasci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noë, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif-Askari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloyz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panasci, L.</span></span> <span> </span><span class="NLM_article-title">Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">147</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.3389%2Ffphar.2015.00147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=26257651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=147&author=A.+Abu-Sanadauthor=Y.+Wangauthor=F.+Hasheminasabauthor=J.+Panasciauthor=A.+No%C3%ABauthor=L.+Roscaauthor=D.+Davidsonauthor=L.+Amreinauthor=B.+Sharif-Askariauthor=R.+Aloyzauthor=L.+Panasci&title=Simultaneous+inhibition+of+ATR+and+PARP+sensitizes+colon+cancer+cell+lines+to+irinotecan&doi=10.3389%2Ffphar.2015.00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan</span></div><div class="casAuthors">Abu-Sanad, Atlal; Wang, Yunzhe; Hasheminasab, Fatemeh; Panasci, Justin; Noe, Alycia; Rosca, Lorena; Davidson, David; Amrein, Lilian; Sharif-Askari, Bahram; Aloyz, Raquel; Panasci, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147/1-147/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Enhanced DNA damage repair is one mechanism involved in colon cancer drug resistance.  Thus, targeting mol. components of repair pathways with specific small mol. inhibitors may improve the efficacy of chemotherapy.  ABT-888 and VE-821, inhibitors of poly-ADP-ribose-polymerase (PARP) and the serine/threonine-kinase Ataxia telangiectasia related (ATR), resp., were used to treat colon cancer cell lines in combination with the topoisomerase-I inhibitor irinotecan (SN38).  Our findings show that each of these DNA repair inhibitors utilized alone at nontoxic single agent concns. resulted in sensitization to SN38 producing a 1.4-3 fold redn. in the 50γ inhibitory concn. (IC50) of SN38 in three colon cancer cell lines.  When combined together, nontoxic concns. of ABT-888 and VE-821 produced a 4.5-27 fold redn. in the IC50 of SN38 with the HCT-116 colon cancer cells demonstrating the highest sensitization as compared to LoVo and HT-29 colon cancer cells.  Furthermore, the combination of all three agents was assocd. with maximal G2 -M arrest and enhanced DNA-damage (γH2AX) in all three colon cancer cell lines.  The mechanism of this enhanced sensitization was assocd. with: (a) maximal suppression of SN38 induced PARP activity in the presence of both inhibitors and (b) ABT-888 producing partial abrogation of the VE-821 enhancement of SN38 induced DNA-PK phosphorylation, resulting in more unrepaired DNA damage; these alterations were only present in the HCT-116 cells which have reduced levels of ATM.  This novel combination of DNA repair inhibitors may be useful to enhance the activity of DNA damaging chemotherapies such as irinotecan and help produce sensitization to this drug in colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQElEUBYfe7rVg90H21EOLACvtfcHk0liNVK-Z8geIYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnP&md5=e2e328685b7218099bed2fbade7c2d67</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00147%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Sanad%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHasheminasab%26aufirst%3DF.%26aulast%3DPanasci%26aufirst%3DJ.%26aulast%3DNo%25C3%25AB%26aufirst%3DA.%26aulast%3DRosca%26aufirst%3DL.%26aulast%3DDavidson%26aufirst%3DD.%26aulast%3DAmrein%26aufirst%3DL.%26aulast%3DSharif-Askari%26aufirst%3DB.%26aulast%3DAloyz%26aufirst%3DR.%26aulast%3DPanasci%26aufirst%3DL.%26atitle%3DSimultaneous%2520inhibition%2520of%2520ATR%2520and%2520PARP%2520sensitizes%2520colon%2520cancer%2520cell%2520lines%2520to%2520irinotecan%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D147%26doi%3D10.3389%2Ffphar.2015.00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstob, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herriott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N.</span></span> <span> </span><span class="NLM_article-title">Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">32396</span>– <span class="NLM_lpage">32409</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.18632%2Foncotarget.6136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=26486089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BC28zjvFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=32396-32409&author=F.+K.+Middletonauthor=M.+J.+Pattersonauthor=C.+J.+Elstobauthor=S.+Fordhamauthor=A.+Herriottauthor=M.+A.+Wadeauthor=A.+McCormickauthor=R.+Edmondsonauthor=F.+E.+Mayauthor=J.+M.+Allanauthor=J.+R.+Pollardauthor=N.+Curtin&title=Common+cancer-associated+imbalances+in+the+DNA+damage+response+confer+sensitivity+to+single+agent+ATR+inhibition&doi=10.18632%2Foncotarget.6136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition</span></div><div class="casAuthors">Middleton Fiona K; Patterson Miranda J; Elstob Claire J; Fordham Sarah; Herriott Ashleigh; Wade Mark A; McCormick Aiste; Edmondson Richard; May Felicity E B; Allan James M; Curtin Nicola J; Pollard John R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">32396-409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints.  Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alone.  We determined the cytotoxicity of the ATR inhibitor VE-821 in isogenically matched cells with DDR imbalance.  Cell cycle arrest, DNA damage accumulation and repair were determined following VE-821 exposure.Defects in homologous recombination repair (HRR: ATM, BRCA2 and XRCC3) and base excision repair (BER: XRCC1) conferred sensitivity to VE-821.  Surprisingly, the loss of different components of the trimeric non-homologous end-joining (NHEJ) protein DNA-PK had opposing effects.  Loss of the DNA-binding component, Ku80, caused hypersensitivity to VE-821, but loss of its partner catalytic subunit, DNA-PKcs, did not.  Unexpectedly, VE-821 was particularly cytotoxic to human and hamster cells expressing high levels of DNA-PKcs.  High DNA-PKcs was associated with replicative stress and activation of the DDR.  VE-821 suppressed HRR, determined by RAD51 focus formation, to a greater extent in cells with high DNA-PKcs.Defects in HRR and BER and high DNA-PKcs expression, that are common in cancer, confer sensitivity to ATR inhibitor monotherapy and may be developed as predictive biomarkers for personalised medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjYzgB7-SM5LZpSb_XWfMrfW6udTcc2eYFIhCUelA157ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zjvFGkug%253D%253D&md5=7798a6c3b3facab563e6daf71d89b736</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6136%26sid%3Dliteratum%253Aachs%26aulast%3DMiddleton%26aufirst%3DF.%2BK.%26aulast%3DPatterson%26aufirst%3DM.%2BJ.%26aulast%3DElstob%26aufirst%3DC.%2BJ.%26aulast%3DFordham%26aufirst%3DS.%26aulast%3DHerriott%26aufirst%3DA.%26aulast%3DWade%26aufirst%3DM.%2BA.%26aulast%3DMcCormick%26aufirst%3DA.%26aulast%3DEdmondson%26aufirst%3DR.%26aulast%3DMay%26aufirst%3DF.%2BE.%26aulast%3DAllan%26aufirst%3DJ.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%26atitle%3DCommon%2520cancer-associated%2520imbalances%2520in%2520the%2520DNA%2520damage%2520response%2520confer%2520sensitivity%2520to%2520single%2520agent%2520ATR%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D32396%26epage%3D32409%26doi%3D10.18632%2Foncotarget.6136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgado-Palacin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafarga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anton, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandoola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzweig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Capetillo, O.</span></span> <span> </span><span class="NLM_article-title">Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">445</span>),  <span class="NLM_fpage">ra91</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aad8243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1126%2Fscisignal.aad8243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=27625305" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=ra91&issue=445&author=I.+Morgado-Palacinauthor=A.+Dayauthor=M.+Murgaauthor=V.+Lafargaauthor=M.+E.+Antonauthor=A.+Tubbsauthor=H.+T.+Chenauthor=A.+Ergenauthor=R.+Andersonauthor=A.+Bhandoolaauthor=K.+G.+Pikeauthor=B.+Barlaamauthor=E.+Cadoganauthor=X.+Wangauthor=A.+J.+Pierceauthor=C.+Hubbardauthor=S.+A.+Armstrongauthor=A.+Nussenzweigauthor=O.+Fernandez-Capetillo&title=Targeting+the+kinase+activities+of+ATR+and+ATM+exhibits+antitumoral+activity+in+mouse+models+of+MLL-rearranged+AML&doi=10.1126%2Fscisignal.aad8243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aad8243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aad8243%26sid%3Dliteratum%253Aachs%26aulast%3DMorgado-Palacin%26aufirst%3DI.%26aulast%3DDay%26aufirst%3DA.%26aulast%3DMurga%26aufirst%3DM.%26aulast%3DLafarga%26aufirst%3DV.%26aulast%3DAnton%26aufirst%3DM.%2BE.%26aulast%3DTubbs%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%2BT.%26aulast%3DErgen%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DR.%26aulast%3DBhandoola%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPierce%26aufirst%3DA.%2BJ.%26aulast%3DHubbard%26aufirst%3DC.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DNussenzweig%26aufirst%3DA.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26atitle%3DTargeting%2520the%2520kinase%2520activities%2520of%2520ATR%2520and%2520ATM%2520exhibits%2520antitumoral%2520activity%2520in%2520mouse%2520models%2520of%2520MLL-rearranged%2520AML%26jtitle%3DSci.%2520Signaling%26date%3D2016%26volume%3D9%26issue%3D445%26spage%3Dra91%26doi%3D10.1126%2Fscisignal.aad8243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafiq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermulen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span> <span> </span><span class="NLM_article-title">ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13837</span>– <span class="NLM_lpage">13850</span>, <span class="refDoi"> DOI: 10.1038/ncomms13837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1038%2Fncomms13837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=27958275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamtrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13837-13850&author=C.+T.+Williamsonauthor=R.+Millerauthor=H.+N.+Pembertonauthor=S.+E.+Jonesauthor=J.+Campbellauthor=A.+Kondeauthor=N.+Badhamauthor=R.+Rafiqauthor=R.+Broughauthor=A.+Gulatiauthor=C.+J.+Ryanauthor=J.+Francisauthor=P.+B.+Vermulenauthor=A.+R.+Reynoldsauthor=P.+M.+Reaperauthor=J.+R.+Pollardauthor=A.+Ashworthauthor=C.+J.+Lord&title=ATR+inhibitors+as+a+synthetic+lethal+therapy+for+tumours+deficient+in+ARID1A&doi=10.1038%2Fncomms13837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A</span></div><div class="casAuthors">Williamson, Chris T.; Miller, Rowan; Pemberton, Helen N.; Jones, Samuel E.; Campbell, James; Konde, Asha; Badham, Nicholas; Rafiq, Rumana; Brough, Rachel; Gulati, Aditi; Ryan, Colm J.; Francis, Jeff; Vermulen, Peter B.; Reynolds, Andrew R.; Reaper, Philip M.; Pollard, John R.; Ashworth, Alan; Lord, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13837</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies.  Mutations in ARID1A represent one of the most common mol. alterations in human cancer, but therapeutic approaches that target these defects are not yet clin. available.  We demonstrate that defects in ARID1A sensitize tumor cells to clin. inhibitors of the DNA damage checkpoint kinase, ATR, both in vitro and in vivo.  Mechanistically, ARID1A deficiency results in topoisomerase 2A and cell cycle defects, which cause an increased reliance on ATR checkpoint activity.  In ARID1A mutant tumor cells, inhibition of ATR triggers premature mitotic entry, genomic instability and apoptosis.  The data presented here provide the pre-clin. and mechanistic rationale for assessing ARID1A defects as a biomarker of single-agent ATR inhibitor response and represents a novel synthetic lethal approach to targeting tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi9cKHrgrcHLVg90H21EOLACvtfcHk0lgumd27Y51DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamtrnI&md5=5b12d69b190de8f14c121366ee0c26a3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fncomms13837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13837%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DPemberton%26aufirst%3DH.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BE.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DKonde%26aufirst%3DA.%26aulast%3DBadham%26aufirst%3DN.%26aulast%3DRafiq%26aufirst%3DR.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DGulati%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DC.%2BJ.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DVermulen%26aufirst%3DP.%2BB.%26aulast%3DReynolds%26aufirst%3DA.%2BR.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26atitle%3DATR%2520inhibitors%2520as%2520a%2520synthetic%2520lethal%2520therapy%2520for%2520tumours%2520deficient%2520in%2520ARID1A%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13837%26epage%3D13850%26doi%3D10.1038%2Fncomms13837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenkort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón-Montaño, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortusewicz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiper, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scobie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3407</span>– <span class="NLM_lpage">3416</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.celrep.2016.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=28009306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=3407-3416&author=K.+Sanjivauthor=A.+Hagenkortauthor=J.+M.+Calder%C3%B3n-Monta%C3%B1oauthor=T.+Koolmeisterauthor=P.+M.+Reaperauthor=O.+Mortusewiczauthor=S.+A.+Jacquesauthor=R.+V.+Kuiperauthor=N.+Schultzauthor=M.+Scobieauthor=P.+A.+Charltonauthor=J.+R.+Pollardauthor=U.+W.+Berglundauthor=M.+Altunauthor=T.+Helleday&title=Cancer-Specific+Synthetic+Lethality+between+ATR+and+CHK1+Kinase+Activities&doi=10.1016%2Fj.celrep.2016.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities [Erratum to document cited in CA165:589929]</span></div><div class="casAuthors">Sanjiv, Kumar; Hagenkort, Anna; Calderon-Montano, Jose Manuel; Koolmeister, Tobias; Reaper, Philip M.; Mortusewicz, Oliver; Jacques, Sylvain A.; Kuiper, Raoul V.; Schultz, Niklas; Scobie, Martin; Charlton, Peter A.; Pollard, John R.; Berglund, Ulrika Warpman; Altun, Mikael; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3407-3416</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-P9L07AcZ7bVg90H21EOLACvtfcHk0lgumd27Y51DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL&md5=1972b2221b3d31fb519def6fb70288e3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DHagenkort%26aufirst%3DA.%26aulast%3DCalder%25C3%25B3n-Monta%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3DKoolmeister%26aufirst%3DT.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DMortusewicz%26aufirst%3DO.%26aulast%3DJacques%26aufirst%3DS.%2BA.%26aulast%3DKuiper%26aufirst%3DR.%2BV.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DScobie%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DCancer-Specific%2520Synthetic%2520Lethality%2520between%2520ATR%2520and%2520CHK1%2520Kinase%2520Activities%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26spage%3D3407%26epage%3D3416%26doi%3D10.1016%2Fj.celrep.2016.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and rad3 related (ATR) kinase with application as an anti-cancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9889</span>– <span class="NLM_lpage">9907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9889-9907&issue=22&author=K.+M.+Footeauthor=J.+W.+M.+Nissinkauthor=T.+M.+McGuireauthor=P.+Turnerauthor=S.+Guichardauthor=J.+T.+Yatesauthor=A.+Lauauthor=K.+Bladesauthor=D.+Heathcoteauthor=R.+Odedraauthor=G.+Wilkinsonauthor=Z.+Wilsonauthor=C.+Woodauthor=P.+J.+Jewsbury&title=Discovery+and+characterization+of+AZD6738%2C+a+potent+inhibitor+of+ataxia+telangiectasia+mutated+and+rad3+related+%28ATR%29+kinase+with+application+as+an+anti-cancer+agent&doi=10.1021%2Facs.jmedchem.8b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span></div><div class="casAuthors">Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; Wilkinson, Gary; Wilson, Zena; Wood, Christine M.; Jewsbury, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9889-9907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and assocd. DNA double-strand breaks.  Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clin. response by increasing replication stress.  Here the authors describe the development of the clin. candidate II (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclin. physicochem. and pharmacokinetic (PK) characteristics.  Compd. II was developed improving aq. soly. and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor I (AZ20).  The clin. candidate II has favorable human PK suitable for once or twice daily dosing and achieves biol. effective exposure at moderate doses.  Compd. II is currently being tested in multiple phase I/II trials as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr419z5SGLz_LVg90H21EOLACvtfcHk0lh81D50vTdfPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F&md5=992b9a9669f1e58926d3e7e4d4e816ba</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01187%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DJ.%2BT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DC.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520AZD6738%252C%2520a%2520potent%2520inhibitor%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520rad3%2520related%2520%2528ATR%2529%2520kinase%2520with%2520application%2520as%2520an%2520anti-cancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D9889%26epage%3D9907%26doi%3D10.1021%2Facs.jmedchem.8b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciuto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padiernos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yutzy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alewine, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aladjem, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Phase I study of ATR inhibitor M6620 in combination with Topotecan in patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.76.6915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1200%2FJCO.2017.76.6915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=29252124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1594-1602&issue=16&author=A.+Thomasauthor=C.+E.+Redonauthor=L.+Sciutoauthor=E.+Padiernosauthor=J.+Jiauthor=M.+J.+Leeauthor=A.+Yunoauthor=S.+Leeauthor=Y.+Zhangauthor=L.+Tranauthor=W.+Yutzyauthor=A.+Rajanauthor=U.+Guhaauthor=H.+Chenauthor=R.+Hassanauthor=C.+C.+Alewineauthor=E.+Szaboauthor=S.+E.+Batesauthor=R.+J.+Kindersauthor=S.+M.+Steinbergauthor=J.+H.+Doroshowauthor=M.+I.+Aladjemauthor=J.+B.+Trepelauthor=Y.+Pommier&title=Phase+I+study+of+ATR+inhibitor+M6620+in+combination+with+Topotecan+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2017.76.6915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors</span></div><div class="casAuthors">Thomas, Anish; Redon, Christophe E.; Sciuto, Linda; Padiernos, Emerson; Ji, Jiuping; Lee, Min-Jung; Yuno, Akira; Lee, Sunmin; Zhang, Yiping; Tran, Lan; Yutzy, William; Rajan, Arun; Guha, Udayan; Chen, Haobin; Hassan, Raffit; Alewine, Christine C.; Szabo, Eva; Bates, Susan E.; Kinders, Robert J.; Steinberg, Seth M.; Doroshow, James H.; Aladjem, Mirit I.; Trepel, Jane B.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1594-1604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Our preclin. work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors.  We hypothesized that a combination of selective ATR inhibitor M6620 (previously VX-970) and topotecan, a selective TOP1 inhibitor, would be tolerable and active, particularly in tumors with high replicative stress.  Patients and Methods This phase I study tested the combination of M6620 and topotecan in 3-wk cycles using 3 + 3 dose escalation.  The primary end point was the identification of the max. tolerated dose of the combination.  Efficacy and pharmacodynamics were secondary end points.  Results Between Sept. 2016 and Feb. 2017, 21 patients enrolled.  The combination was well tolerated, which allowed for dose escalation to the highest planned dose level (topotecan 1.25 mg/m2, days 1 to 5; M6620 210 mg/m2, days 2 and 5).  One of six patients at this dose level experienced grade 4 thrombocytopenia that required transfusion, a dose-limiting toxicity.  Most common treatment-related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%); and thrombocytopenia (10%).  Two partial responses (≥ 18 mo, ≥ 7 mo) and seven stable disease responses ≥ 3 mo (median, 9 mo; range, 3 to 12 mo) were seen.  Three of five patients with small-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, ≥ 6, and ≥ 7 mo).  Pharmacodynamic studies showed preliminary evidence of ATR inhibition and enhanced DNA double-stranded breaks in response to the combination.  Conclusion To our knowledge, this report is the first of an ATR inhibitor-chemotherapy combination.  The max. dose of topotecan plus M6620 is tolerable.  The combination seems particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to topotecan alone.  Phase II studies with biomarker evaluation are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHK6PpVIvW0rVg90H21EOLACvtfcHk0lhz7LmMzpzSog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCiurg%253D&md5=f76544a67091d0e15a205fe42abfc29c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.76.6915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.76.6915%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DSciuto%26aufirst%3DL.%26aulast%3DPadiernos%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DYuno%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DYutzy%26aufirst%3DW.%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DGuha%26aufirst%3DU.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DHassan%26aufirst%3DR.%26aulast%3DAlewine%26aufirst%3DC.%2BC.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DAladjem%26aufirst%3DM.%2BI.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DPhase%2520I%2520study%2520of%2520ATR%2520inhibitor%2520M6620%2520in%2520combination%2520with%2520Topotecan%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D16%26spage%3D1594%26epage%3D1602%26doi%3D10.1200%2FJCO.2017.76.6915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thies, J. E.</span></span> <span> </span><span class="NLM_article-title">An efficient synthesis of arylpyrazines and bipyridines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2055</span>, <span class="refDoi"> DOI: 10.1021/jo00244a037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00244a037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaL1cXhvVKlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=2052-2055&author=W.+J.+Thompsonauthor=J.+H.+Jonesauthor=P.+A.+Lyleauthor=J.+E.+Thies&title=An+efficient+synthesis+of+arylpyrazines+and+bipyridines&doi=10.1021%2Fjo00244a037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of arylpyrazines and bipyridines</span></div><div class="casAuthors">Thompson, Wayne J.; Jones, James H.; Lyle, Paulette A.; Thies, J. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2052-5</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The coupling of chloro- or bromopyrazines and -pyridines with areneboronic acids in the presence of Pd(0) catalysts is described.  By use of the appropriate catalyst, the coupling of pyridineboronic acids was also achieved.  A convergent synthesis of the previously unknown 4-Me deriv. of the cardiotonic milrinone (I) is also described.  Thus, coupling of bromopyridine II (R = Br) with 4-pyridineboronic acid in the presence of Pd(OAc)2 and 1,1'-bis(diphenylphosphino)ferrocene gave 22% of the substituted bipyridine II (R = 4-pyridyl).  Hydrolysis of II (R = 4-pyridyl) gave 85% I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUNKqc4dZb7LVg90H21EOLACvtfcHk0lhz7LmMzpzSog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhvVKlu7c%253D&md5=ce1acf1d87830e12c01e5ca909aefd17</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjo00244a037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00244a037%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DW.%2BJ.%26aulast%3DJones%26aufirst%3DJ.%2BH.%26aulast%3DLyle%26aufirst%3DP.%2BA.%26aulast%3DThies%26aufirst%3DJ.%2BE.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520arylpyrazines%2520and%2520bipyridines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1988%26volume%3D53%26spage%3D2052%26epage%3D2055%26doi%3D10.1021%2Fjo00244a037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavapeddi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavarajappa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramya, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span> <span> </span><span class="NLM_article-title">Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating <i>Mycobacterium tuberculosis</i></span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1021/cb300510w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300510w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2gsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=519-523&author=P.+S.+Shirudeauthor=P.+Madhavapeddiauthor=J.+A.+Tuckerauthor=K.+Muruganauthor=V.+Patilauthor=H.+Basavarajappaauthor=A.+V.+Raichurkarauthor=V.+Humnabadkarauthor=S.+Husseinauthor=S.+Sharmaauthor=V.+K.+Ramyaauthor=C.+B.+Narayanauthor=T.+S.+Balganeshauthor=V.+K.+Sambandamurthy&title=Aminopyrazinamides%3A+novel+and+specific+GyrB+inhibitors+that+kill+replicating+and+nonreplicating+Mycobacterium+tuberculosis&doi=10.1021%2Fcb300510w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis</span></div><div class="casAuthors">Shirude, Pravin S.; Madhavapeddi, Prashanti; Tucker, Julie A.; Murugan, Kannan; Patil, Vikas; Basavarajappa, Halesha; Raichurkar, Anandkumar V.; Humnabadkar, Vaishali; Hussein, Syeed; Sharma, Sreevalli; Ramya, V. K.; Narayan, Chandan B.; Balganesh, Tanjore S.; Sambandamurthy, Vasan K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-523</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aminopyrazinamides originated from a high throughput screen targeting the Mycobacterium smegmatis (Msm) GyrB ATPase.  This series displays chem. tractability, robust structure-activity relationship, and potent antitubercular activity.  The crystal structure of Msm GyrB in complex with one of the aminopyrazinamides revealed promising attributes of specificity against other broad spectrum pathogens and selectivity against eukaryotic kinases due to novel interactions at hydrophobic pocket, unlike other known GyrB inhibitors.  The aminopyrazinamides display excellent mycobacterial kill under in vitro, intracellular, and hypoxic conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVejwI5h6ePLVg90H21EOLACvtfcHk0liWG7hsCPhoEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2gsLrI&md5=4f8053bd1721c40019c70fab7f6147be</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcb300510w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300510w%26sid%3Dliteratum%253Aachs%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DMadhavapeddi%26aufirst%3DP.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DMurugan%26aufirst%3DK.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DBasavarajappa%26aufirst%3DH.%26aulast%3DRaichurkar%26aufirst%3DA.%2BV.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DHussein%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DRamya%26aufirst%3DV.%2BK.%26aulast%3DNarayan%26aufirst%3DC.%2BB.%26aulast%3DBalganesh%26aufirst%3DT.%2BS.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26atitle%3DAminopyrazinamides%253A%2520novel%2520and%2520specific%2520GyrB%2520inhibitors%2520that%2520kill%2520replicating%2520and%2520nonreplicating%2520Mycobacterium%2520tuberculosis%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D519%26epage%3D523%26doi%3D10.1021%2Fcb300510w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoegdin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Alfredsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soederman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormoe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelissen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerning, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer’s disease: design, synthesis, and characterization of pyrazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9107</span>– <span class="NLM_lpage">9119</span>, <span class="refDoi"> DOI: 10.1021/jm201724m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201724m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9107-9119&author=S.+Bergauthor=M.+Berghauthor=S.+Hellbergauthor=K.+Hoegdinauthor=Y.+Lo-Alfredssonauthor=P.+Soedermanauthor=S.+von+Bergauthor=T.+Weigeltauthor=M.+Ormoeauthor=Y.+Xueauthor=J.+Tuckerauthor=J.+Neelissenauthor=E.+Jerningauthor=Y.+Nilssonauthor=R.+Bhat&title=Discovery+of+novel+potent+and+highly+selective+glycogen+synthase+kinase-3%CE%B2+%28GSK3%CE%B2%29+inhibitors+for+Alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+and+characterization+of+pyrazines&doi=10.1021%2Fjm201724m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines</span></div><div class="casAuthors">Berg, Stefan; Bergh, Margareta; Hellberg, Sven; Hoegdin, Katharina; Lo-Alfredsson, Yvonne; Soederman, Peter; von Berg, Stefan; Weigelt, Tatjana; Ormoe, Mats; Xue, Yafeng; Tucker, Julie; Neelissen, Jan; Jerning, Eva; Nilsson, Yvonne; Bhat, Ratan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9107-9119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metab.  Active forms of GSK3β localize to pretangle pathol. including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain.  By using a high throughput screening (HTS) approach to search for new chem. series and cocrystn. of key analogs to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetration.  The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDR4w7EMbaI7Vg90H21EOLACvtfcHk0liWG7hsCPhoEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D&md5=f1475e38163a8e81e9ca9a24b271a0be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm201724m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201724m%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DBergh%26aufirst%3DM.%26aulast%3DHellberg%26aufirst%3DS.%26aulast%3DHoegdin%26aufirst%3DK.%26aulast%3DLo-Alfredsson%26aufirst%3DY.%26aulast%3DSoederman%26aufirst%3DP.%26aulast%3Dvon%2BBerg%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DT.%26aulast%3DOrmoe%26aufirst%3DM.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DNeelissen%26aufirst%3DJ.%26aulast%3DJerning%26aufirst%3DE.%26aulast%3DNilsson%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520and%2520highly%2520selective%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520%2528GSK3%25CE%25B2%2529%2520inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520pyrazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9107%26epage%3D9119%26doi%3D10.1021%2Fjm201724m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, K. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of new benzofuranyl isoxazoles as antitubercular, antibacterial and antifungal agents</span>. <i>Indian J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-88&author=K.+Mannaauthor=Y.+K.+Agarwalauthor=K.+K.+Srinivasan&title=Synthesis+and+biological+evaluation+of+new+benzofuranyl+isoxazoles+as+antitubercular%2C+antibacterial+and+antifungal+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of new benzofuranyl isoxazoles as antitubercular, antibacterial and antifungal agents</span></div><div class="casAuthors">Manna, K.; Agarwal, Y. K.; Srinivasan, K. K.</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">IJCHEI</span>;
        ISSN:<span class="NLM_cas:issn">0971-1627</span>.
    
            (<span class="NLM_cas:orgname">Prof. R. S. Varma</span>)
        </div><div class="casAbstract">Substituted benzofuran-chalcones were prepd. by the reaction of 2-acetylbenzofuran with different arom. aldehydes in presence of strong base.  Benzofuran-chalcones on cyclocondensation with hydroxylamine hydrochloride in presence of sodium acetate, gave various 3-(1-benzofuran-2-yl)-5-phenylisoxazoles.  The structure of benzofuran-isoxazoles were established on the basis of spectral (IR, 1H NMR, Mass) data.  The benzofuran-isoxazoles were evaluated for their, antitubercular, antimicrobial and antiinflammatory activities.  Some of the compds. have shown promising antitubercular and antibacterial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgT2v5i4obYLVg90H21EOLACvtfcHk0liWG7hsCPhoEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrbE&md5=20647a9fa0dfc7b5049fb97cee953138</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManna%26aufirst%3DK.%26aulast%3DAgarwal%26aufirst%3DY.%2BK.%26aulast%3DSrinivasan%26aufirst%3DK.%2BK.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520benzofuranyl%2520isoxazoles%2520as%2520antitubercular%252C%2520antibacterial%2520and%2520antifungal%2520agents%26jtitle%3DIndian%2520J.%2520Heterocycl.%2520Chem.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Detistov, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuravel’, I. O.</span></span> <span> </span><span class="NLM_article-title">Isomeric 3-isoxadiazolylcoumarins and their derivatives</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/jhet.893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1002%2Fjhet.893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlaitLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=883-892&author=O.+S.+Detistovauthor=V.+D.+Orlovauthor=I.+O.+Zhuravel%E2%80%99&title=Isomeric+3-isoxadiazolylcoumarins+and+their+derivatives&doi=10.1002%2Fjhet.893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Isomeric 3-isoxadiazolylcoumarins and their derivatives</span></div><div class="casAuthors">Detistov, Oleksandr S.; Orlov, Valeriy D.; Zhuravel', Irina O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Preparative methods of synthesis of isomeric 3-isoxadiazolylcoumarins and their derivs. are presented.  Two new synthetic methods have been developed for 3-[1,2,4-oxadiazol-5-yl]coumarins I [R1 = H, 6-Br, 7-MeO, etc.; R2 = Ph, 4-MeOC6H4, 4-MeC6H4].  The first method is based on a three-component condensation of coumarin-3-carboxylic acids, 1,1'-carbonyldiimidazole, and amidoximes.  The second method uses cyclization of 5-cyanomethyl-1,2,4-oxadiazoles with salicylic aldehydes.  General approach for prepn. of 3-[1,2,4-oxadiazol-3-yl]coumarins has been developed.  Moreover, the aforementioned synthetic ways open the way for the synthesis of 2-iminoderivatives not described before, those were diversified by the reaction of nucleophilic substitution of 2-imino group with a numerous amino compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHapfSMapebVg90H21EOLACvtfcHk0lhoOjdnqDCaJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlaitLjL&md5=16b74cc54dca7b983a4852a6942771bb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fjhet.893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.893%26sid%3Dliteratum%253Aachs%26aulast%3DDetistov%26aufirst%3DO.%2BS.%26aulast%3DOrlov%26aufirst%3DV.%2BD.%26aulast%3DZhuravel%25E2%2580%2599%26aufirst%3DI.%2BO.%26atitle%3DIsomeric%25203-isoxadiazolylcoumarins%2520and%2520their%2520derivatives%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D883%26epage%3D892%26doi%3D10.1002%2Fjhet.893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisonette, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6793</span>– <span class="NLM_lpage">6799</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.bmcl.2011.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=21978683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6793-6799&author=D.+S.+Mortensenauthor=S.+M.+Perrin-Ninkovicauthor=R.+Harrisauthor=B.+G.+S.+Leeauthor=G.+Shevlinauthor=M.+Hickmanauthor=G.+Khambattaauthor=R.+R.+Bisonetteauthor=K.+E.+Fultzauthor=S.+Sankar&title=Discovery+and+SAR+exploration+of+a+novel+series+of+imidazo%5B4%2C5-b%5Dpyrazin-2-ones+as+potent+and+selective+mTOR+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2011.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span></div><div class="casAuthors">Mortensen, Deborah S.; Perrin-Ninkovic, Sophie M.; Harris, Roy; Lee, Branden G. S.; Shevlin, Graziella; Hickman, Matt; Khambatta, Gody; Bisonette, Rene R.; Fultz, Kimberly E.; Sankar, Sabita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6793-6799</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report here the discovery of a novel series of selective mTOR kinase inhibitors.  A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compds. with excellent mTOR potency and exquisite kinase selectivity.  Potent compds. from this series show >1000-fold selectivity over the related PI3Kα lipid kinase.  Further, compds. such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWly4sBJXgerVg90H21EOLACvtfcHk0lhoOjdnqDCaJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P&md5=d422a7d505c1032951547d997ac2e033</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%2BM.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DB.%2BG.%2BS.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBisonette%26aufirst%3DR.%2BR.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DSankar%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520SAR%2520exploration%2520of%2520a%2520novel%2520series%2520of%2520imidazo%255B4%252C5-b%255Dpyrazin-2-ones%2520as%2520potent%2520and%2520selective%2520mTOR%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6793%26epage%3D6799%26doi%3D10.1016%2Fj.bmcl.2011.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Epps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiamengo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotecki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martineza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertab, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morytkoa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekharc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinnere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewartb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallacea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design and synthesis of tricyclic cores for kinase inhibition</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.bmcl.2012.11.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=23265875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=693-698&author=S.+Van%0AEppsauthor=B.+Fiamengoauthor=J.+Edmundsauthor=A.+Ericssonauthor=K.+Frankauthor=M.+Friedmanauthor=D.+Georgeauthor=J.+Georgeauthor=E.+Goedkenauthor=B.+Koteckiauthor=G.+Martinezaauthor=P.+Mertabauthor=M.+Morytkoaauthor=S.+Shekharcauthor=B.+Skinnereauthor=K.+Stewartbauthor=J.+Vossaauthor=G.+Wallaceaauthor=L.+Wangaauthor=L.+Wangaauthor=N.+Wishart&title=Design+and+synthesis+of+tricyclic+cores+for+kinase+inhibition&doi=10.1016%2Fj.bmcl.2012.11.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tricyclic cores for kinase inhibition</span></div><div class="casAuthors">Van Epps, Stacy; Fiamengo, Bryan; Edmunds, Jeremy; Ericsson, Anna; Frank, Kristine; Friedman, Michael; George, Dawn; George, Jonathan; Goedken, Eric; Kotecki, Brian; Martinez, Gloria; Merta, Philip; Morytko, Michael; Shekhar, Shashank; Skinner, Barbara; Stewart, Kent; Voss, Jeffrey; Wallace, Grier; Wang, Lu; Wishart, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-698</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interest in therapeutic kinase inhibitors continues to grow beyond success in oncol.  To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores.  We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine.  Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw43t_VvXMbbVg90H21EOLACvtfcHk0lgpW7HpSPZHIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ&md5=59cb993b841a73569309f0fca703b4c4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BEpps%26aufirst%3DS.%26aulast%3DFiamengo%26aufirst%3DB.%26aulast%3DEdmunds%26aufirst%3DJ.%26aulast%3DEricsson%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DD.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DGoedken%26aufirst%3DE.%26aulast%3DKotecki%26aufirst%3DB.%26aulast%3DMartineza%26aufirst%3DG.%26aulast%3DMertab%26aufirst%3DP.%26aulast%3DMorytkoa%26aufirst%3DM.%26aulast%3DShekharc%26aufirst%3DS.%26aulast%3DSkinnere%26aufirst%3DB.%26aulast%3DStewartb%26aufirst%3DK.%26aulast%3DVossa%26aufirst%3DJ.%26aulast%3DWallacea%26aufirst%3DG.%26aulast%3DWanga%26aufirst%3DL.%26aulast%3DWanga%26aufirst%3DL.%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tricyclic%2520cores%2520for%2520kinase%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D693%26epage%3D698%26doi%3D10.1016%2Fj.bmcl.2012.11.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meudtner, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional “clickates” as versatile extended heteroaromatic building blocks: efficient synthesis via click chemistry, conformational preferences, and metal coordination</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">9834</span>– <span class="NLM_lpage">9840</span>, <span class="refDoi"> DOI: 10.1002/chem.200701240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1002%2Fchem.200701240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=17948330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1yltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=9834-9840&author=R.+M.+Meudtnerauthor=M.+Ostermeierauthor=R.+Goddardauthor=C.+Limbergauthor=S.+Hecht&title=Multifunctional+%E2%80%9Cclickates%E2%80%9D+as+versatile+extended+heteroaromatic+building+blocks%3A+efficient+synthesis+via+click+chemistry%2C+conformational+preferences%2C+and+metal+coordination&doi=10.1002%2Fchem.200701240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional "clickates" as versatile extended heteroaromatic building blocks: efficient synthesis via click chemistry, conformational preferences, and metal coordination</span></div><div class="casAuthors">Meudtner, Robert M.; Ostermeier, Marc; Goddard, Richard; Limberg, Christian; Hecht, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">9834-9840</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Click chem. was used to access 2,6-bis(1-aryl-1,2,3-triazol-4-yl)pyridines (BTPs) as versatile extended heteroarom. building blocks for their exploitation in supra-mol. chem., in particular foldamer and ligand design.  In addn. to their high-yielding synthesis using Cu1-catalyzed Huisgen-type 1,3-dipolar cycloaddn. reactions the formed triazole moieties constitute an integral part of the BTP framework and encode both its pronounced conformational preferences as well as its chelating ability.  A diverse set of sym. and nonsym. BTPs carrying electron-donating and -withdrawing substituents at both terminal aryl and the central pyridine moieties has efficiently been synthesized and could also readily be postfunctionalized with amphiphilic side chains and porphyrin chromophores.  In both soln. and solid state, the BTP scaffold adopts a highly conserved horseshoe-like anti-anti conformation.  Upon protonation or metal coordination, the BTP scaffold switches to the chelating syn-syn conformation.  Iron and europium complexes were prepd., successfully characterized by single-crystal x-ray diffraction anal., and investigated with regard to their spin state and luminescent properties.  The extended heteroarom. BTP scaffold should prove useful for the design of responsive foldamer backbones and the prepn. of new magnetic and emissive materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9LFkfQlOSbVg90H21EOLACvtfcHk0lgpW7HpSPZHIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1yltw%253D%253D&md5=933cf2919c758519bb706f90d25f4cce</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fchem.200701240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200701240%26sid%3Dliteratum%253Aachs%26aulast%3DMeudtner%26aufirst%3DR.%2BM.%26aulast%3DOstermeier%26aufirst%3DM.%26aulast%3DGoddard%26aufirst%3DR.%26aulast%3DLimberg%26aufirst%3DC.%26aulast%3DHecht%26aufirst%3DS.%26atitle%3DMultifunctional%2520%25E2%2580%259Cclickates%25E2%2580%259D%2520as%2520versatile%2520extended%2520heteroaromatic%2520building%2520blocks%253A%2520efficient%2520synthesis%2520via%2520click%2520chemistry%252C%2520conformational%2520preferences%252C%2520and%2520metal%2520coordination%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2007%26volume%3D13%26spage%3D9834%26epage%3D9840%26doi%3D10.1002%2Fchem.200701240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidner-Wells, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henninger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga-Spano, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argentieri, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachter, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hlasta, D. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4307</span>– <span class="NLM_lpage">4311</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.05.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.bmcl.2004.05.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=15261292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVWjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4307-4311&author=M.+A.+Weidner-Wellsauthor=T.+C.+Henningerauthor=S.+A.+Fraga-Spanoauthor=C.+M.+Boggsauthor=M.+Matheisauthor=D.+M.+Ritchieauthor=D.+C.+Argentieriauthor=M.+P.+Wachterauthor=D.+J.+Hlasta&title=Synthesis+and+structure%E2%80%93activity+relationships+of+3%2C5-diarylisoxazoles+and+3%2C5-diaryl-1%2C2%2C4-oxadiazoles%2C+novel+classes+of+small+molecule+interleukin-8+%28IL-8%29+receptor+antagonists&doi=10.1016%2Fj.bmcl.2004.05.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists</span></div><div class="casAuthors">Weidner-Wells, Michele A.; Henninger, Todd C.; Fraga-Spano, Stephanie A.; Boggs, Christine M.; Matheis, Michele; Ritchie, David M.; Argentieri, Dennis C.; Wachter, Michael P.; Hlasta, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4307-4311</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of 3,5-diarylisoxazole and 3,5-diaryl-1,2,4-oxadiazole, e.g., I, has been identified as IL-8 inhibitors.  These compds. exhibit activity in an IL-8 binding assay as well as in a functional assay of IL-8 induced elastase release from neutrophils.  In addn., one of the compds. exhibits oral activity in a rat adjuvant arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpefTRhch6g5LVg90H21EOLACvtfcHk0liwbMsD925GYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVWjt70%253D&md5=5ba3cc1cab2d534d1faaaeadd9320160</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.05.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.05.080%26sid%3Dliteratum%253Aachs%26aulast%3DWeidner-Wells%26aufirst%3DM.%2BA.%26aulast%3DHenninger%26aufirst%3DT.%2BC.%26aulast%3DFraga-Spano%26aufirst%3DS.%2BA.%26aulast%3DBoggs%26aufirst%3DC.%2BM.%26aulast%3DMatheis%26aufirst%3DM.%26aulast%3DRitchie%26aufirst%3DD.%2BM.%26aulast%3DArgentieri%26aufirst%3DD.%2BC.%26aulast%3DWachter%26aufirst%3DM.%2BP.%26aulast%3DHlasta%26aufirst%3DD.%2BJ.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25203%252C5-diarylisoxazoles%2520and%25203%252C5-diaryl-1%252C2%252C4-oxadiazoles%252C%2520novel%2520classes%2520of%2520small%2520molecule%2520interleukin-8%2520%2528IL-8%2529%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4307%26epage%3D4311%26doi%3D10.1016%2Fj.bmcl.2004.05.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoarau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsais, F.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed direct (hetero)arylation of ethyl oxazole-4-carboxylate: an efficient access to (hetero)aryloxazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">7383</span>– <span class="NLM_lpage">7386</span>, <span class="refDoi"> DOI: 10.1021/jo801093n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801093n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVarsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=7383-7386&author=C.+Verrierauthor=T.+Martinauthor=C.+Hoarauauthor=F.+Marsais&title=Palladium-catalyzed+direct+%28hetero%29arylation+of+ethyl+oxazole-4-carboxylate%3A+an+efficient+access+to+%28hetero%29aryloxazoles&doi=10.1021%2Fjo801093n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Direct (Hetero)arylation of Ethyl Oxazole-4-carboxylate: An Efficient Access to (Hetero)aryloxazoles</span></div><div class="casAuthors">Verrier, Cecile; Martin, Thibaut; Hoarau, Christophe; Marsais, Francis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7383-7386</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A straightforward route toward 2-(hetero)arylated and 2,5-di(hetero)arylated oxazoles through regiocontrolled palladium-catalyzed direct (hetero)arylation of Et oxazole-4-carboxylate with iodo-, bromo-, and chloro(hetero)aroms. followed by a two-step hydrolysis/decarboxylation sequence was described.  The method was applied here to a neat synthesis of two 2,5-di(hetero)aryloxazole natural products, balsoxin and texaline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJK_x9guZfj7Vg90H21EOLACvtfcHk0liwbMsD925GYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVarsLg%253D&md5=d34b4dd16ec3449962a90f0649b0866d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo801093n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801093n%26sid%3Dliteratum%253Aachs%26aulast%3DVerrier%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DHoarau%26aufirst%3DC.%26aulast%3DMarsais%26aufirst%3DF.%26atitle%3DPalladium-catalyzed%2520direct%2520%2528hetero%2529arylation%2520of%2520ethyl%2520oxazole-4-carboxylate%253A%2520an%2520efficient%2520access%2520to%2520%2528hetero%2529aryloxazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D7383%26epage%3D7386%26doi%3D10.1021%2Fjo801093n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besselievre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrequier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahuteau-Betzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piguel, S.</span></span> <span> </span><span class="NLM_article-title">C-H bond activation: a versatile protocol for the direct arylation and alkenylation of oxazoles</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2009</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3511</span>– <span class="NLM_lpage">3518</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1216987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1055%2Fs-0029-1216987" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=3511-3518&issue=20&author=F.+Besselievreauthor=S.+Lebrequierauthor=F.+Mahuteau-Betzerauthor=S.+Piguel&title=C-H+bond+activation%3A+a+versatile+protocol+for+the+direct+arylation+and+alkenylation+of+oxazoles&doi=10.1055%2Fs-0029-1216987"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1216987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1216987%26sid%3Dliteratum%253Aachs%26aulast%3DBesselievre%26aufirst%3DF.%26aulast%3DLebrequier%26aufirst%3DS.%26aulast%3DMahuteau-Betzer%26aufirst%3DF.%26aulast%3DPiguel%26aufirst%3DS.%26atitle%3DC-H%2520bond%2520activation%253A%2520a%2520versatile%2520protocol%2520for%2520the%2520direct%2520arylation%2520and%2520alkenylation%2520of%2520oxazoles%26jtitle%3DSynthesis%26date%3D2009%26volume%3D2009%26issue%3D20%26spage%3D3511%26epage%3D3518%26doi%3D10.1055%2Fs-0029-1216987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endres, G. W.</span>; <span class="NLM_string-name">Lee, P. H.</span>; <span class="NLM_string-name">Olson, K. L.</span>; <span class="NLM_string-name">Kramer, J. B.</span>; <span class="NLM_string-name">Ciske, F. L.</span>; <span class="NLM_string-name">Barrett, S. D.</span></span> <span> </span><span class="NLM_article-title">Multiheteroaryl Compounds as Inhibitors of H-PGDS and Their Use for Treating Prostaglandin D2Mediated Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO 2010033977 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=G.+W.+Endres&author=P.+H.+Lee&author=K.+L.+Olson&author=J.+B.+Kramer&author=F.+L.+Ciske&author=S.+D.+Barrett&title=Multiheteroaryl+Compounds+as+Inhibitors+of+H-PGDS+and+Their+Use+for+Treating+Prostaglandin+D2Mediated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEndres%26aufirst%3DG.%2BW.%26atitle%3DMultiheteroaryl%2520Compounds%2520as%2520Inhibitors%2520of%2520H-PGDS%2520and%2520Their%2520Use%2520for%2520Treating%2520Prostaglandin%2520D2Mediated%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molander, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. R.</span></span> <span> </span><span class="NLM_article-title">Suzuki–Miyaura cross-coupling reactions of potassium vinyltrifluoroborate with aryl and heteroaryl electrophiles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">9681</span>– <span class="NLM_lpage">9686</span>, <span class="refDoi"> DOI: 10.1021/jo0617013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0617013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=9681-9686&issue=26&author=G.+A.+Molanderauthor=A.+R.+Brown&title=Suzuki%E2%80%93Miyaura+cross-coupling+reactions+of+potassium+vinyltrifluoroborate+with+aryl+and+heteroaryl+electrophiles&doi=10.1021%2Fjo0617013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Suzuki-Miyaura cross-coupling reactions of potassium vinyltrifluoroborate with aryl and heteroaryl electrophiles</span></div><div class="casAuthors">Molander, Gary A.; Brown, Adam R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9681-9686</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed cross-coupling reaction of potassium vinyltrifluoroborate with aryl electrophiles was described.  Recent progress in optimizing the reaction, as well as outlining the scope and limitations of the reaction were presented.  The cross-coupling reaction could generally be effected using 2 mol % of PdCl2 and 6 mol % of PPh3 as a catalyst system in THF/H2O with Cs2CO3 as a base.  Moderate to good yields were obtained in the presence of a variety of functional groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MqLzCH3iurVg90H21EOLACvtfcHk0lg_vrrlpIDKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN&md5=67aef9e362d578497bce6c9f89effcf4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjo0617013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0617013%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DBrown%26aufirst%3DA.%2BR.%26atitle%3DSuzuki%25E2%2580%2593Miyaura%2520cross-coupling%2520reactions%2520of%2520potassium%2520vinyltrifluoroborate%2520with%2520aryl%2520and%2520heteroaryl%2520electrophiles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26issue%3D26%26spage%3D9681%26epage%3D9686%26doi%3D10.1021%2Fjo0617013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramón, D. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 3,5-disubstituted isoxazoles and isoxazolines in deep eutectic solvents</span>. <i>ACS Sustainable Chem. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2343</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1021/acssuschemeng.5b00689</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acssuschemeng.5b00689" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlelsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=2343-2349&author=J.+M.+Perezauthor=D.+J.+Ram%C3%B3n&title=Synthesis+of+3%2C5-disubstituted+isoxazoles+and+isoxazolines+in+deep+eutectic+solvents&doi=10.1021%2Facssuschemeng.5b00689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 3,5-Disubstituted Isoxazoles and Isoxazolines in Deep Eutectic Solvents</span></div><div class="casAuthors">Perez, Juana M.; Ramon, Diego J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Sustainable Chemistry & Engineering</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2343-2349</span>CODEN:
                <span class="NLM_cas:coden">ASCECG</span>;
        ISSN:<span class="NLM_cas:issn">2168-0485</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of different 3,5-disubstituted isoxazoles and related isoxazolines using choline chloride:urea as deep eutectic solvent (DES) in a one-pot three step reaction has been accomplished successfully.  The use of highly nucleophilic functionalized DES did not affect the process where highly electrophilic reagents or intermediates are involved.  The presence of DES showed to be essential since the reaction in absence of this media did not proceed.  The DES media could be reused up to five times without a detrimental effect on the yield of the reaction.  To exemplify the synthetic potential of this methodol., the reaction was scaled up to the gram scale without any noticeable problem.  Finally, different isoxazoles were easily transformed into β-aminoenones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Id_XridrBLVg90H21EOLACvtfcHk0lg_vrrlpIDKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlelsrjJ&md5=fbfd32e2a776ab20d38a291bfdd6fe67</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facssuschemeng.5b00689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facssuschemeng.5b00689%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DJ.%2BM.%26aulast%3DRam%25C3%25B3n%26aufirst%3DD.%2BJ.%26atitle%3DSynthesis%2520of%25203%252C5-disubstituted%2520isoxazoles%2520and%2520isoxazolines%2520in%2520deep%2520eutectic%2520solvents%26jtitle%3DACS%2520Sustainable%2520Chem.%2520Eng.%26date%3D2015%26volume%3D3%26spage%3D2343%26epage%3D2349%26doi%3D10.1021%2Facssuschemeng.5b00689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotaiah, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikrishna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraju, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkata Rao, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antioxidant activity of 1,3,4-oxadiazole tagged thieno[2,3-d]pyrimidine derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.ejmech.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=23149297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOrsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=340-345&author=Y.+Kotaiahauthor=N.+Harikrishnaauthor=K.+Nagarajuauthor=C.+Venkata+Rao&title=Synthesis+and+antioxidant+activity+of+1%2C3%2C4-oxadiazole+tagged+thieno%5B2%2C3-d%5Dpyrimidine+derivatives&doi=10.1016%2Fj.ejmech.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antioxidant activity of 1,3,4-oxadiazole tagged thieno[2,3-d]pyrimidine derivatives</span></div><div class="casAuthors">Kotaiah, Y.; Harikrishna, N.; Nagaraju, K.; Venkata Rao, C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This study represents the synthesis of a new series of N-substituted phenyl-5-methyl-6-(5-(4-substituted phenyl)-1,3,4-oxadiazol-2-yl)thieno[2,3-d]pyrimidin-4-amine derivs. and substituted phenylamino-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid derivs.  The newly synthesized compds. were characterized by 1H NMR, 13C NMR, LC-MS and IR analyses.  All these novel compds. were screened for their in vitro antioxidant activity by employing DPPH, hydrogen peroxide, and nitric oxide radical scavenging assays.  Four compds., e.g., I (R = H, Cl), showed significant radical scavenging due to the presence of electron donating substituent on both sides of the thienopyrimidine ring enhances the activity and electron withdrawing groups like nitro decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKqSFgEPyNrrVg90H21EOLACvtfcHk0ljP11xuin41yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOrsr3F&md5=3bae7d7cef6f1968733acd49dbd40e3f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DKotaiah%26aufirst%3DY.%26aulast%3DHarikrishna%26aufirst%3DN.%26aulast%3DNagaraju%26aufirst%3DK.%26aulast%3DVenkata%2BRao%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520antioxidant%2520activity%2520of%25201%252C3%252C4-oxadiazole%2520tagged%2520thieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D58%26spage%3D340%26epage%3D345%26doi%3D10.1016%2Fj.ejmech.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kocevar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanovnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisler, M.</span></span> <span> </span><span class="NLM_article-title">Syntheses and transformations of some 1,2,4-oxadiazolylpyrazines</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570190629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1002%2Fjhet.5570190629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaL3sXhsVegtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1982&pages=1397-1402&issue=6&author=M.+Kocevarauthor=B.+Stanovnikauthor=M.+Tisler&title=Syntheses+and+transformations+of+some+1%2C2%2C4-oxadiazolylpyrazines&doi=10.1002%2Fjhet.5570190629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and transformations of some 1,2,4-oxadiazolylpyrazines</span></div><div class="casAuthors">Kocevar, M.; Stanovnik, B.; Tisler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1397-402</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">Cyanopyrazines with 2-amino, 2-oxo, and other groups are transformed into the corresponding amidoximes, e.g. I.  From these the corresponding 1,2,4-oxadiazolyl derivs., e.g. II, can be prepd. and interconversions to the corresponding pteridine 3-oxides, e.g. III, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRPDzt4JuAeLVg90H21EOLACvtfcHk0ljP11xuin41yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsVegtbk%253D&md5=b36096204b7d362be36541550be7caab</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570190629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570190629%26sid%3Dliteratum%253Aachs%26aulast%3DKocevar%26aufirst%3DM.%26aulast%3DStanovnik%26aufirst%3DB.%26aulast%3DTisler%26aufirst%3DM.%26atitle%3DSyntheses%2520and%2520transformations%2520of%2520some%25201%252C2%252C4-oxadiazolylpyrazines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1982%26volume%3D19%26issue%3D6%26spage%3D1397%26epage%3D1402%26doi%3D10.1002%2Fjhet.5570190629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwöbel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, R. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüürmann, G.</span></span> <span> </span><span class="NLM_article-title">Prediction of the intrinsic hydrogen bond acceptor strength of organic compounds by local molecular parameters</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">956</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1021/ci900040z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900040z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BD1MzgtVChuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=956-962&author=J.+Schw%C3%B6belauthor=R.+U.+Ebertauthor=R.+K%C3%BChneauthor=G.+Sch%C3%BC%C3%BCrmann&title=Prediction+of+the+intrinsic+hydrogen+bond+acceptor+strength+of+organic+compounds+by+local+molecular+parameters&doi=10.1021%2Fci900040z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the intrinsic hydrogen bond acceptor strength of organic compounds by local molecular parameters</span></div><div class="casAuthors">Schwobel Johannes; Ebert Ralf-Uwe; Kuhne Ralph; Schuurmann Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">956-62</span>
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    </div><div class="casAbstract">A quantum chemical model has been developed for predicting the hydrogen bond (HB) acceptor strength of monofunctional organic compounds from electronic ground-state properties of the single molecules.  Local molecular parameters are used to quantify electrostatic, polarizability, and charge transfer components to hydrogen bonding, employing the ab initio and density functional theory levels HF/6-31G** and B3LYP/6-31G**.  The model can handle lone pairs of intermediate and strong HB acceptor heteroatoms (N, O, S) as well as of weak HB acceptor halogens (F, Cl, Br) and includes also olefinic, alkyne, and aromatic pi-bonds as weak HB acceptor sites.  The model calibration with 403 compounds and experimental values for the Abraham HB acceptor strength B yielded squared correlation coefficients r(2) around 0.95, outperforming existing fragment-based schemes.  Model validation was performed applying a leave-50%-out procedure, yielding predictive squared correlation coefficients q(2) of around 0.95 for the subsets that both cover the whole chemical domain as well as (almost) the whole target value range of the data set.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRePc6NffI_hBJ5E29YNGvQfW6udTcc2eZNyyGhisngfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzgtVChuw%253D%253D&md5=169584aa718e974920c1dab9b49a81df</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fci900040z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900040z%26sid%3Dliteratum%253Aachs%26aulast%3DSchw%25C3%25B6bel%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DR.%2BU.%26aulast%3DK%25C3%25BChne%26aufirst%3DR.%26aulast%3DSch%25C3%25BC%25C3%25BCrmann%26aufirst%3DG.%26atitle%3DPrediction%2520of%2520the%2520intrinsic%2520hydrogen%2520bond%2520acceptor%2520strength%2520of%2520organic%2520compounds%2520by%2520local%2520molecular%2520parameters%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D956%26epage%3D962%26doi%3D10.1021%2Fci900040z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hariharan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pople, J. A.</span></span> <span> </span><span class="NLM_article-title">The influence of polarization functions on molecular orbital hydrogenation energies</span>. <i>Theor. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1007/BF00533485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1007%2FBF00533485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaE3sXhtFGnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1973&pages=213-222&author=P.+C.+Hariharanauthor=J.+A.+Pople&title=The+influence+of+polarization+functions+on+molecular+orbital+hydrogenation+energies&doi=10.1007%2FBF00533485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of polarization functions on MO hydrogenation energies</span></div><div class="casAuthors">Hariharan, P. C.; Pople, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Theoretica Chimica Acta</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-22</span>CODEN:
                <span class="NLM_cas:coden">TCHAAM</span>;
        ISSN:<span class="NLM_cas:issn">0040-5744</span>.
    </div><div class="casAbstract">The hydrogenation energies of mols. involving H, C, O, N, and F with 2 non-H atoms were calcd. by a basis including polarization functions.  The mean abs. deviation between theory and expt. for heats of hydrogenation of the closed shell species is 4 kcal/mole for the basis set with full polarization.  Ests. of hydrogenation energy errors at the Hartree-Fock limit are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFfQCpw_j23bVg90H21EOLACvtfcHk0liJKkYeMpyEMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXhtFGnsL4%253D&md5=a762a12b4ae5f50d14b4e29147b214e5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2FBF00533485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00533485%26sid%3Dliteratum%253Aachs%26aulast%3DHariharan%26aufirst%3DP.%2BC.%26aulast%3DPople%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520influence%2520of%2520polarization%2520functions%2520on%2520molecular%2520orbital%2520hydrogenation%2520energies%26jtitle%3DTheor.%2520Chim.%2520Acta%26date%3D1973%26volume%3D28%26spage%3D213%26epage%3D222%26doi%3D10.1007%2FBF00533485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional exchange-energy approximation with correct asymptotic-behavior</span>. <i>Phys. Rev. A: At., Mol., Opt. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3100</span>, <span class="refDoi"> DOI: 10.1103/PhysRevA.38.3098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1103%2FPhysRevA.38.3098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=9900728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaL1cXmtlOhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1988&pages=3098-3100&author=A.+D.+Becke&title=Density-functional+exchange-energy+approximation+with+correct+asymptotic-behavior&doi=10.1103%2FPhysRevA.38.3098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional exchange-energy approximation with correct asymptotic behavior</span></div><div class="casAuthors">Becke, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Review A:  Atomic, Molecular, and Optical Physics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3098-100</span>CODEN:
                <span class="NLM_cas:coden">PLRAAN</span>;
        ISSN:<span class="NLM_cas:issn">0556-2791</span>.
    </div><div class="casAbstract">Current gradient-cor. d.-functional approxns. for the exchange energies of at. and mol. systems fail to reproduce the correct 1/r asymptotic behavior of the exchange-energy d.  A gradient-cor. exchange-energy functional is given with the proper asymptotic limit.  This functional, contg. only one parameter, fits the exact Hartree-Fock exchange energies of a wide variety of at. systems with remarkable accuracy, surpassing the performance of previous functionals contg. two parameters or more.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKr-bPUej6TLVg90H21EOLACvtfcHk0liJKkYeMpyEMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtlOhsLo%253D&md5=d4d219c134a5a90f689a8abed04d82cc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1103%2FPhysRevA.38.3098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevA.38.3098%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520exchange-energy%2520approximation%2520with%2520correct%2520asymptotic-behavior%26jtitle%3DPhys.%2520Rev.%2520A%253A%2520At.%252C%2520Mol.%252C%2520Opt.%2520Phys.%26date%3D1988%26volume%3D38%26spage%3D3098%26epage%3D3100%26doi%3D10.1103%2FPhysRevA.38.3098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabalowski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span></span> <span> </span><span class="NLM_article-title">Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields</span>. <i>J. Phys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">11623</span>– <span class="NLM_lpage">11627</span>, <span class="refDoi"> DOI: 10.1021/j100096a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/j100096a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaK2cXmvVSitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1994&pages=11623-11627&author=P.+J.+Stephensauthor=F.+J.+Devlinauthor=C.+F.+Chabalowskiauthor=M.+J.+Frisch&title=Ab+initio+calculation+of+vibrational+absorption+and+circular+dichroism+spectra+using+density+functional+force+fields&doi=10.1021%2Fj100096a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields</span></div><div class="casAuthors">Stephens, P. J.; Devlin, F. J.; Chabalowski, C. F.; Frisch, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11623-7</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">The unpolarized absorption and CD spectra of the fundamental vibrational transitions of the chiral mol. 4-methyl-2-oxetanone are calcd. ab initio.  Harmonic force fields are obtained using d. functional theory (DFT), MP2 and SCF methodologies, and a [5s4p2d/3s2p] (TZ2P) basis set.  DFT calcns. use the LSDA, BLYP, and Becke3LYP (B3LYP) d. functionals.  Mid-IR spectra predicted using LSDA, BLYP, and B3LYP force fields are of significantly different quality, the B3LYP force field yielding spectra in clearly superior, and overall excellent, agreement with expt.  The MP2 force field yields spectra in slightly worse agreement with expt. than the B3LYP force field.  The SCF force field yields spectra in poor agreement with expt.  The basis set dependence of B3LYP force fields is also explored: the 6-31G* and TZ2P basis sets give very similar results while the 3-21G basis set yields spectra in substantially worse agreement with expt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpodK8tBZ2embVg90H21EOLACvtfcHk0ligq7iKbfwOAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvVSitbY%253D&md5=93486da1864d900b4527d020cf36171f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fj100096a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100096a001%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DDevlin%26aufirst%3DF.%2BJ.%26aulast%3DChabalowski%26aufirst%3DC.%2BF.%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26atitle%3DAb%2520initio%2520calculation%2520of%2520vibrational%2520absorption%2520and%2520circular%2520dichroism%2520spectra%2520using%2520density%2520functional%2520force%2520fields%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1994%26volume%3D98%26spage%3D11623%26epage%3D11627%26doi%3D10.1021%2Fj100096a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">J Med Chem. 2015, A survey of the role of noncovalent sulfur interactions in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4438</span>, <span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-4438&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=J+Med+Chem.+2015%2C+A+survey+of+the+role+of+noncovalent+sulfur+interactions+in+drug+design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0ligq7iKbfwOAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DJ%2520Med%2520Chem.%25202015%252C%2520A%2520survey%2520of%2520the%2520role%2520of%2520noncovalent%2520sulfur%2520interactions%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4383%26epage%3D4438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unsal-Kaçmaz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhov, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancar, A.</span></span> <span> </span><span class="NLM_article-title">Preferential binding of ATR protein to UV-damaged DNA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">6673</span>– <span class="NLM_lpage">6678</span>, <span class="refDoi"> DOI: 10.1073/pnas.102167799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1073%2Fpnas.102167799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=12011431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFCrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=6673-6678&author=K.+Unsal-Ka%C3%A7mazauthor=A.+M.+Makhovauthor=J.+D.+Griffithauthor=A.+Sancar&title=Preferential+binding+of+ATR+protein+to+UV-damaged+DNA&doi=10.1073%2Fpnas.102167799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Preferential binding of ATR protein to UV-damaged DNA</span></div><div class="casAuthors">Unsal-Kacmaz, Keziban; Makhov, Alexander M.; Griffith, Jack D.; Sancar, Aziz</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6673-6678</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The ATR protein is a member of the phosphoinositide 3-kinase-related kinase family and plays an important role in UV-induced DNA damage checkpoint response.  Its role as a signal transducer in cell cycle checkpoint is well established, but it is currently unclear whether ATR functions as a damage sensor as well.  Here we have purified the ATR protein and investigated its interaction with DNA by using biochem. anal. and electron microscopy.  We find that ATR is a DNA-binding protein with higher affinity to UV-damaged than undamaged DNA.  In addn., damaged DNA stimulates the kinase activity of ATR to a significantly higher level than undamaged DNA.  Our data suggest that ATR may function as an initial sensor in the DNA damage checkpoint response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1jwvkqkTQfrVg90H21EOLACvtfcHk0ligq7iKbfwOAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFCrs7s%253D&md5=ef944c34e3ce8d2a45a263485bf4269f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.102167799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.102167799%26sid%3Dliteratum%253Aachs%26aulast%3DUnsal-Ka%25C3%25A7maz%26aufirst%3DK.%26aulast%3DMakhov%26aufirst%3DA.%2BM.%26aulast%3DGriffith%26aufirst%3DJ.%2BD.%26aulast%3DSancar%26aufirst%3DA.%26atitle%3DPreferential%2520binding%2520of%2520ATR%2520protein%2520to%2520UV-damaged%2520DNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D6673%26epage%3D6678%26doi%3D10.1073%2Fpnas.102167799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span> <span> </span><span class="NLM_article-title">High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1177/108705719600100115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1177%2F108705719600100115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaK2sXkslSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=47-51&author=A.+M.+Pittauthor=C.+Lee&title=High+throughput+screening+protein+kinase+assays+optimized+for+reaction%2C+binding%2C+and+detection+totally+within+a+96-well+plate&doi=10.1177%2F108705719600100115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate</span></div><div class="casAuthors">Pitt, Aldo M.; Lee, Carolyn</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-51</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Liebert</span>)
        </div><div class="casAbstract">Signal transduction assays, particularly for protein kinases, are an area of increasing interest and activity for labs. investigating the regulation of cellular functions.  The traditional kinase assay methods require the tedious and time consuming manipulation of phosphocellulose disks typically used to bind the phosphorylated substrate.  Drug discovery research requires the availability of rapid and reliable procedures to evaluate large nos. of samples for bioactivity.  The 96-well phosphocellulose MultiScreen® assay plates were specifically developed to meet these assay requirements.  A cyclic-AMP-dependent protein kinase A (PKA) assay was optimized to be performed entirely within the phosphocellulose MultiScreen plate, including reagent and sample addn., incubation, washing, and direct microplate scintillation counting.  The protocol is directly adaptable to a high throughput kinase screen.  Both the Kemptide peptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) and the histone H1 protein were used as the phosphorylation substrates.  Crude and purified PKA enzymes were found to have a sensitivity of 0.4 U for Kemptide substrate, which was comparable to the assay performed by the traditional transfer to phosphocellulose paper.  The results demonstrate that kinase assays can be performed entirely in a MultiScreen phosphocellulose plate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonrwX6aYs2_rVg90H21EOLACvtfcHk0lhf8MYPzxLGfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslSksA%253D%253D&md5=d859992a0a8214289483419417007a7f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1177%2F108705719600100115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F108705719600100115%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DC.%26atitle%3DHigh%2520throughput%2520screening%2520protein%2520kinase%2520assays%2520optimized%2520for%2520reaction%252C%2520binding%252C%2520and%2520detection%2520totally%2520within%2520a%252096-well%2520plate%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D1996%26volume%3D1%26spage%3D47%26epage%3D51%26doi%3D10.1177%2F108705719600100115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prichard, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prichard, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, C.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Strategic design and three-dimensional analysis of antiviral drug combinations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.3.540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1128%2FAAC.37.3.540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=8384816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaK3sXitVCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=540-545&author=M.+N.+Prichardauthor=L.+E.+Prichardauthor=C.+Shipman&title=Strategic+design+and+three-dimensional+analysis+of+antiviral+drug+combinations&doi=10.1128%2FAAC.37.3.540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic design and three-dimensional analysis of antiviral drug combinations</span></div><div class="casAuthors">Prichard, Mark N.; Prichard, Lynn E.; Shipman, Charles, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">540-5</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The development of new drugs effective against human viral diseases has proven to be both difficult and time-consuming.  Indeed, there are but 10 drugs licensed for such applications in the United States today.  An attractive soln. to this problem may be to optimize the efficacy and selectivity of existing antiviral drugs by combining them with agents that strategically block carefully selected metabolic pathways.  This approach was used in the rational design of a 3-drug combination to increase the apparent potency of acyclovir against herpes simplex virus.  Recent advances in anal. techniques have made the evaluation of this complex drug strategy both possible and practical.  A modified version of a previously described anal. method was used to identify optimal drug concns. and to quantitate statistically significant synergy.  Concns. of 0.25 μM 5-fluorodeoxyuridine, 3.6 μM 2-acetylpyridine thiosemicarbazone, and 0.3 μM acyclovir were detd. to be optimal in terms of antiviral activity.  The vol. of synergy produced was nearly 2,000 μM3% at a 95% level of confidence (corresponding to a 186-fold decrease in the apparent 50% inhibitory concn. of acyclovir with the addn. of 0.25 μM 5-fluorodeoxyuridine and 3.6 μM 2-acetylpyridine thiosemicarbazone).  We anticipate that this strategic approach and the supporting three-dimensional anal. method will prove valuable in designing and understanding multidrug therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh_6_mJUc-YbVg90H21EOLACvtfcHk0lhf8MYPzxLGfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitVCktLY%253D&md5=12bfac78b4d866f48eeccc5e73a575e8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.3.540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.3.540%26sid%3Dliteratum%253Aachs%26aulast%3DPrichard%26aufirst%3DM.%2BN.%26aulast%3DPrichard%26aufirst%3DL.%2BE.%26aulast%3DShipman%26aufirst%3DC.%26atitle%3DStrategic%2520design%2520and%2520three-dimensional%2520analysis%2520of%2520antiviral%2520drug%2520combinations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26spage%3D540%26epage%3D545%26doi%3D10.1128%2FAAC.37.3.540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samuel H. Myers, Jose Antonio Ortega, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Cavalli</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Lethality through the Lens of Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14151-14183. <a href="https://doi.org/10.1021/acs.jmedchem.0c00766" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00766%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BLethality%252Bthrough%252Bthe%252BLens%252Bof%252BMedicinal%252BChemistry%26aulast%3DMyers%26aufirst%3DSamuel%2BH.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06052020%26date%3D02112020%26volume%3D63%26issue%3D23%26spage%3D14151%26epage%3D14183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nadia  Terranova</span>, <span class="hlFld-ContribAuthor ">Mendel  Jansen</span>, <span class="hlFld-ContribAuthor ">Martin  Falk</span>, <span class="hlFld-ContribAuthor ">Bart S.  Hendriks</span>. </span><span class="cited-content_cbyCitation_article-title">Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2021,</strong> <em>87 </em>
                                    (2)
                                     , 185-196. <a href="https://doi.org/10.1007/s00280-020-04184-z" title="DOI URL">https://doi.org/10.1007/s00280-020-04184-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-020-04184-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-020-04184-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DPopulation%252Bpharmacokinetics%252Bof%252BATR%252Binhibitor%252Bberzosertib%252Bin%252Bphase%252BI%252Bstudies%252Bfor%252Bdifferent%252Bcancer%252Btypes%26aulast%3DTerranova%26aufirst%3DNadia%26date%3D2021%26date%3D2020%26volume%3D87%26issue%3D2%26spage%3D185%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lukas  Gorecki</span>, <span class="hlFld-ContribAuthor ">Martin  Andrs</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 795. <a href="https://doi.org/10.3390/cancers13040795" title="DOI URL">https://doi.org/10.3390/cancers13040795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040795%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DClinical%252BCandidates%252BTargeting%252Bthe%252BATR%2525E2%252580%252593CHK1%2525E2%252580%252593WEE1%252BAxis%252Bin%252BCancer%26aulast%3DGorecki%26aufirst%3DLukas%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franca M.  Cordero</span>, <span class="hlFld-ContribAuthor ">Luisa  Lascialfari</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Machetti</span>. </span><span class="cited-content_cbyCitation_article-title">Five-membered ring systems with O and N atoms. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 365-395. <a href="https://doi.org/10.1016/B978-0-323-89812-6.00011-0" title="DOI URL">https://doi.org/10.1016/B978-0-323-89812-6.00011-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-89812-6.00011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-89812-6.00011-0%26sid%3Dliteratum%253Aachs%26atitle%3DFive-membered%252Bring%252Bsystems%252Bwith%252BO%252Band%252BN%252Batoms%26aulast%3DCordero%26aufirst%3DFranca%2BM.%26date%3D2021%26spage%3D365%26epage%3D395%26pub%3DElsevier%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. Alison  Rinderspacher</span>. </span><span class="cited-content_cbyCitation_article-title">Six-membered ring systems: diazines and benzo derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 431-466. <a href="https://doi.org/10.1016/B978-0-323-89812-6.00013-4" title="DOI URL">https://doi.org/10.1016/B978-0-323-89812-6.00013-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-89812-6.00013-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-89812-6.00013-4%26sid%3Dliteratum%253Aachs%26atitle%3DSix-membered%252Bring%252Bsystems%25253A%252Bdiazines%252Band%252Bbenzo%252Bderivatives%26aulast%3DRinderspacher%26aufirst%3DK.%2BAlison%26date%3D2021%26spage%3D431%26epage%3D466%26pub%3DElsevier%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francis M.  Barnieh</span>, <span class="hlFld-ContribAuthor ">Paul M.  Loadman</span>, <span class="hlFld-ContribAuthor ">Robert A.  Falconer</span>. </span><span class="cited-content_cbyCitation_article-title">Progress towards a clinically-successful ATR inhibitor for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Current Research in Pharmacology and Drug Discovery</span><span> <strong>2021,</strong> <em>2 </em>, 100017. <a href="https://doi.org/10.1016/j.crphar.2021.100017" title="DOI URL">https://doi.org/10.1016/j.crphar.2021.100017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.crphar.2021.100017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.crphar.2021.100017%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Research%2520in%2520Pharmacology%2520and%2520Drug%2520Discovery%26atitle%3DProgress%252Btowards%252Ba%252Bclinically-successful%252BATR%252Binhibitor%252Bfor%252Bcancer%252Btherapy%26aulast%3DBarnieh%26aufirst%3DFrancis%2BM.%26date%3D2021%26volume%3D2%26spage%3D100017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrycja  Gralewska</span>, <span class="hlFld-ContribAuthor ">Arkadiusz  Gajek</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Marczak</span>, <span class="hlFld-ContribAuthor ">Aneta  Rogalska</span>. </span><span class="cited-content_cbyCitation_article-title">Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00874-6" title="DOI URL">https://doi.org/10.1186/s13045-020-00874-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00874-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00874-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DParticipation%252Bof%252Bthe%252BATR%25252FCHK1%252Bpathway%252Bin%252Breplicative%252Bstress%252Btargeted%252Btherapy%252Bof%252Bhigh-grade%252Bovarian%252Bcancer%26aulast%3DGralewska%26aufirst%3DPatrycja%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manav  Gupta</span>, <span class="hlFld-ContribAuthor ">Carla P.  Concepcion</span>, <span class="hlFld-ContribAuthor ">Caroline G.  Fahey</span>, <span class="hlFld-ContribAuthor ">Hasmik  Keshishian</span>, <span class="hlFld-ContribAuthor ">Arjun  Bhutkar</span>, <span class="hlFld-ContribAuthor ">Christine F.  Brainson</span>, <span class="hlFld-ContribAuthor ">Francisco J.  Sanchez-Rivera</span>, <span class="hlFld-ContribAuthor ">Patrizia  Pessina</span>, <span class="hlFld-ContribAuthor ">Jonathan Y.  Kim</span>, <span class="hlFld-ContribAuthor ">Antoine  Simoneau</span>, <span class="hlFld-ContribAuthor ">Margherita  Paschini</span>, <span class="hlFld-ContribAuthor ">Mary C.  Beytagh</span>, <span class="hlFld-ContribAuthor ">Caroline R.  Stanclift</span>, <span class="hlFld-ContribAuthor ">Monica  Schenone</span>, <span class="hlFld-ContribAuthor ">D.R.  Mani</span>, <span class="hlFld-ContribAuthor ">Chendi  Li</span>, <span class="hlFld-ContribAuthor ">Audris  Oh</span>, <span class="hlFld-ContribAuthor ">Fei  Li</span>, <span class="hlFld-ContribAuthor ">Hai  Hu</span>, <span class="hlFld-ContribAuthor ">Angeliki  Karatza</span>, <span class="hlFld-ContribAuthor ">Roderick T.  Bronson</span>, <span class="hlFld-ContribAuthor ">Alice T.  Shaw</span>, <span class="hlFld-ContribAuthor ">Aaron N.  Hata</span>, <span class="hlFld-ContribAuthor ">Kwok-Kin  Wong</span>, <span class="hlFld-ContribAuthor ">Lee  Zou</span>, <span class="hlFld-ContribAuthor ">Steven A.  Carr</span>, <span class="hlFld-ContribAuthor ">Tyler  Jacks</span>, <span class="hlFld-ContribAuthor ">Carla F.  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (18)
                                     , 3841-3854. <a href="https://doi.org/10.1158/0008-5472.CAN-20-1744" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-20-1744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-20-1744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-20-1744%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DBRG1%252BLoss%252BPredisposes%252BLung%252BCancers%252Bto%252BReplicative%252BStress%252Band%252BATR%252BDependency%26aulast%3DGupta%26aufirst%3DManav%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D18%26spage%3D3841%26epage%3D3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lukas  Gorecki</span>, <span class="hlFld-ContribAuthor ">Martin  Andrs</span>, <span class="hlFld-ContribAuthor ">Martina  Rezacova</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>210 </em>, 107518. <a href="https://doi.org/10.1016/j.pharmthera.2020.107518" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2020.107518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2020.107518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2020.107518%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DDiscovery%252Bof%252BATR%252Bkinase%252Binhibitor%252Bberzosertib%252B%252528VX-970%25252C%252BM6620%252529%25253A%252BClinical%252Bcandidate%252Bfor%252Bcancer%252Btherapy%26aulast%3DGorecki%26aufirst%3DLukas%26date%3D2020%26volume%3D210%26spage%3D107518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alice  Bradbury</span>, <span class="hlFld-ContribAuthor ">Sally  Hall</span>, <span class="hlFld-ContribAuthor ">Nicola  Curtin</span>, <span class="hlFld-ContribAuthor ">Yvette  Drew</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>207 </em>, 107450. <a href="https://doi.org/10.1016/j.pharmthera.2019.107450" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2019.107450</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2019.107450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2019.107450%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTargeting%252BATR%252Bas%252BCancer%252BTherapy%25253A%252BA%252Bnew%252Bera%252Bfor%252Bsynthetic%252Blethality%252Band%252Bsynergistic%252Bcombinations%25253F%26aulast%3DBradbury%26aufirst%3DAlice%26date%3D2020%26volume%3D207%26spage%3D107450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antje M.  Wengner</span>, <span class="hlFld-ContribAuthor ">Gerhard  Siemeister</span>, <span class="hlFld-ContribAuthor ">Ulrich  Lücking</span>, <span class="hlFld-ContribAuthor ">Julien  Lefranc</span>, <span class="hlFld-ContribAuthor ">Lars  Wortmann</span>, <span class="hlFld-ContribAuthor ">Philip  Lienau</span>, <span class="hlFld-ContribAuthor ">Benjamin  Bader</span>, <span class="hlFld-ContribAuthor ">Ulf  Bömer</span>, <span class="hlFld-ContribAuthor ">Dieter  Moosmayer</span>, <span class="hlFld-ContribAuthor ">Uwe  Eberspächer</span>, <span class="hlFld-ContribAuthor ">Sven  Golfier</span>, <span class="hlFld-ContribAuthor ">Christoph A.  Schatz</span>, <span class="hlFld-ContribAuthor ">Simon J.  Baumgart</span>, <span class="hlFld-ContribAuthor ">Bernard  Haendler</span>, <span class="hlFld-ContribAuthor ">Pascale  Lejeune</span>, <span class="hlFld-ContribAuthor ">Andreas  Schlicker</span>, <span class="hlFld-ContribAuthor ">Franz  von Nussbaum</span>, <span class="hlFld-ContribAuthor ">Michael  Brands</span>, <span class="hlFld-ContribAuthor ">Karl  Ziegelbauer</span>, <span class="hlFld-ContribAuthor ">Dominik  Mumberg</span>. </span><span class="cited-content_cbyCitation_article-title">The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     , 26-38. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0019" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0019%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DThe%252BNovel%252BATR%252BInhibitor%252BBAY%252B1895344%252BIs%252BEfficacious%252Bas%252BMonotherapy%252Band%252BCombined%252Bwith%252BDNA%252BDamage%2525E2%252580%252593Inducing%252Bor%252BRepair%2525E2%252580%252593Compromising%252BTherapies%252Bin%252BPreclinical%252BCancer%252BModels%26aulast%3DWengner%26aufirst%3DAntje%2BM.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D1%26spage%3D26%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoyi  Sun</span>, <span class="hlFld-ContribAuthor ">Qi  Jia</span>, <span class="hlFld-ContribAuthor ">Zaihui  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of amide isosteres in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2535-2550. <a href="https://doi.org/10.1016/j.bmcl.2019.07.033" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DApplications%252Bof%252Bamide%252Bisosteres%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DSun%26aufirst%3DShaoyi%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2535%26epage%3D2550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mary-Ann  Bjornsti</span>, <span class="hlFld-ContribAuthor ">Scott H.  Kaufmann</span>. </span><span class="cited-content_cbyCitation_article-title">Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. </span><span class="cited-content_cbyCitation_journal-name">F1000Research</span><span> <strong>2019,</strong> <em>8 </em>, 1704. <a href="https://doi.org/10.12688/f1000research.20201.1" title="DOI URL">https://doi.org/10.12688/f1000research.20201.1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/f1000research.20201.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Ff1000research.20201.1%26sid%3Dliteratum%253Aachs%26jtitle%3DF1000Research%26atitle%3DTopoisomerases%252Band%252Bcancer%252Bchemotherapy%25253A%252Brecent%252Badvances%252Band%252Bunanswered%252Bquestions%26aulast%3DBjornsti%26aufirst%3DMary-Ann%26date%3D2019%26date%3D2019%26volume%3D8%26spage%3D1704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of compound <b>1</b> (VE-821) and compound <b>2</b> (VX-970/M6620).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Comparison of anilide <b>1</b> (in green) versus a benzimidazole isostere (in cyan) in a model of the active site of ATM based on PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a>. The benzimidazole is thought to experience steric hindrance from Tyr2755 in ATM. In response it rotates away from Tyr2755, which allows it to escape a steric clash with Pro2775 (Gly in ATR). (b) Replacing the benzimidazole with a phenyl substituted monocyclic heteroaryl (in cyan) yields a better mimic of the original anilide and avoids movement of the inhibitor due to steric hindrance with Tyr2755.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (4-isopropylsulfonylphenyl)boronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd[P(<i>t</i>-Bu)<sub>3</sub>]<sub>2</sub>, MeCN/H<sub>2</sub>O (4:1), 60 °C, 2 h, 97%; (b) LiOH, THF, rt, 2 h, 96%; (c) diethoxyphosphorylformonitrile, aniline, Et<sub>3</sub>N, DME, 120 °C, 18 h, 96%; (d) <i>N</i>-methoxymethanamine hydrochloride, HOBt, DIPEA, 3-(ethyliminomethyleneamino)-<i>N</i>,<i>N</i>-dimethylpropan-1-amine, THF, rt, 18 h, 77%; (e) MeMgBr 3 M in THF, THF, −20 °C, 1 h, 80%; (f) benzaldehyde, NaOH, MeOH/DCM (1:1), rt, 18 h, 70%; (g) hydroxylamine hydrochloride, NaOAc, EtOH/AcOH (10/3), 130 °C, 1 h, 17%; (h) CDI, <i>N</i>-hydroxybenzamidine, rt to 120 °C, 5 h, 67%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (4-isopropylsulfonylphenyl)boronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd[P(<i>t</i>-Bu)<sub>3</sub>]<sub>2</sub>, MeCN/H<sub>2</sub>O (4/1), 60 °C, 1 h, 87%; (b) NBS, DMF, rt, 3 h, 84%; (c) (trimethylsilyl)acetylene, CuI, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 0 °C to rt, 1 h, 81%; (d) Boc<sub>2</sub>O, DMAP, Et<sub>3</sub>N, DCM, rt, 18 h, 100%; (e) Na<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 1 h, 97%; (f) azidobenzene (0.5 M in MTBE), (+)-sodium <span class="smallcaps smallerCapital">l</span>-ascorbate, CuSO<sub>4</sub>·5H<sub>2</sub>O, <i>t</i>-BuOH/H<sub>2</sub>O (1:1), rt to 40 °C, 12 h, 41%; (g) TFA/DCM (1/3), rt, 1 h, 80%; (h) <i>N</i>-hydroxybenzimidoyl chloride, Et<sub>3</sub>N, DMF, 60 °C, 45 min, then TFA/DCM, rt, 1 h, 52%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-phenyloxazole, Ag<sub>2</sub>CO<sub>3</sub>, PPh<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, water, 70 °C, 24 h, 29%; (b) 5-phenyloxazole, <i>t</i>-BuOLi, Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, 140 °C in μwave, 3 h, 46%; (c) vinylpotassium trifluoroborate, Pd(dppf)Cl<sub>2</sub>, Et<sub>3</sub>N, <i>n</i>-PrOH, 100 °C in μwave, 40 min, 57%; (d) <i>N</i>-hydroxybenzimidoyl chloride, Et<sub>3</sub>N, DMF, 65 °C, 1 h, 58%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzohydrazide, PPh<sub>3</sub>Br<sub>2</sub>, MeCN, rt, 1 h, then DIPEA, 0 °C, 1 h, 80%; (b) benzothiohydrazide, PPh<sub>3</sub>Br<sub>2</sub>, MeCN, rt, 3 h, 39%; (c) hydroxylamine hydrochloride, Et<sub>3</sub>N, MeOH, 0 °C to rt, 3 h, 76%; (d) benzoyl chloride, Et<sub>3</sub>N, DCM, rt, 16 h, 93%; (e) PPA, 70 °C, 7 h, 88%; (f) (4-isopropylsulfonylphenyl)boronic acid, Na<sub>3</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, dioxane, 100 °C in μwave, 25 min, 34–69%.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Intramolecular polar interactions within heteroaryl ATR inhibitors. Polar interactions between the central five-membered heteroaryl ring atoms X and Y and the 2-aminopyrazine hinge binder determine whether the bioactive conformation (left) is energetically preferred.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Compound <b>4</b> docked in a homology model of the ATR active site based on PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a> with ATR represented by its electrostatic potential map. An area of high negative charge (in red) is located to the right of the phenyl ring of compound <b>4</b>. (b) Compound <b>2</b> docked into the active site of ATR. Hydrogen bonds to the hinge, the unique residues Gly2385, Asn2480 and Asp2494 that are part of the conserved magnesium binding site and salt bridge are indicated. Polar residues around the phenyl ring are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Ligand interaction diagram showing nearby residues, aromatic stacking (green lines), and key hydrogen bonds (purple lines) involving compound <b>2</b> as docked into our ATR homology model derived from PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/medium/jm-2019-004266_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Macsynergy plots for compounds <b>1</b> and <b>2</b> dosed in combination with cisplatin in an HCT116 MTS cell assay. Synergistic or antagonistic interactions between ATR inhibitors and cisplatin are represented as deviations above or below the plane (at <i>z</i> = 0) that corresponds to additivity. Compound <b>2</b> achieves similar synergy with cisplatin as <b>1</b> at a ∼10-fold lower concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00426/20190607/images/large/jm-2019-004266_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00426&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortimore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2320</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1021/jm101488z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101488z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2320-2330&author=J.+D.+Charrierauthor=S.+J.+Durrantauthor=J.+M.+Golecauthor=D.+P.+Kayauthor=R.+M.+Knegtelauthor=S.+MacCormickauthor=M.+Mortimoreauthor=M.+E.+O%E2%80%99Donnellauthor=J.+L.+Pinderauthor=P.+M.+Reaperauthor=A.+P.+Rutherfordauthor=P.+S.+Wangauthor=S.+C.+Youngauthor=J.+R.+Pollard&title=Discovery+of+potent+and+selective+inhibitors+of+ataxia+telangiectasia+mutated+and+Rad3+related+%28ATR%29+protein+kinase+as+potential+anticancer+agents&doi=10.1021%2Fjm101488z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents</span></div><div class="casAuthors">Charrier, Jean-Damien; Durrant, Steven J.; Golec, Julian M. C.; Kay, David P.; Knegtel, Ronald M. A.; MacCormick, Somhairle; Mortimore, Michael; O'Donnell, Michael E.; Pinder, Joanne L.; Reaper, Philip M.; Rutherford, Alistair P.; Wang, Paul S. H.; Young, Stephen C.; Pollard, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2320-2330</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA-damaging agents are among the most frequently used anticancer drugs.  However, they provide only modest benefit in most cancers.  This may be attributed to a genome maintenance network, the DNA damage response (DDR), that recognizes and repairs damaged DNA.  ATR is a major regulator of the DDR and an attractive anticancer target.  Herein, we describe the discovery of a series of aminopyrazines with potent and selective ATR inhibition.  Compd. (I) inhibits ATR with a Ki of 6 nM, shows >600-fold selectivity over related kinases ATM or DNA-PK, and blocks ATR signaling in cells with an IC50 of 0.42 μM.  Using I, here it is shown that ATR inhibition markedly enhances death induced by DNA-damaging agents in certain cancers but not normal cells.  This differential response between cancer and normal cells highlights the great potential for ATR inhibition as a novel mechanism to dramatically increase the efficacy of many established drugs and ionizing radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp56O6NNQ8JNbVg90H21EOLACvtfcHk0lhaL4E1k7LIEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D&md5=4f17e7c44fc6c7bdc32886e3415722c8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm101488z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101488z%26sid%3Dliteratum%253Aachs%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DDurrant%26aufirst%3DS.%2BJ.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DKay%26aufirst%3DD.%2BP.%26aulast%3DKnegtel%26aufirst%3DR.%2BM.%26aulast%3DMacCormick%26aufirst%3DS.%26aulast%3DMortimore%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BE.%26aulast%3DPinder%26aufirst%3DJ.%2BL.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DRutherford%26aufirst%3DA.%2BP.%26aulast%3DWang%26aufirst%3DP.%2BS.%26aulast%3DYoung%26aufirst%3DS.%2BC.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3%2520related%2520%2528ATR%2529%2520protein%2520kinase%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2320%26epage%3D2330%26doi%3D10.1021%2Fjm101488z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">How do real tumors become resistant to cisplatin?</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.4161/cc.7.10.5930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.4161%2Fcc.7.10.5930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=18418074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptF2jtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1353-1359&author=P.+Borstauthor=S.+Rottenbergauthor=J.+Jonkers&title=How+do+real+tumors+become+resistant+to+cisplatin%3F&doi=10.4161%2Fcc.7.10.5930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">How do real tumors become resistant to cisplatin?</span></div><div class="casAuthors">Borst, Piet; Rottenberg, Sven; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1353-1359</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Lab research on cultured tumor cells selected for resistance to platinum compds. has turned up a diverse array of resistance mechanisms.  In contrast, we recently found that mouse mammary tumors contg. irrepairable null alleles of the Brca1 gene do not become resistant to cisplatin ever, although they invariably become resistant to a variety of other anti-cancer drugs.  Each new treatment with cisplatin shrinks the tumor to a very small remnant, but relapse always occurs.  The BRCA1 missing in these mouse tumors is essential for the homol.-directed DNA repair (HR) that allows error-free repair of the duplex breaks caused by the excision of platin-DNA adducts.  The mouse tumor results therefore raise the question whether the cisplatin resistance mechanisms identified in vitro can actually overcome an irreversible defect in DNA repair in real tumors.  This question is underlined by recent analyses of tumor samples of patients with ovarian cancer that have uncovered a new platin resistance mechanism: these tumors were initially sensitive to platin through a defect in the BRCA2 gene, also required for HR, like BRCA1.  Resistance in these patients,-after an initial response of the tumor,-was due to secondary mutations in the defective BRCA2 gene, restoring BRCA2 function.  These clin. observations show the overriding importance of a functional HR system for tumor cells to survive platin-induced DNA lesions.  Taken together with the mouse mammary tumor data, these observations raise the possibility that proliferating cells have no readily available mechanism to escape from cisplatin DNA damage once their HR is irreversibly inactivated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyQw5rHh6uHbVg90H21EOLACvtfcHk0lhs-tG17gTKTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptF2jtrk%253D&md5=e3da1eaace11c873ce91825ea6963d22</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4161%2Fcc.7.10.5930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.7.10.5930%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHow%2520do%2520real%2520tumors%2520become%2520resistant%2520to%2520cisplatin%253F%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D1353%26epage%3D1359%26doi%3D10.4161%2Fcc.7.10.5930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span> <span> </span><span class="NLM_article-title">ATR signaling: more than meeting at the fork</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>436</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1042/BJ20102162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1042%2FBJ20102162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=21615334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2gs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2011&pages=527-536&author=E.+A.+Namauthor=D.+Cortez&title=ATR+signaling%3A+more+than+meeting+at+the+fork&doi=10.1042%2FBJ20102162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">ATR signalling: more than meeting at the fork</span></div><div class="casAuthors">Nam, Edward A.; Cortez, David</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Preservation of genome integrity via the DNA-damage response is crit. to prevent disease.  ATR (ataxia telangiectasia mutated- and Rad3-related) is essential for life and functions as a master regulator of the DNA-damage response, esp. during DNA replication.  ATR controls and coordinates DNA replication origin firing, replication fork stability, cell cycle checkpoints and DNA repair.  Since its identification 15 years ago, a model of ATR activation and signaling has emerged that involves localization to sites of DNA damage and activation through protein-protein interactions.  Recent research has added an increasingly detailed understanding of the canonical ATR pathway, and an appreciation that the canonical model does not fully capture the complexity of ATR regulation.  In the present article, we review the ATR signaling process, focusing on mechanistic findings garnered from the identification of new ATR-interacting proteins and substrates.  We discuss how to incorporate these new insights into a model of ATR regulation and point out the significant gaps in our understanding of this essential genome-maintenance pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeDUcTrABTZbVg90H21EOLACvtfcHk0lhs-tG17gTKTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2gs7w%253D&md5=8550e1270a78aef9a1be36a35b7f9606</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2FBJ20102162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20102162%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DE.%2BA.%26aulast%3DCortez%26aufirst%3DD.%26atitle%3DATR%2520signaling%253A%2520more%2520than%2520meeting%2520at%2520the%2520fork%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D436%26spage%3D527%26epage%3D536%26doi%3D10.1042%2FBJ20102162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halazonetis, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgoulis, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span> <span> </span><span class="NLM_article-title">An oncogene-induced DNA damage model for cancer development</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>319</i></span> (<span class="NLM_issue">5868</span>),  <span class="NLM_fpage">1352</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.1140735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1126%2Fscience.1140735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=18323444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislSkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2008&pages=1352-1355&issue=5868&author=T.+D.+Halazonetisauthor=V.+G.+Gorgoulisauthor=J.+Bartek&title=An+oncogene-induced+DNA+damage+model+for+cancer+development&doi=10.1126%2Fscience.1140735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An oncogene-induced DNA damage model for cancer development</span></div><div class="casAuthors">Halazonetis, Thanos D.; Gorgoulis, Vassilis G.; Bartek, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">5868</span>),
    <span class="NLM_cas:pages">1352-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Of all types of DNA damage, DNA double-strand breaks (DSBs) pose the greatest challenge to cells.  One might have, therefore, anticipated that a sizable no. of DNA DSBs would be incompatible with cell proliferation.  Yet recent exptl. findings suggest that, in both precancerous lesions and cancers, activated oncogenes induce stalling and collapse of DNA replication forks, which in turn leads to formation of DNA DSBs.  This continuous formation of DNA DSBs may contribute to the genomic instability that characterizes the vast majority of human cancers.  In addn., in precancerous lesions, these DNA DSBs activate p53, which, by inducing apoptosis or senescence, raises a barrier to tumor progression.  Breach of this barrier by various mechanisms, most notably by p53 mutations, that impair the DNA damage response pathway allows cancers to develop.  Thus, oncogene-induced DNA damage may explain two key features of cancer: genomic instability and the high frequency of p53 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooknsDjHPy5LVg90H21EOLACvtfcHk0lhIrpRmG9ctgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislSkt7c%253D&md5=5cacb04a384638ccc28d82d0ab84dec0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1140735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1140735%26sid%3Dliteratum%253Aachs%26aulast%3DHalazonetis%26aufirst%3DT.%2BD.%26aulast%3DGorgoulis%26aufirst%3DV.%2BG.%26aulast%3DBartek%26aufirst%3DJ.%26atitle%3DAn%2520oncogene-induced%2520DNA%2520damage%2520model%2520for%2520cancer%2520development%26jtitle%3DScience%26date%3D2008%26volume%3D319%26issue%3D5868%26spage%3D1352%26epage%3D1355%26doi%3D10.1126%2Fscience.1140735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nchembio.573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1038%2Fnchembio.573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=21490603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1agtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=428-430&author=P.+M.+Reaperauthor=M.+R.+Griffithsauthor=J.+M.+Longauthor=J.+D.+Charrierauthor=S.+Maccormickauthor=P.+A.+Charltonauthor=J.+M.+Golecauthor=J.+R.+Pollard&title=Selective+killing+of+ATM-+or+p53-deficient+cancer+cells+through+inhibition+of+ATR&doi=10.1038%2Fnchembio.573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR</span></div><div class="casAuthors">Reaper, Philip M.; Griffiths, Matthew R.; Long, Joanna M.; Charrier, Jean-Damien; MacCormick, Somhairle; Charlton, Peter A.; Golec, Julian M. C.; Pollard, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-430</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we report a comprehensive biol. characterization of a potent and selective small-mol. inhibitor of the DNA damage response (DDR) kinase ATR.  We show a profound synthetic lethal interaction between ATR and the ATM-p53 tumor suppressor pathway in cells treated with DNA-damaging agents and establish ATR inhibition as a way to transform the outcome for patients with cancer treated with ionizing radiation or genotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRYth09UxMbVg90H21EOLACvtfcHk0lhIrpRmG9ctgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1agtrs%253D&md5=58c63122b550b1ca5e9064c4bbf3d68f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.573%26sid%3Dliteratum%253Aachs%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DGriffiths%26aufirst%3DM.%2BR.%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DMaccormick%26aufirst%3DS.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DSelective%2520killing%2520of%2520ATM-%2520or%2520p53-deficient%2520cancer%2520cells%2520through%2520inhibition%2520of%2520ATR%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D428%26epage%3D430%26doi%3D10.1038%2Fnchembio.573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoddusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holash, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taricani, L.</span></span> <span> </span><span class="NLM_article-title">A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1158%2F1541-7786.MCR-14-0240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25232030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1amu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=120-129&author=D.+L.+Menezesauthor=J.+Holtauthor=Y.+Tangauthor=J.+Fengauthor=P.+Barsantiauthor=Y.+Panauthor=M.+Ghoddusiauthor=W.+Zhangauthor=G.+Thomasauthor=J.+Holashauthor=E.+Leesauthor=L.+Taricani&title=A+synthetic+lethal+screen+reveals+enhanced+sensitivity+to+ATR+inhibitor+treatment+in+mantle+cell+lymphoma+with+ATM+loss-of-function&doi=10.1158%2F1541-7786.MCR-14-0240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function</span></div><div class="casAuthors">Menezes, Daniel L.; Holt, Jenny; Tang, Yan; Feng, Jiajia; Barsanti, Paul; Pan, Yue; Ghoddusi, Majid; Zhang, Wei; Thomas, George; Holash, Jocelyn; Lees, Emma; Taricani, Lorena</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mechanisms to maintain genomic integrity are essential for cells to remain viable.  Not surprisingly, disruption of key DNA damage response pathway factors, such as ataxia telangiectasia-mutated (ATM)/ataxia telangiectasia and RAD3-related (ATR) results in loss of genomic integrity.  Here, a synthetic lethal siRNA-screening approach not only confirmed ATM but identified addnl. replication checkpoint proteins, when ablated, enhanced ATR inhibitor (ATRi) response in a high-content γ-H2AX assay.  Cancers with inactivating ATM mutations exhibit impaired DNA double-stranded break (DSB) repair and rely on compensatory repair pathways for survival.  Therefore, impairing ATR activity may selectively sensitize cancer cells to killing.  ATR inhibition in an ATM-deficient context results in phosphorylation of DNA-dependent protein kinase catalytic subunits (DNA-PKcs) and leads to induction of γ-H2AX.  Using both in vitro and in vivo models, ATR inhibition enhanced efficacy in ATM loss-of-function mantle cell lymphoma (MCL) compared with ATM wild-type cancer cells.  In summary, single-agent ATR inhibitors have therapeutic utility in the treatment of cancers, like MCL, in which ATM function has been lost.  Implications: These data suggest that single-agent ATR inhibitors have therapeutic utility and that ATR uses a complex and coordinated set of proteins to maintain genomic stability that could be further exploited.  Mol Cancer Res; 13(1); 120-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodCbVkU8MDzLVg90H21EOLACvtfcHk0lis0hEgCj_mvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1amu7s%253D&md5=9e2b1d1832e9ead204ad96caa90d41e2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0240%26sid%3Dliteratum%253Aachs%26aulast%3DMenezes%26aufirst%3DD.%2BL.%26aulast%3DHolt%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DBarsanti%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DGhoddusi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DTaricani%26aufirst%3DL.%26atitle%3DA%2520synthetic%2520lethal%2520screen%2520reveals%2520enhanced%2520sensitivity%2520to%2520ATR%2520inhibitor%2520treatment%2520in%2520mantle%2520cell%2520lymphoma%2520with%2520ATM%2520loss-of-function%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26spage%3D120%26epage%3D129%26doi%3D10.1158%2F1541-7786.MCR-14-0240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vendetti, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrads, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakkenist, C. J.</span></span> <span> </span><span class="NLM_article-title">The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">42</span>),  <span class="NLM_fpage">44289</span>– <span class="NLM_lpage">44305</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.18632%2Foncotarget.6247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=26517239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BC28zmvVyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44289-44305&issue=42&author=F.+P.+Vendettiauthor=A.+Lauauthor=S.+Schamusauthor=T.+P.+Conradsauthor=M.+J.+O%E2%80%99Connorauthor=C.+J.+Bakkenist&title=The+orally+active+and+bioavailable+ATR+kinase+inhibitor+AZD6738+potentiates+the+anti-tumor+effects+of+cisplatin+to+resolve+ATM-deficient+non-small+cell+lung+cancer+in+vivo&doi=10.18632%2Foncotarget.6247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo</span></div><div class="casAuthors">Vendetti Frank P; Schamus Sandra; Bakkenist Christopher J; Lau Alan; O'Connor Mark J; Conrads Thomas P; Bakkenist Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">44289-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ATR and ATM are DNA damage signaling kinases that phosphorylate several thousand substrates.  ATR kinase activity is increased at damaged replication forks and resected DNA double-strand breaks (DSBs).  ATM kinase activity is increased at DSBs.  ATM has been widely studied since ataxia telangiectasia individuals who express no ATM protein are the most radiosensitive patients identified.  Since ATM is not an essential protein, it is widely believed that ATM kinase inhibitors will be well-tolerated in the clinic.  ATR has been widely studied, but advances have been complicated by the finding that ATR is an essential protein and it is widely believed that ATR kinase inhibitors will be toxic in the clinic.  We describe AZD6738, an orally active and bioavailable ATR kinase inhibitor.  AZD6738 induces cell death and senescence in non-small cell lung cancer (NSCLC) cell lines.  AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells.  In contrast to expectations, daily administration of AZD6738 and ATR kinase inhibition for 14 consecutive days is tolerated in mice and enhances the therapeutic efficacy of cisplatin in xenograft models.  Remarkably, the combination of cisplatin and AZD6738 resolves ATM-deficient lung cancer xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGZGrn92xggGyYR5VtavbzfW6udTcc2eZ-fJ0F8gvQsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zmvVyhsA%253D%253D&md5=eeb235ade15503e435eb69f929c64068</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6247%26sid%3Dliteratum%253Aachs%26aulast%3DVendetti%26aufirst%3DF.%2BP.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DSchamus%26aufirst%3DS.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBakkenist%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520orally%2520active%2520and%2520bioavailable%2520ATR%2520kinase%2520inhibitor%2520AZD6738%2520potentiates%2520the%2520anti-tumor%2520effects%2520of%2520cisplatin%2520to%2520resolve%2520ATM-deficient%2520non-small%2520cell%2520lung%2520cancer%2520in%2520vivo%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D42%26spage%3D44289%26epage%3D44305%26doi%3D10.18632%2Foncotarget.6247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcina, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies McKenna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span> <span> </span><span class="NLM_article-title">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/cddis.2012.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1038%2Fcddis.2012.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=23222511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=e441-450&author=E.+Fokasauthor=R.+Prevoauthor=J.+R.+Pollardauthor=P.+M.+Reaperauthor=P.+A.+Charltonauthor=B.+Cornelissenauthor=K.+A.+Vallisauthor=E.+M.+Hammondauthor=M.+M.+Olcinaauthor=W.+Gillies+McKennaauthor=R.+J.+Muschelauthor=T.+B.+Brunner&title=Targeting+ATR+in+vivo+using+the+novel+inhibitor+VE-822+results+in+selective+sensitization+of+pancreatic+tumors+to+radiation&doi=10.1038%2Fcddis.2012.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span></div><div class="casAuthors">Fokas, E.; Prevo, R.; Pollard, J. R.; Reaper, P. M.; Charlton, P. A.; Cornelissen, B.; Vallis, K. A.; Hammond, E. M.; Olcina, M. M.; McKenna, W. Gillies; Muschel, R. J.; Brunner, T. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">e441, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application.  Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells.  We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization.  Chk1 phosphorylation was used to indicate ATR activity, γH2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity.  Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo.  Murine intestinal damage was evaluated after abdominal XRT.  VE-822 inhibited ATR in vitro and in vivo.  VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells.  VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.  VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity.  These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp66nE6ZdMorVg90H21EOLACvtfcHk0lio6wTD2vuilA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D&md5=7223df6ec5dbca8c50889b5df8e4cce6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2012.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2012.181%26sid%3Dliteratum%253Aachs%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DPrevo%26aufirst%3DR.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DCornelissen%26aufirst%3DB.%26aulast%3DVallis%26aufirst%3DK.%2BA.%26aulast%3DHammond%26aufirst%3DE.%2BM.%26aulast%3DOlcina%26aufirst%3DM.%2BM.%26aulast%3DGillies%2BMcKenna%26aufirst%3DW.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26atitle%3DTargeting%2520ATR%2520in%2520vivo%2520using%2520the%2520novel%2520inhibitor%2520VE-822%2520results%2520in%2520selective%2520sensitization%2520of%2520pancreatic%2520tumors%2520to%2520radiation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2012%26volume%3D3%26spage%3De441%26epage%3D450%26doi%3D10.1038%2Fcddis.2012.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prevo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span> <span> </span><span class="NLM_article-title">The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1072</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.4161/cbt.21093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.4161%2Fcbt.21093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=22825331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1arurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1072-1081&author=R.+Prevoauthor=E.+Fokasauthor=P.+M.+Reaperauthor=P.+A.+Charltonauthor=J.+R.+Pollardauthor=W.+G.+McKennaauthor=R.+J.+Muschelauthor=T.+B.+Brunner&title=The+novel+ATR+inhibitor+VE-821+increases+sensitivity+of+pancreatic+cancer+cells+to+radiation+and+chemotherapy&doi=10.4161%2Fcbt.21093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy</span></div><div class="casAuthors">Prevo, Remko; Fokas, Emmanouil; Reaper, Philip M.; Charlton, Peter A.; Pollard, John R.; McKenna, W. Gillies; Muschel, Ruth J.; Brunner, Thomas B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1072-1081</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">DNA damaging agents such as radiotherapy and gemcitabine are frequently used for the treatment of pancreatic cancer.  However, these treatments typically provide only modest benefit.  Improving the low survival rate for pancreatic cancer patients therefore remains a major challenge in oncol.  Inhibition of the key DNA damage response kinase ATR has been suggested as an attractive approach for sensitization of tumor cells to DNA damaging agents, but specific ATR inhibitors have remained elusive.  Here we investigated the sensitization potential of the first highly selective and potent ATR inhibitor, VE-821, in vitro.  VE-821 inhibited radiation- and gemcitabine-induced phosphorylation of Chk1, confirming inhibition of ATR signaling.  Consistently, VE-821 significantly enhanced the sensitivity of PSN-1, MiaPaCa-2 and primary PancM pancreatic cancer cells to radiation and gemcitabine under both normoxic and hypoxic conditions.  ATR inhibition by VE-821 led to inhibition of radiation-induced G2/M arrest in cancer cells.  Reduced cancer cell radiosurvival following treatment with VE-821 was also accompanied by increased DNA damage and inhibition of homologous recombination repair, as evidenced by persistence of γH2AX and 53BP1 foci and inhibition of Rad51 foci, resp.  These findings support ATR inhibition as a novel approach to improve the efficacy and therapeutic index of std. cancer treatments across a large proportion of pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSSwRbubi0WbVg90H21EOLACvtfcHk0lio6wTD2vuilA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1arurw%253D&md5=186dd5276627880104362bf7b5c47556</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4161%2Fcbt.21093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.21093%26sid%3Dliteratum%253Aachs%26aulast%3DPrevo%26aufirst%3DR.%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMcKenna%26aufirst%3DW.%2BG.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26atitle%3DThe%2520novel%2520ATR%2520inhibitor%2520VE-821%2520increases%2520sensitivity%2520of%2520pancreatic%2520cancer%2520cells%2520to%2520radiation%2520and%2520chemotherapy%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2012%26volume%3D13%26spage%3D1072%26epage%3D1081%26doi%3D10.4161%2Fcbt.21093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thommes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2125</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6-%5B1-%28methylsulfonyl%29cyclopropyl%5Dpyrimidin-2-yl%7D-1H-indole+%28AZ20%29%3A+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity</span></div><div class="casAuthors">Foote, Kevin M.; Blades, Kevin; Cronin, Anna; Fillery, Shaun; Guichard, Sylvie S.; Hassall, Lorraine; Hickson, Ian; Jacq, Xavier; Jewsbury, Philip J.; McGuire, Thomas M.; Nissink, J. Willem M.; Odedra, Rajesh; Page, Ken; Perkins, Paula; Suleman, Abid; Tam, Kin; Thommes, Pia; Broadhurst, Rebecca; Wood, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2125-2138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways.  We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition.  Optimization from a high quality screening hit within tight SAR space led to compd. I (AZ20) which inhibits ATR immunopptd. from HeLa nuclear exts. with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.  Compd. I potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses.  At well tolerated doses I leads to significant growth inhibition of LoVo xenografts grown in nude mice.  Compd. I is a useful compd. to explore ATR pharmacol. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpY5_RVxXl9LVg90H21EOLACvtfcHk0lg3UYcCRb2c8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D&md5=60d2f6fe78e2b82695198b9cba930ae7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6-%255B1-%2528methylsulfonyl%2529cyclopropyl%255Dpyrimidin-2-yl%257D-1H-indole%2520%2528AZ20%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520ATR%2520protein%2520kinase%2520with%2520monotherapy%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jossé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormanoglu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">6968</span>– <span class="NLM_lpage">6979</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1158%2F0008-5472.CAN-13-3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25269479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=6968-6979&author=R.+Joss%C3%A9author=S.+E.+Martinauthor=R.+Guhaauthor=P.+Ormanogluauthor=T.+D.+Pfisterauthor=P.+M.+Reaperauthor=C.+S.+Barnesauthor=J.+Jonesauthor=P.+Charltonauthor=J.+R.+Pollardauthor=J.+Morrisauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=ATR+inhibitors+VE-821+and+VX-970+sensitize+cancer+cells+to+topoisomerase+I+inhibitors+by+disabling+DNA+replication+initiation+and+fork+elongation+responses&doi=10.1158%2F0008-5472.CAN-13-3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses</span></div><div class="casAuthors">Josse, Rozenn; Martin, Scott E.; Guha, Rajarshi; Ormanoglu, Pinar; Pfister, Thomas D.; Reaper, Philip M.; Barnes, Christopher S.; Jones, Julie; Charlton, Peter; Pollard, John R.; Morris, Joel; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6968-6979</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">By showing how the DNA damage sensing kinase ATR confers resistance to topoisomerase I inhibitors, a widely used class of cytotoxic drugs in the oncol. clinic, this study provides a mechanistic rationale for combination trials to evaluate the efficacy of ATR inhibitors.  Camptothecin and its derivs., topotecan and irinotecan, are specific topoisomerase I (Top1) inhibitors and potent anticancer drugs killing cancer cells by producing replication-assocd. DNA double-strand breaks, and the indenoisoquinoline LMP-400 (indotecan) is a novel Top1 inhibitor in clin. trial.  To develop novel drug combinations, we conducted a synthetic lethal siRNA screen using a library that targets nearly 7,000 human genes.  Depletion of ATR, the main transducer of replication stress, came as a top candidate gene for camptothecin synthetic lethality.  Validation studies using ATR siRNA and the ATR inhibitor VE-821 confirmed marked antiproliferative synergy with camptothecin and even greater synergy with LMP-400.  Single-cell analyses and DNA fiber combing assays showed that VE-821 abrogates the S-phase replication elongation checkpoint and the replication origin-firing checkpoint induced by camptothecin and LMP-400.  As expected, the combination of Top1 inhibitors with VE-821 inhibited the phosphorylation of ATR and Chk1; however, it strongly induced γH2AX.  In cells treated with the combination, the γH2AX pattern changed over time from the well-defined Top1-induced damage foci to an intense peripheral and diffuse nuclear staining, which could be used as response biomarker.  Finally, the clin. deriv. of VE-821, VX-970, enhanced the in vivo tumor response to irinotecan without addnl. toxicity.  A key implication of our work is the mechanistic rationale and proof of principle it provides to evaluate the combination of Top1 inhibitors with ATR inhibitors in clin. trials.  Cancer Res; 74(23); 6968-79. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz9ocPrt4fmrVg90H21EOLACvtfcHk0lh2z_MRHLRpOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrvK&md5=438498ef25a2b0e8637c36dbb74427e5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-3369%26sid%3Dliteratum%253Aachs%26aulast%3DJoss%25C3%25A9%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DOrmanoglu%26aufirst%3DP.%26aulast%3DPfister%26aufirst%3DT.%2BD.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DBarnes%26aufirst%3DC.%2BS.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DATR%2520inhibitors%2520VE-821%2520and%2520VX-970%2520sensitize%2520cancer%2520cells%2520to%2520topoisomerase%2520I%2520inhibitors%2520by%2520disabling%2520DNA%2520replication%2520initiation%2520and%2520fork%2520elongation%2520responses%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D6968%26epage%3D6979%26doi%3D10.1158%2F0008-5472.CAN-13-3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eustace, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5674</span>– <span class="NLM_lpage">5685</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.18632%2Foncotarget.2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25010037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5674-5685&author=A.+B.+Hallauthor=D.+Newsomeauthor=Y.+Wangauthor=D.+M.+Boucherauthor=B.+Eustaceauthor=Y.+Guauthor=B.+Hareauthor=M.+A.+Johnsonauthor=H.+Liauthor=S.+Miltonauthor=C.+E.+Murphyauthor=D.+Takemotoauthor=C.+Tolmanauthor=M.+Woodauthor=P.+Charltonauthor=J.+D.+Charrierauthor=B.+Fureyauthor=J.+Golecauthor=P.+M.+Reaperauthor=J.+R.+Pollard&title=Potentiation+of+tumor+responses+to+DNA+damaging+therapy+by+the+selective+ATR+inhibitor+VX-970&doi=10.18632%2Foncotarget.2158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span></div><div class="casAuthors">Hall Amy B; Newsome Dave; Wang Yuxin; Boucher Diane M; Eustace Brenda; Gu Yong; Hare Brian; Johnson Mac A; Milton Sean; Murphy Cheryl E; Takemoto Darin; Tolman Crystal; Wood Mark; Furey Brinley; Charlton Peter; Charrier Jean-Damien; Golec Julian; Reaper Philip M; Pollard John R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5674-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor.  This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR).  ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents.  However, there are limited in vivo proof-of-concept data for ATR inhibition.  To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1.  VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed.  In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts.  The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model.  These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8Vj8UJVglDeLt9HypzAgQfW6udTcc2eaKw33Svu8kLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D&md5=8901708b1d60ad622d534a14da665414</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2158%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%2BB.%26aulast%3DNewsome%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBoucher%26aufirst%3DD.%2BM.%26aulast%3DEustace%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMilton%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DC.%2BE.%26aulast%3DTakemoto%26aufirst%3DD.%26aulast%3DTolman%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DFurey%26aufirst%3DB.%26aulast%3DGolec%26aufirst%3DJ.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DPotentiation%2520of%2520tumor%2520responses%2520to%2520DNA%2520damaging%2520therapy%2520by%2520the%2520selective%2520ATR%2520inhibitor%2520VX-970%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5674%26epage%3D5685%26doi%3D10.18632%2Foncotarget.2158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeitany, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryll, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganem, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bersani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvà, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussin, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span> <span> </span><span class="NLM_article-title">Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1126/science.1257216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1126%2Fscience.1257216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25593184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=273-277&author=R.+L.+Flynnauthor=K.+E.+Coxauthor=M.+Jeitanyauthor=H.+Wakimotoauthor=A.+R.+Bryllauthor=N.+J.+Ganemauthor=F.+Bersaniauthor=J.+R.+Pinedaauthor=M.+L.+Suv%C3%A0author=C.+H.+Benesauthor=D.+A.+Haberauthor=F.+D.+Boussinauthor=L.+Zou&title=Alternative+lengthening+of+telomeres+renders+cancer+cells+hypersensitive+to+ATR+inhibitors&doi=10.1126%2Fscience.1257216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors</span></div><div class="casAuthors">Flynn, Rachel Litman; Cox, Kelli E.; Jeitany, Maya; Wakimoto, Hiroaki; Bryll, Alysia R.; Ganem, Neil J.; Bersani, Francesca; Pineda, Jose R.; Suva, Mario L.; Benes, Cyril H.; Haber, Daniel A.; Boussin, Francois D.; Zou, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6219</span>),
    <span class="NLM_cas:pages">273-277</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cancer cells rely on telomerase or the alternative lengthening of telomeres (ALT) pathway to overcome replicative mortality.  ALT is mediated by recombination and is prevalent in a subset of human cancers, yet whether it can be exploited therapeutically remains unknown.  Loss of the chromatin-remodeling protein ATRX assocs. with ALT in cancers.  Here, we show that ATRX loss compromises cell-cycle regulation of the telomeric noncoding RNA TERRA and leads to persistent assocn. of replication protein A (RPA) with telomeres after DNA replication, creating a recombinogenic nucleoprotein structure.  Inhibition of the protein kinase ATR, a crit. regulator of recombination recruited by RPA, disrupts ALT and triggers chromosome fragmentation and apoptosis in ALT cells.  The cell death induced by ATR inhibitors is highly selective for cancer cells that rely on ALT, suggesting that such inhibitors may be useful for treatment of ALT-pos. cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41jOdyYH-ILVg90H21EOLACvtfcHk0lim5SWNdAL2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFGgsQ%253D%253D&md5=4ae9bc8508056a59454748ad679208bd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1257216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1257216%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DR.%2BL.%26aulast%3DCox%26aufirst%3DK.%2BE.%26aulast%3DJeitany%26aufirst%3DM.%26aulast%3DWakimoto%26aufirst%3DH.%26aulast%3DBryll%26aufirst%3DA.%2BR.%26aulast%3DGanem%26aufirst%3DN.%2BJ.%26aulast%3DBersani%26aufirst%3DF.%26aulast%3DPineda%26aufirst%3DJ.%2BR.%26aulast%3DSuv%25C3%25A0%26aufirst%3DM.%2BL.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DBoussin%26aufirst%3DF.%2BD.%26aulast%3DZou%26aufirst%3DL.%26atitle%3DAlternative%2520lengthening%2520of%2520telomeres%2520renders%2520cancer%2520cells%2520hypersensitive%2520to%2520ATR%2520inhibitors%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D273%26epage%3D277%26doi%3D10.1126%2Fscience.1257216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A. J.</span></span> <span> </span><span class="NLM_article-title">ATM and ATR as therapeutic targets in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.pharmthera.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=25512053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2015&pages=124-138&author=A.+M.+Weberauthor=A.+J.+Ryan&title=ATM+and+ATR+as+therapeutic+targets+in+cancer&doi=10.1016%2Fj.pharmthera.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ATM and ATR as therapeutic targets in cancer</span></div><div class="casAuthors">Weber, Anika Maria; Ryan, Anderson Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  In order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA damage or DNA replication stress to be resolved.  Key mediators of this DNA damage response (DDR) are the ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets.  Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to genotoxic therapies has been assocd. with increased DDR signalling, and (ii) many cancers have defects in certain components of the DDR rendering them highly dependent on the remaining DDR pathways for survival.  ATM and ATR act as the apical regulators of the response to DNA double strand breaks and replication stress, resp., with overlapping but non-redundant activities.  Highly selective small mol. inhibitors of ATM and ATR are currently in preclin. and clin. development, resp.  Preclin. data have provided a strong rationale for clin. testing of these compds. both in combination with radio- or chemotherapy, and in synthetic lethal approaches to treat tumors with deficiencies in certain DDR components.  Whole genome sequencing studies have reported that mutations in DDR genes occur with a high frequency in many common tumor types, suggesting that a synthetic lethal approach with ATM or ATR inhibitors could have widespread utility, providing that appropriate biomarkers are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNTHNVGQUGbVg90H21EOLACvtfcHk0lim5SWNdAL2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D&md5=204198bfeef4fc9cdf3d0e8968334363</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BM.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26atitle%3DATM%2520and%2520ATR%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D149%26spage%3D124%26epage%3D138%26doi%3D10.1016%2Fj.pharmthera.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Sanad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasheminasab, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panasci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noë, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif-Askari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloyz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panasci, L.</span></span> <span> </span><span class="NLM_article-title">Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">147</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.3389%2Ffphar.2015.00147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=26257651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=147&author=A.+Abu-Sanadauthor=Y.+Wangauthor=F.+Hasheminasabauthor=J.+Panasciauthor=A.+No%C3%ABauthor=L.+Roscaauthor=D.+Davidsonauthor=L.+Amreinauthor=B.+Sharif-Askariauthor=R.+Aloyzauthor=L.+Panasci&title=Simultaneous+inhibition+of+ATR+and+PARP+sensitizes+colon+cancer+cell+lines+to+irinotecan&doi=10.3389%2Ffphar.2015.00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan</span></div><div class="casAuthors">Abu-Sanad, Atlal; Wang, Yunzhe; Hasheminasab, Fatemeh; Panasci, Justin; Noe, Alycia; Rosca, Lorena; Davidson, David; Amrein, Lilian; Sharif-Askari, Bahram; Aloyz, Raquel; Panasci, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147/1-147/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Enhanced DNA damage repair is one mechanism involved in colon cancer drug resistance.  Thus, targeting mol. components of repair pathways with specific small mol. inhibitors may improve the efficacy of chemotherapy.  ABT-888 and VE-821, inhibitors of poly-ADP-ribose-polymerase (PARP) and the serine/threonine-kinase Ataxia telangiectasia related (ATR), resp., were used to treat colon cancer cell lines in combination with the topoisomerase-I inhibitor irinotecan (SN38).  Our findings show that each of these DNA repair inhibitors utilized alone at nontoxic single agent concns. resulted in sensitization to SN38 producing a 1.4-3 fold redn. in the 50γ inhibitory concn. (IC50) of SN38 in three colon cancer cell lines.  When combined together, nontoxic concns. of ABT-888 and VE-821 produced a 4.5-27 fold redn. in the IC50 of SN38 with the HCT-116 colon cancer cells demonstrating the highest sensitization as compared to LoVo and HT-29 colon cancer cells.  Furthermore, the combination of all three agents was assocd. with maximal G2 -M arrest and enhanced DNA-damage (γH2AX) in all three colon cancer cell lines.  The mechanism of this enhanced sensitization was assocd. with: (a) maximal suppression of SN38 induced PARP activity in the presence of both inhibitors and (b) ABT-888 producing partial abrogation of the VE-821 enhancement of SN38 induced DNA-PK phosphorylation, resulting in more unrepaired DNA damage; these alterations were only present in the HCT-116 cells which have reduced levels of ATM.  This novel combination of DNA repair inhibitors may be useful to enhance the activity of DNA damaging chemotherapies such as irinotecan and help produce sensitization to this drug in colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQElEUBYfe7rVg90H21EOLACvtfcHk0lim5SWNdAL2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnP&md5=e2e328685b7218099bed2fbade7c2d67</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00147%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Sanad%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHasheminasab%26aufirst%3DF.%26aulast%3DPanasci%26aufirst%3DJ.%26aulast%3DNo%25C3%25AB%26aufirst%3DA.%26aulast%3DRosca%26aufirst%3DL.%26aulast%3DDavidson%26aufirst%3DD.%26aulast%3DAmrein%26aufirst%3DL.%26aulast%3DSharif-Askari%26aufirst%3DB.%26aulast%3DAloyz%26aufirst%3DR.%26aulast%3DPanasci%26aufirst%3DL.%26atitle%3DSimultaneous%2520inhibition%2520of%2520ATR%2520and%2520PARP%2520sensitizes%2520colon%2520cancer%2520cell%2520lines%2520to%2520irinotecan%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D147%26doi%3D10.3389%2Ffphar.2015.00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstob, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herriott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N.</span></span> <span> </span><span class="NLM_article-title">Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">32396</span>– <span class="NLM_lpage">32409</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.18632%2Foncotarget.6136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=26486089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BC28zjvFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=32396-32409&author=F.+K.+Middletonauthor=M.+J.+Pattersonauthor=C.+J.+Elstobauthor=S.+Fordhamauthor=A.+Herriottauthor=M.+A.+Wadeauthor=A.+McCormickauthor=R.+Edmondsonauthor=F.+E.+Mayauthor=J.+M.+Allanauthor=J.+R.+Pollardauthor=N.+Curtin&title=Common+cancer-associated+imbalances+in+the+DNA+damage+response+confer+sensitivity+to+single+agent+ATR+inhibition&doi=10.18632%2Foncotarget.6136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition</span></div><div class="casAuthors">Middleton Fiona K; Patterson Miranda J; Elstob Claire J; Fordham Sarah; Herriott Ashleigh; Wade Mark A; McCormick Aiste; Edmondson Richard; May Felicity E B; Allan James M; Curtin Nicola J; Pollard John R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">32396-409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints.  Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alone.  We determined the cytotoxicity of the ATR inhibitor VE-821 in isogenically matched cells with DDR imbalance.  Cell cycle arrest, DNA damage accumulation and repair were determined following VE-821 exposure.Defects in homologous recombination repair (HRR: ATM, BRCA2 and XRCC3) and base excision repair (BER: XRCC1) conferred sensitivity to VE-821.  Surprisingly, the loss of different components of the trimeric non-homologous end-joining (NHEJ) protein DNA-PK had opposing effects.  Loss of the DNA-binding component, Ku80, caused hypersensitivity to VE-821, but loss of its partner catalytic subunit, DNA-PKcs, did not.  Unexpectedly, VE-821 was particularly cytotoxic to human and hamster cells expressing high levels of DNA-PKcs.  High DNA-PKcs was associated with replicative stress and activation of the DDR.  VE-821 suppressed HRR, determined by RAD51 focus formation, to a greater extent in cells with high DNA-PKcs.Defects in HRR and BER and high DNA-PKcs expression, that are common in cancer, confer sensitivity to ATR inhibitor monotherapy and may be developed as predictive biomarkers for personalised medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjYzgB7-SM5LZpSb_XWfMrfW6udTcc2eb-FVL3flvHJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zjvFGkug%253D%253D&md5=7798a6c3b3facab563e6daf71d89b736</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6136%26sid%3Dliteratum%253Aachs%26aulast%3DMiddleton%26aufirst%3DF.%2BK.%26aulast%3DPatterson%26aufirst%3DM.%2BJ.%26aulast%3DElstob%26aufirst%3DC.%2BJ.%26aulast%3DFordham%26aufirst%3DS.%26aulast%3DHerriott%26aufirst%3DA.%26aulast%3DWade%26aufirst%3DM.%2BA.%26aulast%3DMcCormick%26aufirst%3DA.%26aulast%3DEdmondson%26aufirst%3DR.%26aulast%3DMay%26aufirst%3DF.%2BE.%26aulast%3DAllan%26aufirst%3DJ.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%26atitle%3DCommon%2520cancer-associated%2520imbalances%2520in%2520the%2520DNA%2520damage%2520response%2520confer%2520sensitivity%2520to%2520single%2520agent%2520ATR%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D32396%26epage%3D32409%26doi%3D10.18632%2Foncotarget.6136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgado-Palacin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafarga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anton, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandoola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzweig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Capetillo, O.</span></span> <span> </span><span class="NLM_article-title">Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">445</span>),  <span class="NLM_fpage">ra91</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aad8243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1126%2Fscisignal.aad8243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=27625305" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=ra91&issue=445&author=I.+Morgado-Palacinauthor=A.+Dayauthor=M.+Murgaauthor=V.+Lafargaauthor=M.+E.+Antonauthor=A.+Tubbsauthor=H.+T.+Chenauthor=A.+Ergenauthor=R.+Andersonauthor=A.+Bhandoolaauthor=K.+G.+Pikeauthor=B.+Barlaamauthor=E.+Cadoganauthor=X.+Wangauthor=A.+J.+Pierceauthor=C.+Hubbardauthor=S.+A.+Armstrongauthor=A.+Nussenzweigauthor=O.+Fernandez-Capetillo&title=Targeting+the+kinase+activities+of+ATR+and+ATM+exhibits+antitumoral+activity+in+mouse+models+of+MLL-rearranged+AML&doi=10.1126%2Fscisignal.aad8243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aad8243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aad8243%26sid%3Dliteratum%253Aachs%26aulast%3DMorgado-Palacin%26aufirst%3DI.%26aulast%3DDay%26aufirst%3DA.%26aulast%3DMurga%26aufirst%3DM.%26aulast%3DLafarga%26aufirst%3DV.%26aulast%3DAnton%26aufirst%3DM.%2BE.%26aulast%3DTubbs%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%2BT.%26aulast%3DErgen%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DR.%26aulast%3DBhandoola%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPierce%26aufirst%3DA.%2BJ.%26aulast%3DHubbard%26aufirst%3DC.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DNussenzweig%26aufirst%3DA.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26atitle%3DTargeting%2520the%2520kinase%2520activities%2520of%2520ATR%2520and%2520ATM%2520exhibits%2520antitumoral%2520activity%2520in%2520mouse%2520models%2520of%2520MLL-rearranged%2520AML%26jtitle%3DSci.%2520Signaling%26date%3D2016%26volume%3D9%26issue%3D445%26spage%3Dra91%26doi%3D10.1126%2Fscisignal.aad8243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafiq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermulen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span> <span> </span><span class="NLM_article-title">ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13837</span>– <span class="NLM_lpage">13850</span>, <span class="refDoi"> DOI: 10.1038/ncomms13837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1038%2Fncomms13837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=27958275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamtrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13837-13850&author=C.+T.+Williamsonauthor=R.+Millerauthor=H.+N.+Pembertonauthor=S.+E.+Jonesauthor=J.+Campbellauthor=A.+Kondeauthor=N.+Badhamauthor=R.+Rafiqauthor=R.+Broughauthor=A.+Gulatiauthor=C.+J.+Ryanauthor=J.+Francisauthor=P.+B.+Vermulenauthor=A.+R.+Reynoldsauthor=P.+M.+Reaperauthor=J.+R.+Pollardauthor=A.+Ashworthauthor=C.+J.+Lord&title=ATR+inhibitors+as+a+synthetic+lethal+therapy+for+tumours+deficient+in+ARID1A&doi=10.1038%2Fncomms13837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A</span></div><div class="casAuthors">Williamson, Chris T.; Miller, Rowan; Pemberton, Helen N.; Jones, Samuel E.; Campbell, James; Konde, Asha; Badham, Nicholas; Rafiq, Rumana; Brough, Rachel; Gulati, Aditi; Ryan, Colm J.; Francis, Jeff; Vermulen, Peter B.; Reynolds, Andrew R.; Reaper, Philip M.; Pollard, John R.; Ashworth, Alan; Lord, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13837</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies.  Mutations in ARID1A represent one of the most common mol. alterations in human cancer, but therapeutic approaches that target these defects are not yet clin. available.  We demonstrate that defects in ARID1A sensitize tumor cells to clin. inhibitors of the DNA damage checkpoint kinase, ATR, both in vitro and in vivo.  Mechanistically, ARID1A deficiency results in topoisomerase 2A and cell cycle defects, which cause an increased reliance on ATR checkpoint activity.  In ARID1A mutant tumor cells, inhibition of ATR triggers premature mitotic entry, genomic instability and apoptosis.  The data presented here provide the pre-clin. and mechanistic rationale for assessing ARID1A defects as a biomarker of single-agent ATR inhibitor response and represents a novel synthetic lethal approach to targeting tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi9cKHrgrcHLVg90H21EOLACvtfcHk0lhUGQVR8WmXUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamtrnI&md5=5b12d69b190de8f14c121366ee0c26a3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fncomms13837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13837%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DPemberton%26aufirst%3DH.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BE.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DKonde%26aufirst%3DA.%26aulast%3DBadham%26aufirst%3DN.%26aulast%3DRafiq%26aufirst%3DR.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DGulati%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DC.%2BJ.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DVermulen%26aufirst%3DP.%2BB.%26aulast%3DReynolds%26aufirst%3DA.%2BR.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26atitle%3DATR%2520inhibitors%2520as%2520a%2520synthetic%2520lethal%2520therapy%2520for%2520tumours%2520deficient%2520in%2520ARID1A%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13837%26epage%3D13850%26doi%3D10.1038%2Fncomms13837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenkort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón-Montaño, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortusewicz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiper, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scobie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3407</span>– <span class="NLM_lpage">3416</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.celrep.2016.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=28009306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=3407-3416&author=K.+Sanjivauthor=A.+Hagenkortauthor=J.+M.+Calder%C3%B3n-Monta%C3%B1oauthor=T.+Koolmeisterauthor=P.+M.+Reaperauthor=O.+Mortusewiczauthor=S.+A.+Jacquesauthor=R.+V.+Kuiperauthor=N.+Schultzauthor=M.+Scobieauthor=P.+A.+Charltonauthor=J.+R.+Pollardauthor=U.+W.+Berglundauthor=M.+Altunauthor=T.+Helleday&title=Cancer-Specific+Synthetic+Lethality+between+ATR+and+CHK1+Kinase+Activities&doi=10.1016%2Fj.celrep.2016.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities [Erratum to document cited in CA165:589929]</span></div><div class="casAuthors">Sanjiv, Kumar; Hagenkort, Anna; Calderon-Montano, Jose Manuel; Koolmeister, Tobias; Reaper, Philip M.; Mortusewicz, Oliver; Jacques, Sylvain A.; Kuiper, Raoul V.; Schultz, Niklas; Scobie, Martin; Charlton, Peter A.; Pollard, John R.; Berglund, Ulrika Warpman; Altun, Mikael; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3407-3416</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-P9L07AcZ7bVg90H21EOLACvtfcHk0lhUGQVR8WmXUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL&md5=1972b2221b3d31fb519def6fb70288e3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DHagenkort%26aufirst%3DA.%26aulast%3DCalder%25C3%25B3n-Monta%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3DKoolmeister%26aufirst%3DT.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DMortusewicz%26aufirst%3DO.%26aulast%3DJacques%26aufirst%3DS.%2BA.%26aulast%3DKuiper%26aufirst%3DR.%2BV.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DScobie%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DCancer-Specific%2520Synthetic%2520Lethality%2520between%2520ATR%2520and%2520CHK1%2520Kinase%2520Activities%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26spage%3D3407%26epage%3D3416%26doi%3D10.1016%2Fj.celrep.2016.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and rad3 related (ATR) kinase with application as an anti-cancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9889</span>– <span class="NLM_lpage">9907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9889-9907&issue=22&author=K.+M.+Footeauthor=J.+W.+M.+Nissinkauthor=T.+M.+McGuireauthor=P.+Turnerauthor=S.+Guichardauthor=J.+T.+Yatesauthor=A.+Lauauthor=K.+Bladesauthor=D.+Heathcoteauthor=R.+Odedraauthor=G.+Wilkinsonauthor=Z.+Wilsonauthor=C.+Woodauthor=P.+J.+Jewsbury&title=Discovery+and+characterization+of+AZD6738%2C+a+potent+inhibitor+of+ataxia+telangiectasia+mutated+and+rad3+related+%28ATR%29+kinase+with+application+as+an+anti-cancer+agent&doi=10.1021%2Facs.jmedchem.8b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span></div><div class="casAuthors">Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; Wilkinson, Gary; Wilson, Zena; Wood, Christine M.; Jewsbury, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9889-9907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and assocd. DNA double-strand breaks.  Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clin. response by increasing replication stress.  Here the authors describe the development of the clin. candidate II (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclin. physicochem. and pharmacokinetic (PK) characteristics.  Compd. II was developed improving aq. soly. and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor I (AZ20).  The clin. candidate II has favorable human PK suitable for once or twice daily dosing and achieves biol. effective exposure at moderate doses.  Compd. II is currently being tested in multiple phase I/II trials as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr419z5SGLz_LVg90H21EOLACvtfcHk0liKzH-FjIKqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F&md5=992b9a9669f1e58926d3e7e4d4e816ba</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01187%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DJ.%2BT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DC.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520AZD6738%252C%2520a%2520potent%2520inhibitor%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520rad3%2520related%2520%2528ATR%2529%2520kinase%2520with%2520application%2520as%2520an%2520anti-cancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D9889%26epage%3D9907%26doi%3D10.1021%2Facs.jmedchem.8b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciuto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padiernos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yutzy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alewine, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aladjem, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Phase I study of ATR inhibitor M6620 in combination with Topotecan in patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.76.6915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1200%2FJCO.2017.76.6915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=29252124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1594-1602&issue=16&author=A.+Thomasauthor=C.+E.+Redonauthor=L.+Sciutoauthor=E.+Padiernosauthor=J.+Jiauthor=M.+J.+Leeauthor=A.+Yunoauthor=S.+Leeauthor=Y.+Zhangauthor=L.+Tranauthor=W.+Yutzyauthor=A.+Rajanauthor=U.+Guhaauthor=H.+Chenauthor=R.+Hassanauthor=C.+C.+Alewineauthor=E.+Szaboauthor=S.+E.+Batesauthor=R.+J.+Kindersauthor=S.+M.+Steinbergauthor=J.+H.+Doroshowauthor=M.+I.+Aladjemauthor=J.+B.+Trepelauthor=Y.+Pommier&title=Phase+I+study+of+ATR+inhibitor+M6620+in+combination+with+Topotecan+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2017.76.6915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors</span></div><div class="casAuthors">Thomas, Anish; Redon, Christophe E.; Sciuto, Linda; Padiernos, Emerson; Ji, Jiuping; Lee, Min-Jung; Yuno, Akira; Lee, Sunmin; Zhang, Yiping; Tran, Lan; Yutzy, William; Rajan, Arun; Guha, Udayan; Chen, Haobin; Hassan, Raffit; Alewine, Christine C.; Szabo, Eva; Bates, Susan E.; Kinders, Robert J.; Steinberg, Seth M.; Doroshow, James H.; Aladjem, Mirit I.; Trepel, Jane B.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1594-1604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Our preclin. work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors.  We hypothesized that a combination of selective ATR inhibitor M6620 (previously VX-970) and topotecan, a selective TOP1 inhibitor, would be tolerable and active, particularly in tumors with high replicative stress.  Patients and Methods This phase I study tested the combination of M6620 and topotecan in 3-wk cycles using 3 + 3 dose escalation.  The primary end point was the identification of the max. tolerated dose of the combination.  Efficacy and pharmacodynamics were secondary end points.  Results Between Sept. 2016 and Feb. 2017, 21 patients enrolled.  The combination was well tolerated, which allowed for dose escalation to the highest planned dose level (topotecan 1.25 mg/m2, days 1 to 5; M6620 210 mg/m2, days 2 and 5).  One of six patients at this dose level experienced grade 4 thrombocytopenia that required transfusion, a dose-limiting toxicity.  Most common treatment-related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%); and thrombocytopenia (10%).  Two partial responses (≥ 18 mo, ≥ 7 mo) and seven stable disease responses ≥ 3 mo (median, 9 mo; range, 3 to 12 mo) were seen.  Three of five patients with small-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, ≥ 6, and ≥ 7 mo).  Pharmacodynamic studies showed preliminary evidence of ATR inhibition and enhanced DNA double-stranded breaks in response to the combination.  Conclusion To our knowledge, this report is the first of an ATR inhibitor-chemotherapy combination.  The max. dose of topotecan plus M6620 is tolerable.  The combination seems particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to topotecan alone.  Phase II studies with biomarker evaluation are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHK6PpVIvW0rVg90H21EOLACvtfcHk0liKzH-FjIKqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCiurg%253D&md5=f76544a67091d0e15a205fe42abfc29c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.76.6915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.76.6915%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DSciuto%26aufirst%3DL.%26aulast%3DPadiernos%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DYuno%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DYutzy%26aufirst%3DW.%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DGuha%26aufirst%3DU.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DHassan%26aufirst%3DR.%26aulast%3DAlewine%26aufirst%3DC.%2BC.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DAladjem%26aufirst%3DM.%2BI.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DPhase%2520I%2520study%2520of%2520ATR%2520inhibitor%2520M6620%2520in%2520combination%2520with%2520Topotecan%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D16%26spage%3D1594%26epage%3D1602%26doi%3D10.1200%2FJCO.2017.76.6915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thies, J. E.</span></span> <span> </span><span class="NLM_article-title">An efficient synthesis of arylpyrazines and bipyridines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2055</span>, <span class="refDoi"> DOI: 10.1021/jo00244a037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00244a037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaL1cXhvVKlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=2052-2055&author=W.+J.+Thompsonauthor=J.+H.+Jonesauthor=P.+A.+Lyleauthor=J.+E.+Thies&title=An+efficient+synthesis+of+arylpyrazines+and+bipyridines&doi=10.1021%2Fjo00244a037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of arylpyrazines and bipyridines</span></div><div class="casAuthors">Thompson, Wayne J.; Jones, James H.; Lyle, Paulette A.; Thies, J. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2052-5</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The coupling of chloro- or bromopyrazines and -pyridines with areneboronic acids in the presence of Pd(0) catalysts is described.  By use of the appropriate catalyst, the coupling of pyridineboronic acids was also achieved.  A convergent synthesis of the previously unknown 4-Me deriv. of the cardiotonic milrinone (I) is also described.  Thus, coupling of bromopyridine II (R = Br) with 4-pyridineboronic acid in the presence of Pd(OAc)2 and 1,1'-bis(diphenylphosphino)ferrocene gave 22% of the substituted bipyridine II (R = 4-pyridyl).  Hydrolysis of II (R = 4-pyridyl) gave 85% I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUNKqc4dZb7LVg90H21EOLACvtfcHk0liKzH-FjIKqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhvVKlu7c%253D&md5=ce1acf1d87830e12c01e5ca909aefd17</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjo00244a037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00244a037%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DW.%2BJ.%26aulast%3DJones%26aufirst%3DJ.%2BH.%26aulast%3DLyle%26aufirst%3DP.%2BA.%26aulast%3DThies%26aufirst%3DJ.%2BE.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520arylpyrazines%2520and%2520bipyridines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1988%26volume%3D53%26spage%3D2052%26epage%3D2055%26doi%3D10.1021%2Fjo00244a037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavapeddi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavarajappa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramya, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span> <span> </span><span class="NLM_article-title">Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating <i>Mycobacterium tuberculosis</i></span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1021/cb300510w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300510w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2gsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=519-523&author=P.+S.+Shirudeauthor=P.+Madhavapeddiauthor=J.+A.+Tuckerauthor=K.+Muruganauthor=V.+Patilauthor=H.+Basavarajappaauthor=A.+V.+Raichurkarauthor=V.+Humnabadkarauthor=S.+Husseinauthor=S.+Sharmaauthor=V.+K.+Ramyaauthor=C.+B.+Narayanauthor=T.+S.+Balganeshauthor=V.+K.+Sambandamurthy&title=Aminopyrazinamides%3A+novel+and+specific+GyrB+inhibitors+that+kill+replicating+and+nonreplicating+Mycobacterium+tuberculosis&doi=10.1021%2Fcb300510w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis</span></div><div class="casAuthors">Shirude, Pravin S.; Madhavapeddi, Prashanti; Tucker, Julie A.; Murugan, Kannan; Patil, Vikas; Basavarajappa, Halesha; Raichurkar, Anandkumar V.; Humnabadkar, Vaishali; Hussein, Syeed; Sharma, Sreevalli; Ramya, V. K.; Narayan, Chandan B.; Balganesh, Tanjore S.; Sambandamurthy, Vasan K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-523</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aminopyrazinamides originated from a high throughput screen targeting the Mycobacterium smegmatis (Msm) GyrB ATPase.  This series displays chem. tractability, robust structure-activity relationship, and potent antitubercular activity.  The crystal structure of Msm GyrB in complex with one of the aminopyrazinamides revealed promising attributes of specificity against other broad spectrum pathogens and selectivity against eukaryotic kinases due to novel interactions at hydrophobic pocket, unlike other known GyrB inhibitors.  The aminopyrazinamides display excellent mycobacterial kill under in vitro, intracellular, and hypoxic conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVejwI5h6ePLVg90H21EOLACvtfcHk0lih2CMYC-MRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2gsLrI&md5=4f8053bd1721c40019c70fab7f6147be</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcb300510w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300510w%26sid%3Dliteratum%253Aachs%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DMadhavapeddi%26aufirst%3DP.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DMurugan%26aufirst%3DK.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DBasavarajappa%26aufirst%3DH.%26aulast%3DRaichurkar%26aufirst%3DA.%2BV.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DHussein%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DRamya%26aufirst%3DV.%2BK.%26aulast%3DNarayan%26aufirst%3DC.%2BB.%26aulast%3DBalganesh%26aufirst%3DT.%2BS.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26atitle%3DAminopyrazinamides%253A%2520novel%2520and%2520specific%2520GyrB%2520inhibitors%2520that%2520kill%2520replicating%2520and%2520nonreplicating%2520Mycobacterium%2520tuberculosis%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D519%26epage%3D523%26doi%3D10.1021%2Fcb300510w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoegdin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Alfredsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soederman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormoe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelissen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerning, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer’s disease: design, synthesis, and characterization of pyrazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9107</span>– <span class="NLM_lpage">9119</span>, <span class="refDoi"> DOI: 10.1021/jm201724m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201724m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9107-9119&author=S.+Bergauthor=M.+Berghauthor=S.+Hellbergauthor=K.+Hoegdinauthor=Y.+Lo-Alfredssonauthor=P.+Soedermanauthor=S.+von+Bergauthor=T.+Weigeltauthor=M.+Ormoeauthor=Y.+Xueauthor=J.+Tuckerauthor=J.+Neelissenauthor=E.+Jerningauthor=Y.+Nilssonauthor=R.+Bhat&title=Discovery+of+novel+potent+and+highly+selective+glycogen+synthase+kinase-3%CE%B2+%28GSK3%CE%B2%29+inhibitors+for+Alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+and+characterization+of+pyrazines&doi=10.1021%2Fjm201724m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines</span></div><div class="casAuthors">Berg, Stefan; Bergh, Margareta; Hellberg, Sven; Hoegdin, Katharina; Lo-Alfredsson, Yvonne; Soederman, Peter; von Berg, Stefan; Weigelt, Tatjana; Ormoe, Mats; Xue, Yafeng; Tucker, Julie; Neelissen, Jan; Jerning, Eva; Nilsson, Yvonne; Bhat, Ratan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9107-9119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metab.  Active forms of GSK3β localize to pretangle pathol. including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain.  By using a high throughput screening (HTS) approach to search for new chem. series and cocrystn. of key analogs to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetration.  The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDR4w7EMbaI7Vg90H21EOLACvtfcHk0lih2CMYC-MRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D&md5=f1475e38163a8e81e9ca9a24b271a0be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm201724m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201724m%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DBergh%26aufirst%3DM.%26aulast%3DHellberg%26aufirst%3DS.%26aulast%3DHoegdin%26aufirst%3DK.%26aulast%3DLo-Alfredsson%26aufirst%3DY.%26aulast%3DSoederman%26aufirst%3DP.%26aulast%3Dvon%2BBerg%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DT.%26aulast%3DOrmoe%26aufirst%3DM.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DNeelissen%26aufirst%3DJ.%26aulast%3DJerning%26aufirst%3DE.%26aulast%3DNilsson%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520and%2520highly%2520selective%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520%2528GSK3%25CE%25B2%2529%2520inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520pyrazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9107%26epage%3D9119%26doi%3D10.1021%2Fjm201724m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, K. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of new benzofuranyl isoxazoles as antitubercular, antibacterial and antifungal agents</span>. <i>Indian J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-88&author=K.+Mannaauthor=Y.+K.+Agarwalauthor=K.+K.+Srinivasan&title=Synthesis+and+biological+evaluation+of+new+benzofuranyl+isoxazoles+as+antitubercular%2C+antibacterial+and+antifungal+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of new benzofuranyl isoxazoles as antitubercular, antibacterial and antifungal agents</span></div><div class="casAuthors">Manna, K.; Agarwal, Y. K.; Srinivasan, K. K.</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">IJCHEI</span>;
        ISSN:<span class="NLM_cas:issn">0971-1627</span>.
    
            (<span class="NLM_cas:orgname">Prof. R. S. Varma</span>)
        </div><div class="casAbstract">Substituted benzofuran-chalcones were prepd. by the reaction of 2-acetylbenzofuran with different arom. aldehydes in presence of strong base.  Benzofuran-chalcones on cyclocondensation with hydroxylamine hydrochloride in presence of sodium acetate, gave various 3-(1-benzofuran-2-yl)-5-phenylisoxazoles.  The structure of benzofuran-isoxazoles were established on the basis of spectral (IR, 1H NMR, Mass) data.  The benzofuran-isoxazoles were evaluated for their, antitubercular, antimicrobial and antiinflammatory activities.  Some of the compds. have shown promising antitubercular and antibacterial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgT2v5i4obYLVg90H21EOLACvtfcHk0lih2CMYC-MRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrbE&md5=20647a9fa0dfc7b5049fb97cee953138</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManna%26aufirst%3DK.%26aulast%3DAgarwal%26aufirst%3DY.%2BK.%26aulast%3DSrinivasan%26aufirst%3DK.%2BK.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520benzofuranyl%2520isoxazoles%2520as%2520antitubercular%252C%2520antibacterial%2520and%2520antifungal%2520agents%26jtitle%3DIndian%2520J.%2520Heterocycl.%2520Chem.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Detistov, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuravel’, I. O.</span></span> <span> </span><span class="NLM_article-title">Isomeric 3-isoxadiazolylcoumarins and their derivatives</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/jhet.893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1002%2Fjhet.893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlaitLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=883-892&author=O.+S.+Detistovauthor=V.+D.+Orlovauthor=I.+O.+Zhuravel%E2%80%99&title=Isomeric+3-isoxadiazolylcoumarins+and+their+derivatives&doi=10.1002%2Fjhet.893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Isomeric 3-isoxadiazolylcoumarins and their derivatives</span></div><div class="casAuthors">Detistov, Oleksandr S.; Orlov, Valeriy D.; Zhuravel', Irina O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Preparative methods of synthesis of isomeric 3-isoxadiazolylcoumarins and their derivs. are presented.  Two new synthetic methods have been developed for 3-[1,2,4-oxadiazol-5-yl]coumarins I [R1 = H, 6-Br, 7-MeO, etc.; R2 = Ph, 4-MeOC6H4, 4-MeC6H4].  The first method is based on a three-component condensation of coumarin-3-carboxylic acids, 1,1'-carbonyldiimidazole, and amidoximes.  The second method uses cyclization of 5-cyanomethyl-1,2,4-oxadiazoles with salicylic aldehydes.  General approach for prepn. of 3-[1,2,4-oxadiazol-3-yl]coumarins has been developed.  Moreover, the aforementioned synthetic ways open the way for the synthesis of 2-iminoderivatives not described before, those were diversified by the reaction of nucleophilic substitution of 2-imino group with a numerous amino compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHapfSMapebVg90H21EOLACvtfcHk0lhRjD1sSwv7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlaitLjL&md5=16b74cc54dca7b983a4852a6942771bb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fjhet.893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.893%26sid%3Dliteratum%253Aachs%26aulast%3DDetistov%26aufirst%3DO.%2BS.%26aulast%3DOrlov%26aufirst%3DV.%2BD.%26aulast%3DZhuravel%25E2%2580%2599%26aufirst%3DI.%2BO.%26atitle%3DIsomeric%25203-isoxadiazolylcoumarins%2520and%2520their%2520derivatives%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D883%26epage%3D892%26doi%3D10.1002%2Fjhet.893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisonette, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6793</span>– <span class="NLM_lpage">6799</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.bmcl.2011.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=21978683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6793-6799&author=D.+S.+Mortensenauthor=S.+M.+Perrin-Ninkovicauthor=R.+Harrisauthor=B.+G.+S.+Leeauthor=G.+Shevlinauthor=M.+Hickmanauthor=G.+Khambattaauthor=R.+R.+Bisonetteauthor=K.+E.+Fultzauthor=S.+Sankar&title=Discovery+and+SAR+exploration+of+a+novel+series+of+imidazo%5B4%2C5-b%5Dpyrazin-2-ones+as+potent+and+selective+mTOR+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2011.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span></div><div class="casAuthors">Mortensen, Deborah S.; Perrin-Ninkovic, Sophie M.; Harris, Roy; Lee, Branden G. S.; Shevlin, Graziella; Hickman, Matt; Khambatta, Gody; Bisonette, Rene R.; Fultz, Kimberly E.; Sankar, Sabita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6793-6799</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report here the discovery of a novel series of selective mTOR kinase inhibitors.  A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compds. with excellent mTOR potency and exquisite kinase selectivity.  Potent compds. from this series show >1000-fold selectivity over the related PI3Kα lipid kinase.  Further, compds. such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWly4sBJXgerVg90H21EOLACvtfcHk0lhRjD1sSwv7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P&md5=d422a7d505c1032951547d997ac2e033</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%2BM.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DB.%2BG.%2BS.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBisonette%26aufirst%3DR.%2BR.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DSankar%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520SAR%2520exploration%2520of%2520a%2520novel%2520series%2520of%2520imidazo%255B4%252C5-b%255Dpyrazin-2-ones%2520as%2520potent%2520and%2520selective%2520mTOR%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6793%26epage%3D6799%26doi%3D10.1016%2Fj.bmcl.2011.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Epps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiamengo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotecki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martineza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertab, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morytkoa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekharc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinnere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewartb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallacea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design and synthesis of tricyclic cores for kinase inhibition</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.bmcl.2012.11.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=23265875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=693-698&author=S.+Van%0AEppsauthor=B.+Fiamengoauthor=J.+Edmundsauthor=A.+Ericssonauthor=K.+Frankauthor=M.+Friedmanauthor=D.+Georgeauthor=J.+Georgeauthor=E.+Goedkenauthor=B.+Koteckiauthor=G.+Martinezaauthor=P.+Mertabauthor=M.+Morytkoaauthor=S.+Shekharcauthor=B.+Skinnereauthor=K.+Stewartbauthor=J.+Vossaauthor=G.+Wallaceaauthor=L.+Wangaauthor=L.+Wangaauthor=N.+Wishart&title=Design+and+synthesis+of+tricyclic+cores+for+kinase+inhibition&doi=10.1016%2Fj.bmcl.2012.11.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tricyclic cores for kinase inhibition</span></div><div class="casAuthors">Van Epps, Stacy; Fiamengo, Bryan; Edmunds, Jeremy; Ericsson, Anna; Frank, Kristine; Friedman, Michael; George, Dawn; George, Jonathan; Goedken, Eric; Kotecki, Brian; Martinez, Gloria; Merta, Philip; Morytko, Michael; Shekhar, Shashank; Skinner, Barbara; Stewart, Kent; Voss, Jeffrey; Wallace, Grier; Wang, Lu; Wishart, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-698</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interest in therapeutic kinase inhibitors continues to grow beyond success in oncol.  To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores.  We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine.  Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw43t_VvXMbbVg90H21EOLACvtfcHk0lhRjD1sSwv7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ&md5=59cb993b841a73569309f0fca703b4c4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BEpps%26aufirst%3DS.%26aulast%3DFiamengo%26aufirst%3DB.%26aulast%3DEdmunds%26aufirst%3DJ.%26aulast%3DEricsson%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DD.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DGoedken%26aufirst%3DE.%26aulast%3DKotecki%26aufirst%3DB.%26aulast%3DMartineza%26aufirst%3DG.%26aulast%3DMertab%26aufirst%3DP.%26aulast%3DMorytkoa%26aufirst%3DM.%26aulast%3DShekharc%26aufirst%3DS.%26aulast%3DSkinnere%26aufirst%3DB.%26aulast%3DStewartb%26aufirst%3DK.%26aulast%3DVossa%26aufirst%3DJ.%26aulast%3DWallacea%26aufirst%3DG.%26aulast%3DWanga%26aufirst%3DL.%26aulast%3DWanga%26aufirst%3DL.%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tricyclic%2520cores%2520for%2520kinase%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D693%26epage%3D698%26doi%3D10.1016%2Fj.bmcl.2012.11.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meudtner, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional “clickates” as versatile extended heteroaromatic building blocks: efficient synthesis via click chemistry, conformational preferences, and metal coordination</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">9834</span>– <span class="NLM_lpage">9840</span>, <span class="refDoi"> DOI: 10.1002/chem.200701240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1002%2Fchem.200701240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=17948330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1yltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=9834-9840&author=R.+M.+Meudtnerauthor=M.+Ostermeierauthor=R.+Goddardauthor=C.+Limbergauthor=S.+Hecht&title=Multifunctional+%E2%80%9Cclickates%E2%80%9D+as+versatile+extended+heteroaromatic+building+blocks%3A+efficient+synthesis+via+click+chemistry%2C+conformational+preferences%2C+and+metal+coordination&doi=10.1002%2Fchem.200701240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional "clickates" as versatile extended heteroaromatic building blocks: efficient synthesis via click chemistry, conformational preferences, and metal coordination</span></div><div class="casAuthors">Meudtner, Robert M.; Ostermeier, Marc; Goddard, Richard; Limberg, Christian; Hecht, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">9834-9840</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Click chem. was used to access 2,6-bis(1-aryl-1,2,3-triazol-4-yl)pyridines (BTPs) as versatile extended heteroarom. building blocks for their exploitation in supra-mol. chem., in particular foldamer and ligand design.  In addn. to their high-yielding synthesis using Cu1-catalyzed Huisgen-type 1,3-dipolar cycloaddn. reactions the formed triazole moieties constitute an integral part of the BTP framework and encode both its pronounced conformational preferences as well as its chelating ability.  A diverse set of sym. and nonsym. BTPs carrying electron-donating and -withdrawing substituents at both terminal aryl and the central pyridine moieties has efficiently been synthesized and could also readily be postfunctionalized with amphiphilic side chains and porphyrin chromophores.  In both soln. and solid state, the BTP scaffold adopts a highly conserved horseshoe-like anti-anti conformation.  Upon protonation or metal coordination, the BTP scaffold switches to the chelating syn-syn conformation.  Iron and europium complexes were prepd., successfully characterized by single-crystal x-ray diffraction anal., and investigated with regard to their spin state and luminescent properties.  The extended heteroarom. BTP scaffold should prove useful for the design of responsive foldamer backbones and the prepn. of new magnetic and emissive materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9LFkfQlOSbVg90H21EOLACvtfcHk0lhBurNKIn55Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1yltw%253D%253D&md5=933cf2919c758519bb706f90d25f4cce</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fchem.200701240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200701240%26sid%3Dliteratum%253Aachs%26aulast%3DMeudtner%26aufirst%3DR.%2BM.%26aulast%3DOstermeier%26aufirst%3DM.%26aulast%3DGoddard%26aufirst%3DR.%26aulast%3DLimberg%26aufirst%3DC.%26aulast%3DHecht%26aufirst%3DS.%26atitle%3DMultifunctional%2520%25E2%2580%259Cclickates%25E2%2580%259D%2520as%2520versatile%2520extended%2520heteroaromatic%2520building%2520blocks%253A%2520efficient%2520synthesis%2520via%2520click%2520chemistry%252C%2520conformational%2520preferences%252C%2520and%2520metal%2520coordination%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2007%26volume%3D13%26spage%3D9834%26epage%3D9840%26doi%3D10.1002%2Fchem.200701240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidner-Wells, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henninger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga-Spano, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argentieri, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachter, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hlasta, D. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4307</span>– <span class="NLM_lpage">4311</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.05.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.bmcl.2004.05.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=15261292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVWjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4307-4311&author=M.+A.+Weidner-Wellsauthor=T.+C.+Henningerauthor=S.+A.+Fraga-Spanoauthor=C.+M.+Boggsauthor=M.+Matheisauthor=D.+M.+Ritchieauthor=D.+C.+Argentieriauthor=M.+P.+Wachterauthor=D.+J.+Hlasta&title=Synthesis+and+structure%E2%80%93activity+relationships+of+3%2C5-diarylisoxazoles+and+3%2C5-diaryl-1%2C2%2C4-oxadiazoles%2C+novel+classes+of+small+molecule+interleukin-8+%28IL-8%29+receptor+antagonists&doi=10.1016%2Fj.bmcl.2004.05.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists</span></div><div class="casAuthors">Weidner-Wells, Michele A.; Henninger, Todd C.; Fraga-Spano, Stephanie A.; Boggs, Christine M.; Matheis, Michele; Ritchie, David M.; Argentieri, Dennis C.; Wachter, Michael P.; Hlasta, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4307-4311</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of 3,5-diarylisoxazole and 3,5-diaryl-1,2,4-oxadiazole, e.g., I, has been identified as IL-8 inhibitors.  These compds. exhibit activity in an IL-8 binding assay as well as in a functional assay of IL-8 induced elastase release from neutrophils.  In addn., one of the compds. exhibits oral activity in a rat adjuvant arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpefTRhch6g5LVg90H21EOLACvtfcHk0lhBurNKIn55Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVWjt70%253D&md5=5ba3cc1cab2d534d1faaaeadd9320160</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.05.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.05.080%26sid%3Dliteratum%253Aachs%26aulast%3DWeidner-Wells%26aufirst%3DM.%2BA.%26aulast%3DHenninger%26aufirst%3DT.%2BC.%26aulast%3DFraga-Spano%26aufirst%3DS.%2BA.%26aulast%3DBoggs%26aufirst%3DC.%2BM.%26aulast%3DMatheis%26aufirst%3DM.%26aulast%3DRitchie%26aufirst%3DD.%2BM.%26aulast%3DArgentieri%26aufirst%3DD.%2BC.%26aulast%3DWachter%26aufirst%3DM.%2BP.%26aulast%3DHlasta%26aufirst%3DD.%2BJ.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25203%252C5-diarylisoxazoles%2520and%25203%252C5-diaryl-1%252C2%252C4-oxadiazoles%252C%2520novel%2520classes%2520of%2520small%2520molecule%2520interleukin-8%2520%2528IL-8%2529%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4307%26epage%3D4311%26doi%3D10.1016%2Fj.bmcl.2004.05.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoarau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsais, F.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed direct (hetero)arylation of ethyl oxazole-4-carboxylate: an efficient access to (hetero)aryloxazoles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">7383</span>– <span class="NLM_lpage">7386</span>, <span class="refDoi"> DOI: 10.1021/jo801093n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801093n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVarsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=7383-7386&author=C.+Verrierauthor=T.+Martinauthor=C.+Hoarauauthor=F.+Marsais&title=Palladium-catalyzed+direct+%28hetero%29arylation+of+ethyl+oxazole-4-carboxylate%3A+an+efficient+access+to+%28hetero%29aryloxazoles&doi=10.1021%2Fjo801093n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Direct (Hetero)arylation of Ethyl Oxazole-4-carboxylate: An Efficient Access to (Hetero)aryloxazoles</span></div><div class="casAuthors">Verrier, Cecile; Martin, Thibaut; Hoarau, Christophe; Marsais, Francis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7383-7386</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A straightforward route toward 2-(hetero)arylated and 2,5-di(hetero)arylated oxazoles through regiocontrolled palladium-catalyzed direct (hetero)arylation of Et oxazole-4-carboxylate with iodo-, bromo-, and chloro(hetero)aroms. followed by a two-step hydrolysis/decarboxylation sequence was described.  The method was applied here to a neat synthesis of two 2,5-di(hetero)aryloxazole natural products, balsoxin and texaline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJK_x9guZfj7Vg90H21EOLACvtfcHk0lhBurNKIn55Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVarsLg%253D&md5=d34b4dd16ec3449962a90f0649b0866d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo801093n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801093n%26sid%3Dliteratum%253Aachs%26aulast%3DVerrier%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DHoarau%26aufirst%3DC.%26aulast%3DMarsais%26aufirst%3DF.%26atitle%3DPalladium-catalyzed%2520direct%2520%2528hetero%2529arylation%2520of%2520ethyl%2520oxazole-4-carboxylate%253A%2520an%2520efficient%2520access%2520to%2520%2528hetero%2529aryloxazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D7383%26epage%3D7386%26doi%3D10.1021%2Fjo801093n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besselievre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrequier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahuteau-Betzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piguel, S.</span></span> <span> </span><span class="NLM_article-title">C-H bond activation: a versatile protocol for the direct arylation and alkenylation of oxazoles</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2009</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3511</span>– <span class="NLM_lpage">3518</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1216987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1055%2Fs-0029-1216987" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=3511-3518&issue=20&author=F.+Besselievreauthor=S.+Lebrequierauthor=F.+Mahuteau-Betzerauthor=S.+Piguel&title=C-H+bond+activation%3A+a+versatile+protocol+for+the+direct+arylation+and+alkenylation+of+oxazoles&doi=10.1055%2Fs-0029-1216987"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1216987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1216987%26sid%3Dliteratum%253Aachs%26aulast%3DBesselievre%26aufirst%3DF.%26aulast%3DLebrequier%26aufirst%3DS.%26aulast%3DMahuteau-Betzer%26aufirst%3DF.%26aulast%3DPiguel%26aufirst%3DS.%26atitle%3DC-H%2520bond%2520activation%253A%2520a%2520versatile%2520protocol%2520for%2520the%2520direct%2520arylation%2520and%2520alkenylation%2520of%2520oxazoles%26jtitle%3DSynthesis%26date%3D2009%26volume%3D2009%26issue%3D20%26spage%3D3511%26epage%3D3518%26doi%3D10.1055%2Fs-0029-1216987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endres, G. W.</span>; <span class="NLM_string-name">Lee, P. H.</span>; <span class="NLM_string-name">Olson, K. L.</span>; <span class="NLM_string-name">Kramer, J. B.</span>; <span class="NLM_string-name">Ciske, F. L.</span>; <span class="NLM_string-name">Barrett, S. D.</span></span> <span> </span><span class="NLM_article-title">Multiheteroaryl Compounds as Inhibitors of H-PGDS and Their Use for Treating Prostaglandin D2Mediated Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO 2010033977 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=G.+W.+Endres&author=P.+H.+Lee&author=K.+L.+Olson&author=J.+B.+Kramer&author=F.+L.+Ciske&author=S.+D.+Barrett&title=Multiheteroaryl+Compounds+as+Inhibitors+of+H-PGDS+and+Their+Use+for+Treating+Prostaglandin+D2Mediated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEndres%26aufirst%3DG.%2BW.%26atitle%3DMultiheteroaryl%2520Compounds%2520as%2520Inhibitors%2520of%2520H-PGDS%2520and%2520Their%2520Use%2520for%2520Treating%2520Prostaglandin%2520D2Mediated%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molander, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. R.</span></span> <span> </span><span class="NLM_article-title">Suzuki–Miyaura cross-coupling reactions of potassium vinyltrifluoroborate with aryl and heteroaryl electrophiles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">9681</span>– <span class="NLM_lpage">9686</span>, <span class="refDoi"> DOI: 10.1021/jo0617013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0617013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=9681-9686&issue=26&author=G.+A.+Molanderauthor=A.+R.+Brown&title=Suzuki%E2%80%93Miyaura+cross-coupling+reactions+of+potassium+vinyltrifluoroborate+with+aryl+and+heteroaryl+electrophiles&doi=10.1021%2Fjo0617013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Suzuki-Miyaura cross-coupling reactions of potassium vinyltrifluoroborate with aryl and heteroaryl electrophiles</span></div><div class="casAuthors">Molander, Gary A.; Brown, Adam R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9681-9686</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed cross-coupling reaction of potassium vinyltrifluoroborate with aryl electrophiles was described.  Recent progress in optimizing the reaction, as well as outlining the scope and limitations of the reaction were presented.  The cross-coupling reaction could generally be effected using 2 mol % of PdCl2 and 6 mol % of PPh3 as a catalyst system in THF/H2O with Cs2CO3 as a base.  Moderate to good yields were obtained in the presence of a variety of functional groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MqLzCH3iurVg90H21EOLACvtfcHk0lgHhV5QssyP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN&md5=67aef9e362d578497bce6c9f89effcf4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjo0617013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0617013%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DBrown%26aufirst%3DA.%2BR.%26atitle%3DSuzuki%25E2%2580%2593Miyaura%2520cross-coupling%2520reactions%2520of%2520potassium%2520vinyltrifluoroborate%2520with%2520aryl%2520and%2520heteroaryl%2520electrophiles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26issue%3D26%26spage%3D9681%26epage%3D9686%26doi%3D10.1021%2Fjo0617013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramón, D. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 3,5-disubstituted isoxazoles and isoxazolines in deep eutectic solvents</span>. <i>ACS Sustainable Chem. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2343</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1021/acssuschemeng.5b00689</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acssuschemeng.5b00689" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlelsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=2343-2349&author=J.+M.+Perezauthor=D.+J.+Ram%C3%B3n&title=Synthesis+of+3%2C5-disubstituted+isoxazoles+and+isoxazolines+in+deep+eutectic+solvents&doi=10.1021%2Facssuschemeng.5b00689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 3,5-Disubstituted Isoxazoles and Isoxazolines in Deep Eutectic Solvents</span></div><div class="casAuthors">Perez, Juana M.; Ramon, Diego J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Sustainable Chemistry & Engineering</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2343-2349</span>CODEN:
                <span class="NLM_cas:coden">ASCECG</span>;
        ISSN:<span class="NLM_cas:issn">2168-0485</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of different 3,5-disubstituted isoxazoles and related isoxazolines using choline chloride:urea as deep eutectic solvent (DES) in a one-pot three step reaction has been accomplished successfully.  The use of highly nucleophilic functionalized DES did not affect the process where highly electrophilic reagents or intermediates are involved.  The presence of DES showed to be essential since the reaction in absence of this media did not proceed.  The DES media could be reused up to five times without a detrimental effect on the yield of the reaction.  To exemplify the synthetic potential of this methodol., the reaction was scaled up to the gram scale without any noticeable problem.  Finally, different isoxazoles were easily transformed into β-aminoenones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Id_XridrBLVg90H21EOLACvtfcHk0lgHhV5QssyP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlelsrjJ&md5=fbfd32e2a776ab20d38a291bfdd6fe67</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facssuschemeng.5b00689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facssuschemeng.5b00689%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DJ.%2BM.%26aulast%3DRam%25C3%25B3n%26aufirst%3DD.%2BJ.%26atitle%3DSynthesis%2520of%25203%252C5-disubstituted%2520isoxazoles%2520and%2520isoxazolines%2520in%2520deep%2520eutectic%2520solvents%26jtitle%3DACS%2520Sustainable%2520Chem.%2520Eng.%26date%3D2015%26volume%3D3%26spage%3D2343%26epage%3D2349%26doi%3D10.1021%2Facssuschemeng.5b00689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotaiah, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikrishna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraju, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkata Rao, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antioxidant activity of 1,3,4-oxadiazole tagged thieno[2,3-d]pyrimidine derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1016%2Fj.ejmech.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=23149297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOrsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=340-345&author=Y.+Kotaiahauthor=N.+Harikrishnaauthor=K.+Nagarajuauthor=C.+Venkata+Rao&title=Synthesis+and+antioxidant+activity+of+1%2C3%2C4-oxadiazole+tagged+thieno%5B2%2C3-d%5Dpyrimidine+derivatives&doi=10.1016%2Fj.ejmech.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antioxidant activity of 1,3,4-oxadiazole tagged thieno[2,3-d]pyrimidine derivatives</span></div><div class="casAuthors">Kotaiah, Y.; Harikrishna, N.; Nagaraju, K.; Venkata Rao, C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This study represents the synthesis of a new series of N-substituted phenyl-5-methyl-6-(5-(4-substituted phenyl)-1,3,4-oxadiazol-2-yl)thieno[2,3-d]pyrimidin-4-amine derivs. and substituted phenylamino-5-methylthieno[2,3-d]pyrimidine-6-carboxylic acid derivs.  The newly synthesized compds. were characterized by 1H NMR, 13C NMR, LC-MS and IR analyses.  All these novel compds. were screened for their in vitro antioxidant activity by employing DPPH, hydrogen peroxide, and nitric oxide radical scavenging assays.  Four compds., e.g., I (R = H, Cl), showed significant radical scavenging due to the presence of electron donating substituent on both sides of the thienopyrimidine ring enhances the activity and electron withdrawing groups like nitro decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKqSFgEPyNrrVg90H21EOLACvtfcHk0libjQEzA4PngQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOrsr3F&md5=3bae7d7cef6f1968733acd49dbd40e3f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DKotaiah%26aufirst%3DY.%26aulast%3DHarikrishna%26aufirst%3DN.%26aulast%3DNagaraju%26aufirst%3DK.%26aulast%3DVenkata%2BRao%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520antioxidant%2520activity%2520of%25201%252C3%252C4-oxadiazole%2520tagged%2520thieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D58%26spage%3D340%26epage%3D345%26doi%3D10.1016%2Fj.ejmech.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kocevar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanovnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisler, M.</span></span> <span> </span><span class="NLM_article-title">Syntheses and transformations of some 1,2,4-oxadiazolylpyrazines</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570190629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1002%2Fjhet.5570190629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaL3sXhsVegtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1982&pages=1397-1402&issue=6&author=M.+Kocevarauthor=B.+Stanovnikauthor=M.+Tisler&title=Syntheses+and+transformations+of+some+1%2C2%2C4-oxadiazolylpyrazines&doi=10.1002%2Fjhet.5570190629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and transformations of some 1,2,4-oxadiazolylpyrazines</span></div><div class="casAuthors">Kocevar, M.; Stanovnik, B.; Tisler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1397-402</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">Cyanopyrazines with 2-amino, 2-oxo, and other groups are transformed into the corresponding amidoximes, e.g. I.  From these the corresponding 1,2,4-oxadiazolyl derivs., e.g. II, can be prepd. and interconversions to the corresponding pteridine 3-oxides, e.g. III, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRPDzt4JuAeLVg90H21EOLACvtfcHk0libjQEzA4PngQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsVegtbk%253D&md5=b36096204b7d362be36541550be7caab</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570190629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570190629%26sid%3Dliteratum%253Aachs%26aulast%3DKocevar%26aufirst%3DM.%26aulast%3DStanovnik%26aufirst%3DB.%26aulast%3DTisler%26aufirst%3DM.%26atitle%3DSyntheses%2520and%2520transformations%2520of%2520some%25201%252C2%252C4-oxadiazolylpyrazines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1982%26volume%3D19%26issue%3D6%26spage%3D1397%26epage%3D1402%26doi%3D10.1002%2Fjhet.5570190629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwöbel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, R. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüürmann, G.</span></span> <span> </span><span class="NLM_article-title">Prediction of the intrinsic hydrogen bond acceptor strength of organic compounds by local molecular parameters</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">956</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1021/ci900040z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900040z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A280%3ADC%252BD1MzgtVChuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=956-962&author=J.+Schw%C3%B6belauthor=R.+U.+Ebertauthor=R.+K%C3%BChneauthor=G.+Sch%C3%BC%C3%BCrmann&title=Prediction+of+the+intrinsic+hydrogen+bond+acceptor+strength+of+organic+compounds+by+local+molecular+parameters&doi=10.1021%2Fci900040z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the intrinsic hydrogen bond acceptor strength of organic compounds by local molecular parameters</span></div><div class="casAuthors">Schwobel Johannes; Ebert Ralf-Uwe; Kuhne Ralph; Schuurmann Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">956-62</span>
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    </div><div class="casAbstract">A quantum chemical model has been developed for predicting the hydrogen bond (HB) acceptor strength of monofunctional organic compounds from electronic ground-state properties of the single molecules.  Local molecular parameters are used to quantify electrostatic, polarizability, and charge transfer components to hydrogen bonding, employing the ab initio and density functional theory levels HF/6-31G** and B3LYP/6-31G**.  The model can handle lone pairs of intermediate and strong HB acceptor heteroatoms (N, O, S) as well as of weak HB acceptor halogens (F, Cl, Br) and includes also olefinic, alkyne, and aromatic pi-bonds as weak HB acceptor sites.  The model calibration with 403 compounds and experimental values for the Abraham HB acceptor strength B yielded squared correlation coefficients r(2) around 0.95, outperforming existing fragment-based schemes.  Model validation was performed applying a leave-50%-out procedure, yielding predictive squared correlation coefficients q(2) of around 0.95 for the subsets that both cover the whole chemical domain as well as (almost) the whole target value range of the data set.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRePc6NffI_hBJ5E29YNGvQfW6udTcc2eboHjOMtjwLLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzgtVChuw%253D%253D&md5=169584aa718e974920c1dab9b49a81df</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fci900040z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900040z%26sid%3Dliteratum%253Aachs%26aulast%3DSchw%25C3%25B6bel%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DR.%2BU.%26aulast%3DK%25C3%25BChne%26aufirst%3DR.%26aulast%3DSch%25C3%25BC%25C3%25BCrmann%26aufirst%3DG.%26atitle%3DPrediction%2520of%2520the%2520intrinsic%2520hydrogen%2520bond%2520acceptor%2520strength%2520of%2520organic%2520compounds%2520by%2520local%2520molecular%2520parameters%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D956%26epage%3D962%26doi%3D10.1021%2Fci900040z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hariharan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pople, J. A.</span></span> <span> </span><span class="NLM_article-title">The influence of polarization functions on molecular orbital hydrogenation energies</span>. <i>Theor. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1007/BF00533485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1007%2FBF00533485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaE3sXhtFGnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1973&pages=213-222&author=P.+C.+Hariharanauthor=J.+A.+Pople&title=The+influence+of+polarization+functions+on+molecular+orbital+hydrogenation+energies&doi=10.1007%2FBF00533485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of polarization functions on MO hydrogenation energies</span></div><div class="casAuthors">Hariharan, P. C.; Pople, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Theoretica Chimica Acta</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-22</span>CODEN:
                <span class="NLM_cas:coden">TCHAAM</span>;
        ISSN:<span class="NLM_cas:issn">0040-5744</span>.
    </div><div class="casAbstract">The hydrogenation energies of mols. involving H, C, O, N, and F with 2 non-H atoms were calcd. by a basis including polarization functions.  The mean abs. deviation between theory and expt. for heats of hydrogenation of the closed shell species is 4 kcal/mole for the basis set with full polarization.  Ests. of hydrogenation energy errors at the Hartree-Fock limit are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFfQCpw_j23bVg90H21EOLACvtfcHk0libjQEzA4PngQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXhtFGnsL4%253D&md5=a762a12b4ae5f50d14b4e29147b214e5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2FBF00533485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00533485%26sid%3Dliteratum%253Aachs%26aulast%3DHariharan%26aufirst%3DP.%2BC.%26aulast%3DPople%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520influence%2520of%2520polarization%2520functions%2520on%2520molecular%2520orbital%2520hydrogenation%2520energies%26jtitle%3DTheor.%2520Chim.%2520Acta%26date%3D1973%26volume%3D28%26spage%3D213%26epage%3D222%26doi%3D10.1007%2FBF00533485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional exchange-energy approximation with correct asymptotic-behavior</span>. <i>Phys. Rev. A: At., Mol., Opt. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3100</span>, <span class="refDoi"> DOI: 10.1103/PhysRevA.38.3098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1103%2FPhysRevA.38.3098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=9900728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaL1cXmtlOhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1988&pages=3098-3100&author=A.+D.+Becke&title=Density-functional+exchange-energy+approximation+with+correct+asymptotic-behavior&doi=10.1103%2FPhysRevA.38.3098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional exchange-energy approximation with correct asymptotic behavior</span></div><div class="casAuthors">Becke, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Review A:  Atomic, Molecular, and Optical Physics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3098-100</span>CODEN:
                <span class="NLM_cas:coden">PLRAAN</span>;
        ISSN:<span class="NLM_cas:issn">0556-2791</span>.
    </div><div class="casAbstract">Current gradient-cor. d.-functional approxns. for the exchange energies of at. and mol. systems fail to reproduce the correct 1/r asymptotic behavior of the exchange-energy d.  A gradient-cor. exchange-energy functional is given with the proper asymptotic limit.  This functional, contg. only one parameter, fits the exact Hartree-Fock exchange energies of a wide variety of at. systems with remarkable accuracy, surpassing the performance of previous functionals contg. two parameters or more.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKr-bPUej6TLVg90H21EOLACvtfcHk0lgtU5RH8Q_4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtlOhsLo%253D&md5=d4d219c134a5a90f689a8abed04d82cc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1103%2FPhysRevA.38.3098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevA.38.3098%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520exchange-energy%2520approximation%2520with%2520correct%2520asymptotic-behavior%26jtitle%3DPhys.%2520Rev.%2520A%253A%2520At.%252C%2520Mol.%252C%2520Opt.%2520Phys.%26date%3D1988%26volume%3D38%26spage%3D3098%26epage%3D3100%26doi%3D10.1103%2FPhysRevA.38.3098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabalowski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span></span> <span> </span><span class="NLM_article-title">Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields</span>. <i>J. Phys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">11623</span>– <span class="NLM_lpage">11627</span>, <span class="refDoi"> DOI: 10.1021/j100096a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/j100096a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaK2cXmvVSitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1994&pages=11623-11627&author=P.+J.+Stephensauthor=F.+J.+Devlinauthor=C.+F.+Chabalowskiauthor=M.+J.+Frisch&title=Ab+initio+calculation+of+vibrational+absorption+and+circular+dichroism+spectra+using+density+functional+force+fields&doi=10.1021%2Fj100096a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields</span></div><div class="casAuthors">Stephens, P. J.; Devlin, F. J.; Chabalowski, C. F.; Frisch, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11623-7</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">The unpolarized absorption and CD spectra of the fundamental vibrational transitions of the chiral mol. 4-methyl-2-oxetanone are calcd. ab initio.  Harmonic force fields are obtained using d. functional theory (DFT), MP2 and SCF methodologies, and a [5s4p2d/3s2p] (TZ2P) basis set.  DFT calcns. use the LSDA, BLYP, and Becke3LYP (B3LYP) d. functionals.  Mid-IR spectra predicted using LSDA, BLYP, and B3LYP force fields are of significantly different quality, the B3LYP force field yielding spectra in clearly superior, and overall excellent, agreement with expt.  The MP2 force field yields spectra in slightly worse agreement with expt. than the B3LYP force field.  The SCF force field yields spectra in poor agreement with expt.  The basis set dependence of B3LYP force fields is also explored: the 6-31G* and TZ2P basis sets give very similar results while the 3-21G basis set yields spectra in substantially worse agreement with expt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpodK8tBZ2embVg90H21EOLACvtfcHk0lgtU5RH8Q_4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvVSitbY%253D&md5=93486da1864d900b4527d020cf36171f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fj100096a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100096a001%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DDevlin%26aufirst%3DF.%2BJ.%26aulast%3DChabalowski%26aufirst%3DC.%2BF.%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26atitle%3DAb%2520initio%2520calculation%2520of%2520vibrational%2520absorption%2520and%2520circular%2520dichroism%2520spectra%2520using%2520density%2520functional%2520force%2520fields%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1994%26volume%3D98%26spage%3D11623%26epage%3D11627%26doi%3D10.1021%2Fj100096a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">J Med Chem. 2015, A survey of the role of noncovalent sulfur interactions in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4438</span>, <span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-4438&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=J+Med+Chem.+2015%2C+A+survey+of+the+role+of+noncovalent+sulfur+interactions+in+drug+design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0lgtU5RH8Q_4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DJ%2520Med%2520Chem.%25202015%252C%2520A%2520survey%2520of%2520the%2520role%2520of%2520noncovalent%2520sulfur%2520interactions%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4383%26epage%3D4438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unsal-Kaçmaz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhov, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancar, A.</span></span> <span> </span><span class="NLM_article-title">Preferential binding of ATR protein to UV-damaged DNA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">6673</span>– <span class="NLM_lpage">6678</span>, <span class="refDoi"> DOI: 10.1073/pnas.102167799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1073%2Fpnas.102167799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=12011431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFCrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=6673-6678&author=K.+Unsal-Ka%C3%A7mazauthor=A.+M.+Makhovauthor=J.+D.+Griffithauthor=A.+Sancar&title=Preferential+binding+of+ATR+protein+to+UV-damaged+DNA&doi=10.1073%2Fpnas.102167799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Preferential binding of ATR protein to UV-damaged DNA</span></div><div class="casAuthors">Unsal-Kacmaz, Keziban; Makhov, Alexander M.; Griffith, Jack D.; Sancar, Aziz</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6673-6678</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The ATR protein is a member of the phosphoinositide 3-kinase-related kinase family and plays an important role in UV-induced DNA damage checkpoint response.  Its role as a signal transducer in cell cycle checkpoint is well established, but it is currently unclear whether ATR functions as a damage sensor as well.  Here we have purified the ATR protein and investigated its interaction with DNA by using biochem. anal. and electron microscopy.  We find that ATR is a DNA-binding protein with higher affinity to UV-damaged than undamaged DNA.  In addn., damaged DNA stimulates the kinase activity of ATR to a significantly higher level than undamaged DNA.  Our data suggest that ATR may function as an initial sensor in the DNA damage checkpoint response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1jwvkqkTQfrVg90H21EOLACvtfcHk0lgtU5RH8Q_4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFCrs7s%253D&md5=ef944c34e3ce8d2a45a263485bf4269f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.102167799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.102167799%26sid%3Dliteratum%253Aachs%26aulast%3DUnsal-Ka%25C3%25A7maz%26aufirst%3DK.%26aulast%3DMakhov%26aufirst%3DA.%2BM.%26aulast%3DGriffith%26aufirst%3DJ.%2BD.%26aulast%3DSancar%26aufirst%3DA.%26atitle%3DPreferential%2520binding%2520of%2520ATR%2520protein%2520to%2520UV-damaged%2520DNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D6673%26epage%3D6678%26doi%3D10.1073%2Fpnas.102167799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span> <span> </span><span class="NLM_article-title">High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1177/108705719600100115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1177%2F108705719600100115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaK2sXkslSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=47-51&author=A.+M.+Pittauthor=C.+Lee&title=High+throughput+screening+protein+kinase+assays+optimized+for+reaction%2C+binding%2C+and+detection+totally+within+a+96-well+plate&doi=10.1177%2F108705719600100115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate</span></div><div class="casAuthors">Pitt, Aldo M.; Lee, Carolyn</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-51</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Liebert</span>)
        </div><div class="casAbstract">Signal transduction assays, particularly for protein kinases, are an area of increasing interest and activity for labs. investigating the regulation of cellular functions.  The traditional kinase assay methods require the tedious and time consuming manipulation of phosphocellulose disks typically used to bind the phosphorylated substrate.  Drug discovery research requires the availability of rapid and reliable procedures to evaluate large nos. of samples for bioactivity.  The 96-well phosphocellulose MultiScreen® assay plates were specifically developed to meet these assay requirements.  A cyclic-AMP-dependent protein kinase A (PKA) assay was optimized to be performed entirely within the phosphocellulose MultiScreen plate, including reagent and sample addn., incubation, washing, and direct microplate scintillation counting.  The protocol is directly adaptable to a high throughput kinase screen.  Both the Kemptide peptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) and the histone H1 protein were used as the phosphorylation substrates.  Crude and purified PKA enzymes were found to have a sensitivity of 0.4 U for Kemptide substrate, which was comparable to the assay performed by the traditional transfer to phosphocellulose paper.  The results demonstrate that kinase assays can be performed entirely in a MultiScreen phosphocellulose plate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonrwX6aYs2_rVg90H21EOLACvtfcHk0lgscNzRP2g3Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslSksA%253D%253D&md5=d859992a0a8214289483419417007a7f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1177%2F108705719600100115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F108705719600100115%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DC.%26atitle%3DHigh%2520throughput%2520screening%2520protein%2520kinase%2520assays%2520optimized%2520for%2520reaction%252C%2520binding%252C%2520and%2520detection%2520totally%2520within%2520a%252096-well%2520plate%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D1996%26volume%3D1%26spage%3D47%26epage%3D51%26doi%3D10.1177%2F108705719600100115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prichard, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prichard, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, C.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Strategic design and three-dimensional analysis of antiviral drug combinations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.3.540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=10.1128%2FAAC.37.3.540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=8384816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;key=1%3ACAS%3A528%3ADyaK3sXitVCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=540-545&author=M.+N.+Prichardauthor=L.+E.+Prichardauthor=C.+Shipman&title=Strategic+design+and+three-dimensional+analysis+of+antiviral+drug+combinations&doi=10.1128%2FAAC.37.3.540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic design and three-dimensional analysis of antiviral drug combinations</span></div><div class="casAuthors">Prichard, Mark N.; Prichard, Lynn E.; Shipman, Charles, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">540-5</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The development of new drugs effective against human viral diseases has proven to be both difficult and time-consuming.  Indeed, there are but 10 drugs licensed for such applications in the United States today.  An attractive soln. to this problem may be to optimize the efficacy and selectivity of existing antiviral drugs by combining them with agents that strategically block carefully selected metabolic pathways.  This approach was used in the rational design of a 3-drug combination to increase the apparent potency of acyclovir against herpes simplex virus.  Recent advances in anal. techniques have made the evaluation of this complex drug strategy both possible and practical.  A modified version of a previously described anal. method was used to identify optimal drug concns. and to quantitate statistically significant synergy.  Concns. of 0.25 μM 5-fluorodeoxyuridine, 3.6 μM 2-acetylpyridine thiosemicarbazone, and 0.3 μM acyclovir were detd. to be optimal in terms of antiviral activity.  The vol. of synergy produced was nearly 2,000 μM3% at a 95% level of confidence (corresponding to a 186-fold decrease in the apparent 50% inhibitory concn. of acyclovir with the addn. of 0.25 μM 5-fluorodeoxyuridine and 3.6 μM 2-acetylpyridine thiosemicarbazone).  We anticipate that this strategic approach and the supporting three-dimensional anal. method will prove valuable in designing and understanding multidrug therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh_6_mJUc-YbVg90H21EOLACvtfcHk0lgscNzRP2g3Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitVCktLY%253D&md5=12bfac78b4d866f48eeccc5e73a575e8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.3.540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.3.540%26sid%3Dliteratum%253Aachs%26aulast%3DPrichard%26aufirst%3DM.%2BN.%26aulast%3DPrichard%26aufirst%3DL.%2BE.%26aulast%3DShipman%26aufirst%3DC.%26atitle%3DStrategic%2520design%2520and%2520three-dimensional%2520analysis%2520of%2520antiviral%2520drug%2520combinations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26spage%3D540%26epage%3D545%26doi%3D10.1128%2FAAC.37.3.540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V','PDB','1E7V'); return false;">PDB: 1E7V</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i37"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00426">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06884"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00426">10.1021/acs.jmedchem.9b00426</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Atomic coordinates of an ATR kinase domain homology model based on PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E7V">1E7V</a> with bound compound <b>2</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and enzyme inhibition data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_002.csv">CSV</a>)</p></li><li><p class="inline">Analytical data for compounds <b>2</b>–<b>20</b> (page S3), HPLC characterization of purity for compounds <b>2</b>–<b>20</b> (page S13), preparation of key intermediates (page S23), enzyme assays (page S29), and cellular assays (page S30) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_001.pdb">jm9b00426_si_001.pdb (185.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_002.csv">jm9b00426_si_002.csv (1.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00426/suppl_file/jm9b00426_si_003.pdf">jm9b00426_si_003.pdf (1.08 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00426%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00426" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667981df7a3324c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
